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Abstract
The fundamental subject of this thesis is the development of tools for the analysis
of DNAmethylation data as well as their application on bisulfite sequencing data
comprising a large number of samples. DNA methylation is one of the major epi-
genetic modifications. It affects the cytosines of the DNA and is essential for the
normal development of cells and tissues. Unusual alterations are associated with
a variety of diseases and, specially, in cancergeneous tissues global changes in
the DNAmethylation level have been detected. To sequence DNAmethylation on
single nucleotide resolution, the sequences are treated with sodium bisulfite be-
fore sequencing, whereby unmethylated cytosines are represented as thymines.
Thus, specialized techniques are required to process and analyze these kind of
data.
Here, the bisulfite analysis toolkit BAT is introduced, that is designed to fa-
cilitate an quick analysis of bisulfite treated DNA methylation sequencing data.
It covers all steps of processing raw sequencing data up to calling of differential
DNAmethylation. At the begin of analysis, sodiumbisulfite treated sequence data
are aligned and DNAmethylation rates for each covered cytosine in the reference
genome are called. Subsequently, BAT integrates annotation data and performs
basic analysis, i. e., methylation rate distribution plots and hierarchical clustering
of the samples. In addition, calling of differentially methylated regions is per-
formed and statistics of called regions are automatically created. Finally, DNA
methylation and gene expression data integration is covered by the calculation
of correlating regions.
Secondly, a novel algorithm, metilene, for the calculation of differentially
methylated regions (DMRs) between two groups of samples is introduced. Exist-
ingmethods are limited in terms of detection sensitivity aswell as time andmem-
ory consumption. Our approach is based on a circular binary segmentation, using
a scoring function to detect sub-regions that show a stronger difference between
the mean methylation levels of two groups than the surrounding background.
These sub-regions are tested using a two-dimensional Kolmogorov Smirnov test
(2D-KS test) [Fasano 1987] for significant differences taking all samples of each
group into account. The use of the non-parametric 2D-KS test allows to avoid as-
sumptions about a background distribution. Furthermore, the two dimensions of
the problem, i. e., (i) the detection of a region, such that (ii) the methylation rates
of the samples in the groups are significantly different, are taken into account in
a single test. The algorithm calls DMRs in sufficiently short time on single sam-
ple comparisons as well as on about 50 samples per group. Furthermore, it works
onwhole-genome bisulfite sequencing (WGBS) and reduced representation bisul-
fite sequencing (RRBS) data and is able so estimate missing data points from the
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methylation rates of other samples in the group. Benchmarks on simulated and
real data sets show that metilene outperforms other existing methods and is
especially suitable for noisy datasets often found for example in cancer analysis.
In the framework of this thesis, the previously introduced methods and algo-
rithms are used to analyze a WGBS dataset of two different subtypes of germinal-
center derived B-cell lymphomas and healthy controls. In both lymphoma sub-
groups genome-wide hypomethylation was found, with an exception for a spe-
cific type of promoter regions, i. e., poised promoters, that were frequently found
to be hypermethylated. Using the previously presented algorithm, DMRs were
called between the three entities. A strong enrichment of DMRs immediately
downstream of the transcription start site was observed, indicating the regula-
tory relevance of this regions. The integration of gene expressiondata of the same
samples, revealed that a considerable amount of the DMRs showed significant
correlation between gene expression andDNAmethylation. Finally, transcription
factor binding sites and mutation data were combined with the methylation and
expression data analysis. This identified strongly altered signaling pathways and
cancer subtype specific genes. Furthermore, the data integration indicates that
mutations and DNA methylation changes may act complementary to another.
Finally, findings from the lymphoma study regarding the hypermethylation
of poised promoters in cancerwere extended to a huge data set comprising a vari-
ety of cancers. We could show that the relation of DNAmethylation at a small set
of frequently poised regions with respect to the background methylation level
is sufficient to classify almost all samples based on DNA methylation data from
450k BeadChips into cancer or non-cancer probes. In addition, we found that the
increase in methylation co-occurs with upregulated gene expression of several
poised promoter regulated genes in almost all fresh cancer samples, implying a
de-poising of poised regions. This upregulated gene expression is in contrast to
the silencing of those genes in cancer cell lines, indicating that the upregulated
gene expressionmight be a temporary status and possibly contributes to cancero-
genesis.
Zusammenfassung
Das grundlegende Thema dieser Arbeit ist die Entwicklung von Hilfsmitteln für
die Analyse von DNA-Methylierungsdaten, sowie deren Anwendung auf eine
große Anzahl von Bisulfit sequenzierter Proben. DNA-Methylierung ist eine
der wichtigsten epigenetische Modifikationen. Es beeinflusst die Cytosine der
DNA und ist essentiell für die normale Entwicklung von Zellen und Geweben.
Ungewöhnlichen Veränderungen sindmit einer Vielzahl von Krankheiten assozi-
iert und insbesondere in kanzerogenen Geweben wurden globale Veränderun-
gen in dem DNA-Methylierungslevel gefunden. Um die DNA-Methylierung Nuk-
leotid genaus zu sequenzieren, werden die Sequenzenmit Natriumbisulfit vor der
Sequenzierung behandelt werden, wobei unmethylierte Cytosine als Thymine
repräsentiert werden. Daher sind spezielle Techniken erforderlich, um diese Art
von Daten zu verarbeiten und zu analysieren.
Zu Beginn wird das Bisulfit-Analyse-Toolkit BAT vorgestellt, das entwickelt
wurde, um eine schnelle Analyse der Bisulfit behandelten Sequenzierungsdaten
zu ermöglichen. Es deckt alle Schritte der Verarbeitung von rohen Sequenzdaten
bis hin zur Detektion differentieller DNA-Methylierung ab. Zuerst werden Bisul-
fit behandelte Sequenzdaten aligniert und die DNA-Methylierungsraten für die
Cytosine im Referenzgenom berechnet. Anschließend ermöglicht BAT die Inte-
gration von Annotationsdaten und führt grundlegende Analysen durch, wie zum
Beispiel die graphischeDarstellung derMethylierungsratenverteilung und ein hi-
erarchisches Clustering der Proben. Zusätzlich werden differentiell methylierte
Regionen detektiert und es werden automatisch Statistiken bezüglich der gefun-
den Regionen erstellt. Schlussendlich wird die DNA-Methylierung mit Genex-
pressionsdaten integriert indem korrelierende Regionen berechnet werden.
Zweitens wird ein neuer Algorithmus, metilene, für die Berechnung von
differentiell methylierter Regionen (DMRs) zwischen zwei Gruppen von Proben
eingeführt. Bereits vorhandene Verfahren sind sowohl im Bezug auf Sensitiv-
ität als auch auf Laufzeit und Speicherbedarf beschränkt. Unser Konzept basiert
auf einer zirkulären binären Segmentierung, diemit Hilfe einer Scoring-Funktion
Subregionen detektiert, die eine stärkere Differenz der mittleren Methylierun-
grate der beiden Gruppen zeigen, als der sie umgebende Hintergrund. Diese
Subregionen werden mit dem zweidimensionalen Kolmogorov Smirnov-Test
(2D-KS-Test) [Fasano 1987] auf signifikante Unterschiede getestet, wobei die
Methylierungsraten aller Proben von beiden Gruppen berücksichtigt werden. Die
Verwendung des nicht-parametrischen 2D-KS Tests erlaubt es, keine Annahmen
über eine Hintergrundverteilung machen zu müssen. Ferner sind die beiden Di-
mensionen des Problems, also (i) die Erfassung eines Bereichs, so dass (ii) die
Methylierungsraten der Proben in den Gruppen signifikant verschieden sind,
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in einem einzigen Test berücksichtigt. Der Algorithmus detektiert DMRs sehr
schnell und ist in der Lage sowohl auf Einzel-Proben-Vergleichen als auch auf
Gruppen mit bis zu 50 Proben zu arbeiten. Desweiteren können DMRs sowohl auf
whole-genome Bisulfite sequencing (WGBS) als auch auf reduced representation
sequencing (RRBS) Daten berechnet werden und fehlende Datenpunkte können
aus denMethylierungsraten anderer Proben derselben Gruppe geschätzt werden.
Vergleiche auf simulierten und realenDatensätzen zeigen, dassmetilene andere
bereits bestehende Methoden übertrifft und sich besonders gut eignet für ver-
rauschte Datensätze wie sie beispielsweise häufig in der Krebsanalyse gefunden
werden.
Im Rahmen dieser Arbeit werden die zuvor eingeführten Methoden und
Algorithmen verwendet, um einen WGBS Datensatz bestehend aus Proben
zweier verschiedener Subtypen von Keimzentrums-B-Zell-Lymphomen und
gesunden Kontrollen zu analysieren. Beide Subtypen zeigten genomweite Hy-
pomethylierung, mit der Ausnahme einer bestimmten Art von Promotorregio-
nen, den Poised Promotoren, die häufig hypermethyliert waren. Unter Ver-
wendung des zuvor vorgestellten Algorithmus wurden DMRs zwischen den drei
Gruppen berechnet. Es wurde beobachtet, dass DMRs unmittelbar abwärts
von der Transkriptionsstartstelle stark angereichert sind, was auf eine regula-
torische Relevanz dieser Regionen hinweist. Die Integration von Genexpres-
sionsdaten aus denselben Proben zeigte, dass eine beträchtliche Menge der
DMRs signifikante Korrelation zwischen Genexpression und DNA-Methylierung
aufweist. Schlussendlich wurde die Information über Transkriptionsfaktor-
Bindungsstellen und Mutationsdaten mit der Methylierung- und Expression-
Datenanalyse kombiniert. Dadurch wurden Signalwege und Krebs-Subtyp spezi-
fische Gene identifiziert, die stark verändert waren. Darüber hinaus konnten wir
durch diese Datenintegration zeigen, dass sich möglicherweise Mutationen und
DNA-Methylierungsänderungen ergänzen.
Schließlich wurden die Erkenntnisse aus der Lymphomstudie über die Hy-
permethylierung von Promotoren im Krebs auf eine große Probenmenge, beste-
hend aus einer Vielzahl von Krebsarten, erweitert. Wir konnten zeigen, dass
das Verhältnis der DNA-Methylierung in einer kleinen Gruppe von häufig als
Poised Promotor klassifizierten Regionen zu der Hintergrundmethylierungsrate
ausreichend ist, um auf Basis von DNA-Methylierungsdaten von 450k BeadChips
fast alle Proben erfolgreich in Krebs- oder nicht-Krebs-Gewebe zu klassifizieren.
Darüber hinaus haben wir festgestellt, dass in fast allen Krebs-Frischgewebe-
Proben der Anstieg in der Methylierungsrate häufig mit der Hochregulation
der Genexpression von Poised Promoter regulierten Genen zusammen fällt, was
ein de-poising der Regionen impliziert. Die hochregulierte Genexpression steht
im Gegensatz zur Abschaltung der Gene in Krebszelllinien, was bedeutet, dass
die Hochregulation der Genexpression ein vorübergehender Status sein und zur
Karzinogenese beiträgen könnte.
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This chapter introduces the basic understanding of how DNA shapes each
organism and I will refer to a second layer of information- the epigenome.
In the second half of the chapter the technical background of assessing the
genomic information by sequencing is given.
1.1 Motivation
Some years after the discovery of the 3D structure of DNA, Crick published the
central dogma of molecular biology, which described the irreversible flow of in-
formation fromDNA towards proteins [Crick 1958]. The term ’irreversible’ meant
that sequence information stored in proteins can not be transfered back into DNA
or RNA.
A modified version was published later byWatson [Watson 1970]. He omitted
the reverse transcription step fromRNA back to DNA and RNAwas degraded to an
intermediate step on the way to protein (Fig. 1.1 (left)). This theory was shown to
be a crude simplification by two independent publications in 1970 with the dis-
covery of the reverse transcriptase by [Temin 1970, Baltimore 1970]. Additionally,
other discoveries like RNA viruses, alternative splicing, prions, and retrotrans-
posons proved Watson’s dogma wrong.
Nevertheless, for several years the idea of DNA being solely the blueprint for
proteins was widely accepted. The long non-protein coding regions were claimed
to be junk DNA and largely ignored. This view bears the problem to explain the
diversity of cells and tissues all carrying the same genetic information. Conse-
quently, opinions emerged that there need to be more layers of information in
the genome than protein-coding genes. One of the additional layers are the non-
coding RNAs (ncRNAs). The other layers are epigenetic modifications primarily
comprising histone modifications and DNA methylation (Fig. 1.1 (right)).
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DNA
RNA
protein
duplication
transcription
translation
Figure 1.1: Central dogma of molecular biology. (left) Flow of information by Watson. DNA
is illustrated to be self-replicating and RNA is only made from DNA during an irreversible step.
RNA itself is translated into protein. (right) Two of the major epigenetic modifications are DNA
methylation and histone modifications. DNA methylation defines the modification of cytosines in
the DNA, whereas histonemodifications define themodification of the amino acid tails of histones.
Figure taken from [Qiu 2006].
Both layers influence the composition of expressed genes in cells. The pre-
cise selection of silenced genes in the set of over 50,000 genes in the human
genome [Harrow 2012] is a crucial factor deciding between cell survival and
death. Disruption of this tightly coordinated process could have a major impact,
e. g., accidental silencing of tumor suppressor genes could lead to cancer and re-
moval of transposon silencing could result in chromatin instability. These exam-
ples are indicative of just how important it is to better understand the interplay
of the layers of information.
1.2 The story of DNA, RNA and proteins
The nuclear genome is the entire genetic material of organisms. This set of in-
structions needed in each living cell for replication, assembly, and maintenance
is encoded in desoxyribnucleic acid or, for some RNA viruses in ribonucleic acid.
In eukaryotes, the nuclear DNA is located in the cell nucleus, whereas the DNA of
prokaryotes is inside the cytoplasm. Exceptions aremitochondrial DNA (mtDNA),
which are found in the mitochondria, and chloroplast DNA (plastome).
DNA is a polymer made from a repeating chain of monomeric building units
called nucleotides. Each nucleotide (nt) itself is composed of a basic structure of
the 5-carbon monosaccharide desoxyribose bound to one of the four nitrogen-
containing bases, i. e., adenine (A), thymine (T), guanine (G) or cytosine (C), and
a phosphate group. RNA has a similar composition, except that uracile (U) re-
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places thymine and ribose is integrated instead of desoxyribose. A covalent bond
between the sugar of the anterior nucleotide and the phosphate of the following
nucleotide links the nucleotides resulting in two chemically different ends of the
DNA strand. This inequality gives the DNA strand an orientation. The end with
the fifth carbon in the sugar ring, termed 5�-end is denoted as the start or up-
stream end of the strand. Consequently, the 3�-end having a hydroxyl group at
the third carbon of the sugar ring, is denoted as terminal or downstream end of
the strand.
Naturally occurring DNA is mostly composed of two of these polymers, ar-
ranged such that the bases of one strand are connected to the bases of the op-
posite strand, forming a coiled double-helix [Watson 1953]. The DNA double-
helix has two anti-parallel sugar-phosphate backbones and is tightened by hydro-
gen bonds between two complementary bases (guanosine-cytosine and adenine-
thymine), also called Watson-Crick base pairs (bp). As a result of this comple-
mentarity, the nucleotide sequence of one DNA strand is sufficient to derive the
sequence of the other strand. In particular, this duplicated storage is crucial dur-
ing DNA replication to copy the genetic information, encoded as the sequence of
the bases, to daughter cells.
The genetic information in a genome is conveyed by genes. A current defini-
tion of genes is “A locatable region of genomic sequence, corresponding to a unit
of inheritance, which is associated with regulatory regions, transcribed regions
and/or other functional sequence regions.” [Pearson 2006] To utilize the genetic
information, a cell type and status dependent set of a genes is expressed. At first,
genes are transcribed by assembling a new sequence of single-stranded RNA us-
ing the coding region of the gene on the DNA as a template. A highly coordinated
interaction of various enzymes and proteins, like RNA polymerase and transcrip-
tion factors, is necessary. Commonly, RNA as well as their underlying genes are
classified into two major groups, depending on their final product. One class are
non-coding RNAs (ncRNAs), which are not translated into proteins, originating
from non-protein-coding genes. The other class is composed of RNAs that are
used to build proteins, calledmessenger RNAs (mRNA), transcribed from protein-
coding genes. In the nucleus of eukaryotic cells, precursor RNAs undergo several
modifications resulting in mature RNAs. The processing includes modifications
of precursor mRNA at its 5� and 3� end. First, a single guanine is added to the 5�
end of precursor mRNA, which gets instantly methylated. Secondly, a sequence
of approximately 200 adenine nucleotides is added to the 3� end of themRNA and
some ncRNAs [Guttman 2009], a process known as polyadenylation. These end
modifications stall the degradation of RNA molecules and promote their binding
to the ribosome. A second important modification, predominantly in higher eu-
karyotes, is splicing. Splicing is the excision of segments from the RNA (introns)
followed by the chaining of the remaining segments (exons) to mature RNA. The
splicing positions may be altered for each RNAmolecule and may vary under dif-
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ferent conditions (alternative splicing), e. g., introns can be retained or exons can
by skipped or extended. The effect is that a restricted number of genes yet result
in a very complex and diverse set of RNAs and consequently also in a multiplicity
of proteins.
In the second stage of gene expression, known as translation, mature mR-
NAs serve as blueprint for the construction of proteins. Therefore, at least in
eukaryotes, the mRNA is transported to the cytoplasm, where it is bound by ri-
bosomes. At the ribosomes, the RNA sequence is read and translated using trans-
fer RNAs (tRNAs) to synthesize proteins. During this process, three consecutive
nucleotides (triplets), called codons, encode for one specific amino acid. tRNAs
contain a complementary anticodon for one of the possible triplets and carry
the corresponding amino acid to the ribozymes. The ribozymes match the tRNA
anticodons to mRNA triplets and successively link the bound amino acids into a
polypeptide. Start as well as end of an amino acid chain are defined by specific
start and stop codons, respectively. A stop codon results in release of the amino
acid chain, whereas the start codon also codes for a regular amino acid. Finally,
this linear amino acid chain folds into a three dimensional structure to become
functional.
1.3 High Throughput Sequencing
The knowledge of DNA sequences is a key to life sciences, e. g., in basic biological
research, molecular diagnostics, biotechnology, drug discovery and many more.
The method to obtain the exact order of nucleotides in fragments of DNA is re-
ferred to as sequencing. The development of sequencing methods started slowly,
but in the last years methods are evolving rapidly. In 1977, Frederick Sanger laid
the foundation for DNA sequencing and published amethod, known as Sanger se-
quencing [Sanger 1977], that was widely used and steadily improved during the
next decades.
The main idea is to divide the DNA into four tubes to separately sequence
the four nucleotides. Each tube contains the template DNA, primers, polymerase
and deoxynucleotides (dATP, dGTP, dCTP and dTTP). In addition, each tube con-
tains a very low concentration of one of the dideoxynucleotides (ddNTPs), i. e.,
either ddATP, ddGTP, ddCTP or ddTTP. Dideoxynucleotides do not contain a 3�-
hydroxyl group. Therefore, the polymerase cannot add further nucleotides after
the incorporation of the ddNTP and the sequencing is stopped. Due to the very
low percentage of ddNTPs within the four tubes, the position at which the ddNTP
is incorporated and hence the sequence elongation is terminated, is evenly dis-
tributed over the template. Subsequently, the copies of the template are sepa-
rated by molecular weight (size) using gel electrophoresis for each tube. Due to
a DNA specific sieving, DNA fragments of a specific length and a specific last nu-
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cleotide appear as distinct bands on the gel. The relative positions of the different
bands among the four lanes then read out the sequence of the DNA template. This
approach has been improved by labeling the ddNTPs with a fluorescent marker
to run the four reactions in a single tube and capillary electrophoresis is used for
size separation.
In 2005, a new generation of sequencing began by the introduction of
high throughput sequencing (HTS), also referred as next-generation sequencing
(NGS). NGS allowed the sequencing of thousands or even millions of templates
in parallel. The main steps of NGS involve random fragmentation of input DNA,
followed by spatial isolation and immobilization of single fragments to sequence
them concurrently. These technologies meant a great improve over Sanger se-
quencing in terms of costs (4-0.1% per Mb of Sanger sequencing costs) and time
(100-1,000 times faster) [Kircher 2010]. NGS allows for a whole new range of ap-
plication of sequencing, e. g., exome sequencing, or re-sequencing, used for iden-
tification of single nucleotide variation (SNV) or copy number variation (CNV). By
reverse transcription of RNA to cDNA, it furthermore allowed the investigation of
the transcriptome (RNA-seq) for differential expression analyses, gene and iso-
form prediction. In combination with capturing techniques it become possible
to map epigenetic markers such as histonemodifications (ChIPseq) on a genome-
wide scale.
1.3.1 Illumina
In this section, I only will focus on the Illumina sequencing technol-
ogy [Bentley 2008], since it is by far the most used sequencing technology. Note
that data analyzed in chapter 5 was produced on Illumina machines. The basic
sequencing workflow (Fig. 1.2) and possible errors are described below.
Library preparation
At first, a so called sequencing library is build. Therefore, the DNA is randomly
fragmented, e. g., by hydrodynamic shearing, resulting in fragments of typically
less than 800 bps. Two different kinds of adapters are ligated to the 5� and 3�
ends of the fragments, respectively. Using short oligonucleotides (primers) com-
plementary to primer regions within the adapter sequences, copies of adapter-
ligated fragments can be generated. By applying this process multiple times
(termed amplification), the library is enriched for fragments with adapters at
both ends.
Cluster generation
The single-stranded library of fragments is washed over a flow cell in a low con-
centration. The surface of the flow cell is coated with oligonucleotides comple-
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Figure 1.2: Illumina sequencing. After fragmentation of the DNA, adapters are ligated for immo-
bilization and cluster generation. Sequencing by synthesis with fluorescently labeled nucleotides
is used to sequence millions of fragments in parallel.
mentary to the adapter sequences. The adapters of the fragments bind to their
complement. Due to an over-representation of adapters on theflow cell, the frag-
ments are distributed by chance over the whole flow cell and bind with sufficient
space to the next fragment. This step is critical since a more dense distribution
of bound fragments will result in a higher throughput but might lead to prob-
lems during the sequencing. The next step is to produce a cluster of copies from
a single fragment, that contains up to 1,000 identical copies. This is done using
a method referred to as bridge amplification. During this process, the end of the
fragment, that is not bound to the flow cell, bends over and hybridizes to another
adapter on the surface. By reverse strand synthesis a double-stranded fragment
bridge is formed. The double-stranded bridges are denatured and the next cluster
generation step follows until clusters are dense. Ultimately, one type of adapter,
e. g., the 5� ones are cut away to ensure that all copies of a cluster have the same
orientation.
Sequencing by synthesis
To initiate the sequencing process, a primer is added to the flow cell and binds to
its complementary region at the fragments. At the beginning of each cycle amix-
ture of the four nucleotides and amodified polymerase are added to the flow cell.
The nucleotides carry a base-specific fluorescent label and their 3� end is chemi-
cally blocked by a reversible terminator. Competition is constituted by using all
four nucleotides at once to minimize the incorporation bias and the modified 3�
end of the nucleotide ensures that only a single base is incorporated in each cycle.
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An imaging step follows the incorporation of a single base into each fragment. A
high-resolution camera records the combined color signal of the fluorescent la-
bels in a cluster and a base caller identifies the newly incorporated nucleotide
based on the reported light. The clarity of the light signal is used to assign a qual-
ity score to each sequenced base indicating their reliability. Consecutively, the
terminator group and the fluorescent label are enzymatically cleaved from each
fragment for the next cycle and remaining chemicals are washed from the flow
cell. The sequencing consists of a specific number of sequencing cycles defining
the read length. Hence, all reads produced from an Illumina sequencing run are
equal in length. Reads are the sequenced part of the biological fragments, possi-
bly containing adapter sequences. Given the fragments are sequenced from both
ends the process is called paired-end sequencing.
Errors
Two of the main errors occurring during the library preparation are the G-C
bias [Aird 2011] and the amplification error. The G-C bias is the dependence be-
tween the G/C content of a sequence and its enrichment during amplification.
Sequences with a intermediate G/C content are overrepresented with respect to
sequences with a very low or very high G/C content. This should be considered,
e. g., in analyses of copy number variations.
Unfortunately, amplification errors cannot be controlled, since an erro-
neously incorporated base during the cluster amplification step may happen
early and can be introduced to an entire cluster. Reads produced by such a clus-
ter show awrong base despite the high base quality and the erroneous base alone
can not be distinguished from mutations.
Signal decay due to de-phasing is an example of sequencing biases. These bi-
ases result in low quality scores of the affected bases. De-phasing describes the
phenomenon that the sequencer is out of phase in one or more fragments in a
cluster. Non-removal of terminators or multiple incorporation of bases results in
unequal elongations of fragments. Then, the light signal of a the cluster becomes
heterogeneous, due to mixed colors from different last nucleotides (fluorescent
labels), and the nucleotide cannot be identified precisely. Other errors are sub-
stitutions and insertion or deletions (InDels), with substitutions being the most
common error type in Illumina sequencing data. Overall, the data quality is very
high. It was shown that the the average error rates are below 1.5%, and as low as
0.1% for high-quality bases [Shendure 2008].
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This chapter introduces the di�erent aspects of the epigenome. The
epigenome comprises all heritable alterations andmodifications that influ-
ence the expression and spatial structure of the genome without changing
its nucleotide sequence. These modifications are not fixed in a specific
composition, but highly variable. Di�erent developmental stages, time
points in cell cycle, tissues, cell types, environments and diseases are char-
acterized by their epigenome. Epigenetic modifications are a multidimen-
sional layer of the genome that enables the development of a variety phe-
notypes based on one genotype [Bernstein 2007]. Furthermore, the tech-
nical and biological background of epigenome sequencing is given.
2.1 Histone modification and ncRNAs
2.1.1 ncRNAs
Non-coding RNAs (ncRNAs) are functional RNAs that are transcribed from DNA
and often post-processed but not translated into proteins. They are highly
abundant and several of them perform a range of complex tasks in the cell,
therefore they are often counted as epigenetic factors [Mercer 2013, Costa 2008,
Bonasio 2010].
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The two best known classes of ncRNAs are transfer RNA (tRNAs) and ribo-
somal RNA (rRNAs). They are essential components of translating messenger
RNA (mRNA) into proteins. In addition to these processing ncRNAs there is a
diverse group of regulatory ncRNAs. There are short ncRNAs e. g., small nuclear
RNAs (snRNAs), microRNAs (miRNAs), short interfering RNAs (siRNAs), or PIWI
interacting RNAs (piRNAs). These short ncRNAs regulate the expression of genes
by influencing the splicing process, guiding enzymes to other RNAs, targeting
mRNA to regulate translation and silencing or enhancing genes. Furthermore
they are involved in transposon control, regulation of chromatin and methyla-
tion of DNA [Collins 2009, Amaral 2008, Bernstein 2005].
While these ncRNAs are quite short (<30 nucleotides) there is another group
of regulating ncRNAs, the long non-coding RNAs (lncRNAs) which are, by defi-
nition, >200 nucleotides. They e. g., silence genes by interacting with proteins,
enhancing DNA methylation, influence the stability of other RNAs and recruit
chromatin modifiers [Mercer 2013].
2.1.2 Histone modifications
Histones are protein octamers necessary for packaging, stabilization and accessi-
bility of DNA [Luger 1997, Annunziato 2008, Jenuwein 2001]. More precisely, the
core histone octamers consist of two H2A-H2B dimers and a H3-H4 tetramer. In
eukaryotes the DNA double helix is wrapped left-handed 1.6 times (145-147 bps)
around histones every 160-240 bps, forming nucleosomes. The DNA between two
adjacent nucleosomes is stabilized by the linker histone H1 [Luger 1997]. This
structure is often called “beads on a string” 10nm fibre (euchromatin) and can be
coiled into a more dense structure (heterochromatin) by wrapping it to a 30 nm
fibre.
The amino acids in the tails of histones are frequently affected by chemi-
cal modifications. Histones are highly conserved and these tissue specific alter-
ations occur post-translationally [Strahl 2000]. The modifications include acety-
lation, phosphorylation, methylation, ubiquitination, ADP-ribosylation, sumoy-
lation, deamination, proline isomerization of a specific set of amino acids (ly-
sine, arginine, serine, threonine, glutamic acid and proline) in the core his-
tones [Jenuwein 2001] (Fig. 2.1). The modifications are reversible and make the
difference between accessible euchromatin and unaccessible, dense heterochro-
matin [Jenuwein 2001]. The common nomenclature of histone modifications is
composed of
• the histone name (H2A, H2B, H3, H4)
• the affected amino acid in single-letter abbreviation (e. g., K for Lysine)
• the position of the modified residue
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Figure 2.1: Histone modifications. (top) Schematic of histone octamers wrapped by DNA (black).
The histone tails are represented in red. (bottom) Frequent histone tail modifications, particularly
acetylation (A), methylation (M), phosphorylation (P) and ubiquitination (Ub), affecting amino
acids lysine (K), serine (S) and glutamic acid (E). (Adapted from Marks et al. [Marks 2001].)
• the type of modification (e. g., me: methylation, ac: acetylation)
• number of methyl groups, if methylated (1, 2 or 3 is mono-, di- or tri-
methylation)
As an example the tri-methylation (me3) of the Lysine (K) at position 4 of histone
H3 is encoded with H3K4me3.
The type of modification, the affected histone and residue and the combi-
nation of modifications has impact on the accessibility and consequently on the
transcription of genes. Some modifications are known to enhance and promote
the binding of proteins to the DNA or to open the chromatin and therefore may
activate transcription, while others are known for suppression and inhibition of
transcription. For some chromatin marks also their relative location, e. g., with
respect to the transcription start site (TSS), is altering their effect. For exam-
ple, H3K36 and H3K9 methylation suppress gene expression when present in the
promoter region, but have a supportive effect when located in the coding re-
gion [Kouzarides 2007].
Activating chromatin marks
The most important chromatin mark activating transcription is H3K4me3.
H3K4me3 marks have been found in the promoter regions of almost all actively
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transcribed genes, this does not hold for mono- and dimethylation of the same
residue [Santos-Rosa 2002]. H3K4 methylation is catalyzed by the Trithorax
group (TrxG) protein complex. Inmammals this specific group of histonemethyl-
transferases (HMT) includes theMixed Lineage Leukemia (MML) proteins and the
SET1A and SET1B proteins, which also methylate arginines or lysines in H3 and
H4 and are associated with gene activation [Shilatifard 2012] and TrxG proteins
are involved in development [Soshnikova 2011]. Other chromatin marks linked
to active transcription are H3K9me1, H3K9ac, H3K27m1, H4K20me1, H3K79me1,
H2BK5me1 and H3K4me2 [Barski 2007].
Repressing chromatin marks
Chromatin marks known to correlate with transcription suppression are
H3K27me3, H3K9me3 and K3K79me3 [Barski 2007]. H3K27me3, which is also
called Polycomb repressive mark, is set by the Polycomb Repressive Com-
plexes (PRCs, esp. PRC2), which are expressed from the Polycomb group (PcG)
genes [Aldiri 2012]. The H3K27me3 chromatin mark is of special interest since
it antagonizes H3K4me3. It is found at the promoter of genes that are sup-
pressed in embryonic stem (ES) cells and involved in development and differenti-
ation [Boyer 2006]. Furthermore PRC were reported to interact with non-coding
RNAs. The inactivation process of themammal X chromosome is accompanied by
PRC2 induced methylation of H3K27. Therefore, PRC2 is guided to the X chromo-
some by interaction with the non-coding RNA Xist, which regulates the inactiva-
tion process [Brockdorff 2013]. Another example of the interaction of PRC2 with
non-coding RNAs is the HOTAIR long non-coding RNA. HOTAIR and PRC2 cooper-
ate to silence tumor suppressor genes of the HOX gene group by trimethylation
of H3K27 [Kogo 2011].
Bivalent chromatin marks
The most notable co-occurrence of counteracting chromatin marks are regions
characterized by overlapping activatingmarks (H3K4me3) and suppressingmarks
(H3K27me3). These regions are called poised, bivalent or paused promoters
and are frequently found in the promoter region of developmentally important
genes [Bernstein 2006]. Poised promoters were reported to be preloaded with
poised polymerase II (Pol II) to prepare genes for fast activation [Gaertner 2012].
Chromatin states
The most widely occurring chromatin modifications annotated by the Encyclo-
pedia of DNA Elements (ENCODE) [ENCODE Project Consortium 2012a] were sum-
marized by Ernst et al. in 2011 [Ernst 2011] for nine human cell lines, among oth-
ers for GM12878. The GM12878 cell line is a lymphoblastoid cell line that was
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Figure 2.2: DNA methylation. DNA methylation is the addition of a methyl group to a cytosine in
the DNA.
produced from peripheral B lymphocytes derived from blood, hence it is a rep-
resentative of non-neoplastic mature B-cells. Ernst et al. used a Hidden Markov
Model (HMM) to cluster the frequency of chromatinmarks into chromatin states.
The advantage is that the hard to interpret, sometimes overlapping annotation
of chromatin marks is condensed into 15 distinct classes of chromatin state seg-
ments, each of them with a meaningful name (Tab. A.1, top). These 15 chromatin
states refer to six main classes: promoter, enhancer, insulator, transcribed, re-
pressed, and inactive states. These states differ in length, positionwith respect to
the TSS, influence on transcription activity of close by genes and represent a cell
type specific and workable annotation of chromatin modification. Consequently,
this annotation or a similar annotation presented by BLUEPRINT (Tab. A.1, bot-
tom) for GM12878 and lymphoma cell lines BL2, DG-75 and KARPAS-422 will be
used in this thesis instead of the single chromatin modifications.
2.2 DNA methylation
DNA methylation is the covalent binding of a methyl group to the fifth C atom
of the base cytosine (C) in the DNA (Fig. 2.2). This methylated form of a cyto-
sine is called 5-methylcytosine (5mC). DNA methylation is found in prokaryotes
as well as in many eukaryotic groups like plants, fungi and animals. In contrast
to eukaryotes, bacteria also carry methylation mark on adenines. In bacteria,
5mC is known to protect the DNA from restriction enzymes [Casadesús 2006]. De-
spite the wide spread occurrence of DNAmethylation in eukaryotes, for some or-
ganisms there is no evidence for DNA methylation, e. g., in the nematode worm
Caenorhabditis elegans. Others, like Saccharomyces cerevisiae, are borderline cases,
where some studies report DNA methylation and others do not. Even if methy-
lation is clearly present, the percentage of methylated cytosines varies consider-
ably between species [Capuano 2014].
DNAmethylation is not uniformly distributed across all cytosines of the DNA.
First of all, in mammals DNA methylation is context specific. 5mC almost ex-
clusively occurs in the symmetric CpG context, were the methylated cytosine
is followed by a guanosine (G). An exception are neurons [Guo 2014b] and em-
bryonic stem (ES) cells, were a 10-25% of methylated cytosines were reported to
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be in non CG context (nonCpG) [Ramsahoye 2000, Lister 2009]. nonCpG methy-
lation was not only found in symmetric sites (mCHG, H=A,T,C) but also in non-
symmetric sites (mCHH, H=A,T,C) [Lister 2009, Ramsahoye 2000]. Furthermore,
some regions of the genome are strongly methylated, while others almost lack
methylation [Weber 2007b]. Low levels of methylation were found on DNA-
protein interaction sites [Lister 2009] and promoters, which are often located in
small CpG rich regions, called CpG-islands. However, CpGs outside such regions
are frequently methylated. Chances in the methylation level are denoted as hy-
pomethylation, when a region is less methylated than a reference, e. g., genome-
wide background, surrounding region, or same region in another sample, while
a gain of methylation with respect to a reference is denoted as hypermethyla-
tion. No context restrictions were found in plants were various contexts were
reported [Chan 2005]. Similar to mammals, the methylation rate in plants varies
between genomic regions. 5mCs are enriched in repeats, transposons and cen-
tomeric regions [Weber 2007b].
2.2.1 Function
DNA methylation is involved in several development processes, e. g., embryoge-
nesis [Guo 2014a, Mayer 2000], stem cell differentiation [Latham 2008], neuronal
and cancers development [Feinberg 2006, Dulac 2010, Esteller 2007], silencing of
regions, e. g., imprinted genes (genes expressed from only maternal or pater-
nal chromosome) [Li 1993] and X-chromosome [Avner 2001, Payer 2008], main-
tenance of genome stability [Weber 2007b], and correlates with the expression of
genes [Meissner 2008, van Eijk 2012, Weber 2007b].
The simplified and obsolete concept of promoter DNA methylation is a nega-
tive correlation between gene expression and themethylation state of the regula-
tory region [Jones 2012]. Either the regulatory region of a gene is highly methy-
lated and consequently the gene expression is repressed or the regulatory re-
gion is unmethylated and the gene is activated. Repression might be due to in-
hibition of protein binding to specific sequences directly by the modification it-
self or due to binding of Methyl-CpG binding domain (MBD) proteins. MBD pro-
teins bind to methylated CpGs and induce chromatin remodeling to a repressive
state [Klose 2006].
Indeed, in somatic cells both, the DNA methylation level and its effect on
gene expression, was found to be dependent on CpG density of the regulatory
regions [Meissner 2008, Weber 2007a]. Promoters with a low CpG density, called
nonCpG promoters, frequently show high methylation levels, whereas the vast
majority of promoters with a high CpG density, i. e., containing or within CpG-
islands, are unmethylated. A third group, promoters of intermediate CpG density,
i. e., containing weak CpG-islands, were found to be prevalently unmethylated.
But even in these regions a considerable proportion (20%) was methylated. At
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low CpG density promoters DNA methylation levels did not necessarily coincide
with activated gene expression. Even high methylation levels did not result in
repressed gene expression. Weber et al. [Weber 2007a] showed that the activity
of the genes at low CpG density promoters is independent from the methylation
level. However, themajority of promoters are high and intermediate CpG density
promoters, that show negative correlation between DNA methylation and gene
expression. While low DNA methylation levels are found at promoters of active
and inactive genes, high methylation levels are associated with repressed gene
expression. Taken together, methylation of promoters with an intermediate
or high CpG density is sufficient to inactivate gene expression, whereas the
sparse methylation marks of of low CpG density promoters are insufficient to
silence the expression of genes. It is important to note that low levels of DNA
methylation do not suffice to initiate the expression of genes.
During mammalian development the DNA methylation is dy-
namic [Guo 2014a]. Both, the maternal and the paternal genome, are de-
methylated in early stages. However, this process differs in schedule and
pace [Guo 2014a, Mayer 2000]. Shortly after zygote formation, active de-
methylation of the paternal genome erases almost all methylation marks. When
replication starts, the maternal genome, which at zygote formation showed
a lower methylation level than the paternal genome, looses its methylation
marks due to replication dependent, passive de-methylation [Guo 2014a]. At the
post-implantation stage global de novo methylation was observed, although CpG
islands were not affected [Guo 2014a]. This process does not affect imprinted
genes.
The parent-of-origin dependent, mono-allelic expression of imprinted genes
is controlled by DNA methylation, histone modifications, insulators and long
non-coding RNAs [Ferguson-Smith 2011, Bartolomei 2009]. The maternal and
paternal alleles are differentially methylated at an imprinting control re-
gion (ICR) which results in repression or activation of a cluster of genes.
This methylation imbalance is already established during early embryonic
development and the methylation pattern is not eliminated by reprogram-
ming [Matsuzaki 2015]. The identification of ICRs by the methyltransferases is
not fully understood [Bartolomei 2009, Li 2013]. However, distance betweenCpGs,
methylation prevention by histone marks and the influence of some transcripts
were shown to be necessary for the establishment of ICRs [Li 2013]. Anyway,
it is widely believed that imprinting of genes is crucial for embryonic devel-
opment, especially for brain and mesodermal development and some disorders
have been associated with 3 the disturbance of ICRs [Li 2013, Matsuzaki 2015,
Bartolomei 2009].
A well investigated imprinting-like phenomenon is the maintenance of X
chromosome inactivation [Avner 2001]. One of the two X chromosomes of female
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mammals is epigenetically silenced to avoid over-expression of X chromosomal
genes. In contrast to imprinting, the inactivation is random and not parent-of-
origin-specific. The inactivation process is initiated by the expression of the non-
coding RNA Xist from the X-chromosome-inactivation-center (Xic). Xist succes-
sively coats the X chromosome and acts in cis to induce silencing of X chromo-
some expression. This initial silencing process includes chromatin remodeling
and promoter hypermethylation. After inactivation, Xist is not necessary any-
more and repressive chromatin marks and hypermethylation ensure long-term
maintenance of the inactive state.
The most prominent group of diseases associated with epigenetic al-
terations are neoplastic malignencies, i. e., cancer [Baylin 2005, Ehrlich 2002,
Feinberg 1983]. These alterations are non random and different tumors types
and subtypes have distinct methylation profiles [Costello 2000]. The vast major-
ity of cancers show global hypomethylation as well as region specific hyperme-
thylation in contrast to the respective normal tissue. Global hypomethylation
in cancers already was found independently twice in the early 80ies by Ehrlich
et al. [Ehrlich 1982] and Feinberg and Vogelstein [Feinberg 1983]. The degree of
global hypomethylation differs between cancer types and stages and primarily
affects heterochromatin and repetitive regions [Ehrlich 2002], as satellite DNA,
Alu and LINE repeats. In contrast, some CpG rich regions, i. e., CpG islands and
promoter regions become hypermethylated early in the development of can-
cer [Ehrlich 2009]. Hypermethylation of unmethylated promoter regions, espe-
cially of tumor suppressor genes, was reported to result in subsequent silencing
of the corresponding gene [Ohm 2007, Baylin 2005]. Silencing by hypermethy-
lation was also found to correlate with loss of function mutations in the other
allel [Baylin 2005].
2.2.2 DNA methyltransferases
The establishment andmaintenance of DNAmethylation is done bymethyltrans-
ferases (DNMTs) (Fig. 2.3). Most DNMTs use S-adenosyl methionine (SAM) as a
methyl group donor to transfer its methyl group to DNA cytosines. They consist
of two domains with some highly conserved sequence motifs. After binding to
the DNA the unmethylated cytosines flips out of the DNA double helix into the
catalytic center of the DNMT where the methyl group is added [Huang 2003].
In mammals, the hereditability of DNA methylation pattern during cell divi-
sion is ensured by the maintenance DNA methyltransferase 1 (DNMT1). DNMT1
restores the methylation information on the daughter strand in the diagonally
symmetric CpG context. During replication, the initially symmetric methylated
CpGs on both strands become hemi-methylated. The daughter strand contains
unmethylated cytosines while themother strand is still methylated. These hemi-
methylated CpGs are detected by DNMT1 and the methylation information from
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Figure 2.3: DNA methyltransferases. DNA methylation (red dot) is established by the de novo
DNA methyltransferase 3A and 3B (DNMT3A, DNMT3B). After replication only the mother strand
is methylated while the newly synthesized strand is unmethylated. In the symmetric CpG context,
the methylation information is copied to the new strand by maintenance DNA methyltransferase
1 (DNMT1).
the mother strand is transferred to the daughter strand, resulting in two fully
methylated double-strands. In a non-symmetric nonCpG context the methyla-
tion information is lost on one of the two new double strands [Chen 2004].
The second family of active methyltransferases in mammals are the
de novo methyltransferase 3 consisting of two members, DNMT3A and
DNMT3B [Okano 1999]. These methyltransferases recognize unmodified
DNA as well in CpG and CHG (H=A,C,T) context as in asymmetric nonCpG context
and establish new methylated cytosines. The activity of de novo methylation is
predominantly found in embryonic tissues.
Other DNA methyltransferase homologs are DNA methyltransferase 2
(DNMT2) and DNA methyltransferase 3-like (DNMT3L). DNMT3L shows no enzy-
matic activity but is essential for maternally imprinted regions through interac-
tion with DNMT3A and DNMT3B [Hata 2002]. In vitro experiments showed that
DNMT3L stimulates the de novo methylation activity of DNMT3A [Suetake 2004]
and responses to themethylation state of the lysine 4 residue of histoneH3 (H3K4)
asmethylated H3K4 inhibits the binding of DNMT3L [Ooi 2007]. Although DNMT2
is highly conserved and able to bind to the DNA, in vitro no DNA methylation ac-
tivity was found [Dong 2001]. Instead, methylation activity at the aspartic acid
transfer RNA (tRNAAsp) was shown [Goll 2006].
2.2.3 DNA de-methylation
Even though DNAmethylation is rather stable in adult tissues, it undergoesmajor
changes in development and tumourigenesis. Therefore, not only de novomethy-
lation is necessary, but also the removal of methyl-groups from a cytosine posi-
tion, called de-methylation. This happens either in an active or passive process
and might occur on a global, genome-wide level or region specific.
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Passive de-methylation
Passive DNA de-methylation depends on the reduced activity or absence of
DNMT1. In each round of replication the newly synthesized strand remains un-
methylated and thereby the methylation pattern is gradually lost.
Active de-methylation
Active de-methylation can either happen via direct removal of the methylated
cytosine or via further modifications of the methylated cytosine. The direct en-
zymatic removal of the methyl-group would need a very high catalytic power
and no specific enzymes were consistently reported, yet. A modification de-
pendent de-methylation pathway has recently been published by Kohli and
Zhang [Kohli 2013] (Fig. 2.4). Key enzymes are the ten-eleven translocation
(TET) enzyme family members and the thymine DNA glycosylase (TDG). TET
enzymes oxidize 5mC to 5-hydroxymethylcytosine (5hmC). However, 5hmC is
only found in some tissues in higher levels, e. g., embryonic stem cells and neu-
rons [Tahiliani 2009, Kriaucionis 2009]. Furthermore, TET iteratively oxidizes
5hmC to 5-formylcytosine (5fC) and 5fC to 5-carboxylcytosine (5acC) [He 2011,
Ito 2011]. Apart from the ability of TDG to remove T-G mismatches by exci-
sion of the thymine [Cortázar 2007], it was reported to also target modified cy-
tosines [Bennett 2006]. Kohli and Zhang combined these enzyme activities to a
possible de-methylation cycle that involves multiple oxidation steps by TET en-
zymes followed by TDG dependent base removal. Finally, the abasic site is re-
placed by an unmodified cytosine by the base excision repair (BER) pathway.
2.2.4 Crosstalk of DNA methylation and histone modifications
DNA methylation and histone modifications are the major components of the
epigenome and associations of some chromatin marks with local but also global
DNA methylation levels were reported [Ooi 2007, Estève 2006]. Histone methyl-
transferases were shown to directly interact with DNMTs [Estève 2006, Viré 2006,
Estève 2009, Wang 2009].
While DNMT3L plays a role in de novo DNA methylation, Ooi et al. [Ooi 2007]
showed that DNMT3L binds specifically to the first residues of the histone H3 tail.
The binding abilitywas not influenced by histonemodifications in the binding re-
gion – except for any kind of methylation of lysine 4 (H3K4me). They concluded,
that H3K4methylation protects the DNA from de novomethylation by preventing
of DNMT3L binding. This finding provides an explanation of the low methyla-
tion level of promoter regions which are characterized by a high level of H3K4
methylation.
In contrast, H3K9was shown to facilitate DNAmethylation [Estève 2006]. The
histone methyltransferases G9a and SUV39H1, which set the transcriptional re-
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Figure 2.4: Active DNA de-methylation. (a) De-methylation pathway for DNA methylation. TET
enzymes oxidize methylated cytosines until the resulting base is excised and replaced with an un-
methylated cytosine. (b) List of reactions and reactants possibly involved in de-methylation. (From
Kohli et al. [Kohli 2013].)
pressive methylation marks at H3K9, also interact with DNMT1, DNMT3A and
DNMT3B. This interaction maintains the histone and DNA methylation during
replication. DNMT1 guides the histone methyltransferases to replication foci,
where they form a catalytically active complex, that methylates both, DNA and
histones.
Furthermore, the PcG protein EZH2, a member of the PRC2, interacts with
the DNMTs and enhances the methylation of EZH2-repressed genes [Viré 2006].
Actually, EZH2 is a histone methyltransferase, that targets histone H4K27 and
initializes transcriptional repression of the associated genes by chromatin rear-
rangement. Another member of the PRC2, EED, interacts with DNMTs, such that
the DNMTs are guided to the EZH2 target genes. Methylation of these regions is
assumed to stabilize the inheritance of the epigenetic repression.
A rather complex interaction of the histone and the DNA methylation sys-
temwas found byWang et al. [Wang 2009]. In absence of lysine-specific demethy-
lase 1 (LSD1), which de-methylates histones H3K4 and H3K9, a global loss of DNA
methylation was found. Wang et al. suggested, that this might be due to the de-
methylation and subsequent destabilization of DNMT1 by LSD1. In addition, an-
other histone methyltransferase (Set7/9) was found that can methylate DNMT1
to de-stabilize the protein [Estève 2009]. These findings give evidence for the
joint regulation of the two epigenetic levels.
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2.3 Sequencing the Epigenome
The most frequent application of Illumina sequencing is the variant discov-
ery in whole-genome re-sequencing or whole-exome capture capture experi-
ments [Metzker 2009]. However, another important application is the genome-
wide sequencing of epigenetic marks, e. g., Methyl-seq, DNase-seq and ChIPseq.
2.3.1 Experimental methods
ChIPseq
ChIPseq is based on the chromatin immunoprecipitation (ChIP) technique pub-
lished in 1988 [Solomon 1988]. ChIP is used to detect interactions between DNA
and proteins, such as transcription factors, chromatin modifying complexes or
chromatin marks in vivo [Solomon 1988, Valouev 2008, Landt 2012, Jothi 2008].
Basically, DNA-protein complexes are crosslinked and antibodies are used to
selectively bind and filter the crosslinked DNA-protein fragments. After re-
moval of the antibodies and proteins, the remaining DNA sequences are en-
riched for the genomic target region, i. e., regions containing the targeted pro-
tein or histone mark. In ChIPseq this enrichment of the DNA fragments is fol-
lowed by high-throughput sequencing to gain the DNA sequences of the frag-
ments [Valouev 2008, Landt 2012].
DNase-seq
DNase-seq is the sequencing of DNase I hypersensitive sites which mark open
chromatin regions that are depleted of nucleosomes. These sites are related to
transcriptional activity and regulatory regions in vivo and sensitive to nuclease
cleavage like DNase I [Gross 1988]. DNase I is used to digest DNA, resulting in DNA
cut at regions with open chromatin [Song 2010]. The short fragments (up to 200
bps) from DNase I hypersensitive sites are separated from the longer nucleosome
containing segments and the purified DNA fragments are sequenced. Further-
more, DNase-seq is used to identify binding sites of some specific transcription
factors [Hesselberth 2009, Neph 2012].
Methyl-seq
Methyl-seq summarizes various approaches to determine the methylation land-
scape of DNA cytosines. Specific methods are necessary since the methylation
information is lost during amplification and hybridizationmethods do not distin-
guish betweenmethylated and unmethylated cytosines [Laird 2010]. DNAmethy-
lation is commonly sequenced either using enrichment based (MeDIP-seq, MiGS-
seq) or bisulfite conversion based (MethylC-seq, BS-seq) methods. Bisulfite con-
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Figure 2.5: Sodium bisulfite treatment. Treatment of unmethylated cytosines with sodium bisul-
fite results in deamination to uracil, while methylated cytosines are not modified. Subsequent
sequencing results in thymine instead of an unmethylated cytosine and methylated cytosines are
represented as cytosines.
version is also used formethylation arrays (e. g., InfiniumHumanMethylation450
BeadChip).
Methyl-DNA immunoprecipitation (MeDIP) [Weber 2005] uses a monoclonal
antibody against methylated cytosines to extract methylated DNA fragments
with immunoprecipitation. A similar approach is used in MBD-isolated Genome
Sequencing (MiGS) [Serre 2010]. Instead of an antibody the methyl-CpG binding
domain of the MBD2 protein is used to isolate methylated DNA. Limitations of
enrichment based methods are the resolution of methylation detection. Single
methylated cytosines are not detected since more than a single methylated cyto-
sine is needed for efficient binding. Enriched fragments spanmore than a few nu-
cleotides therefore a binary methylation call is assigned to a whole window. Fur-
thermore, non-methylated regions can not be distinguished from non-covered
regions and lowly methylated cytosines may be missed [Harris 2010].
Bisulfite conversion based methods involve the pretreatment of DNA with
sodium bisulfite which results in the conversion of unmethylated cytosines
into uracil while methylated cytosines remain unaffected [Frommer 1992] (Fig.
2.5). Three techniques are used to build bisulfite libraries for sequencing,
MethylC-seq [Lister 2008] and BS-seq [Cokus 2008] especially for whole-genome
bisulfite sequencing (WGBS) and reduced representation bisulfite sequencing
(RRBS) [Meissner 2005]. In the MethylC-seq protocol methylated universal
adapters are used before treatment with sodium bisulfite and complementary
primers are used in PCR amplification. This results in two types of reads, +FW and
-FW, occurring at a balanced fraction. The BS-seq protocol involves two primer
ligation steps to avoid the amplification of insufficiently converted sequences.
First, adapters containing unmethylated cytosines and DpnI restriction sites are
ligated to the fragments. Sodium bisulfite treated fragments are amplified using
22 2 The other layer: Epigenetics
Figure 2.6: Read types. Depending on the protocol used for bisulfite sequencing, four types of
reads occur (+FW, +RW, -FC, -RC). Methylated cytosines (red) in the genome (left) are sequenced
represented as Cs in the reads (right) and unmethylated cytosines (blue) are represented as Ts in
the reads. The +FW and +RC (-FW and -RC) reads are obtained from the plus (minus) strand and
contain methylation information about cytosines on the plus (minus) strand, although the +RC (-
RC) reads show the sequence, except bisulfite related changes, of the minus (plus) strand.
complementary adapters to the completely converted first adapters. Then DpnI
is used to digest the first set of adapters and Illumina adapters are ligated for
a second round of amplification. Due to the two amplification steps, 4 kinds of
reads are obtained. Two of them are from the plus strand, +FW and +RC, and two
are from the minus strand, -FW and -RC (Fig. 2.6). The RRBS protocol is similar
to the MethylC protocol, but employs prior digestion with MspI. MspI cleaves at
CpGs, thus the fragments will have CpGs at the ends and the library is enriched
for CpG dense regions [Gu 2011].
The bisulfite conversion based methods allow for single-base resolution and
the methylation level rather than a binary call can be assigned to each covered
cytosine. Hence, hemi-methylation at allele specific methylated regions or het-
erogeneous methylation across cells can be detected. Due to its precision and
genome-wide coverage, bisulfite sequencing is the gold-standard technology for
DNA methylation analysis. However, the main limitation of bisulfite treatment
is that hydroxymethylated cytosines are not distinguishable from methylated
cytosines after conversion. The hydroxymethylated cytosines are converted in
cytosine-methylsulfonate which is sequenced as a regular cytosine [Huang 2010].
Since hydroxymethylated cytosines are present in mammalian DNA new ap-
proaches were developed for hydroxymethylation specific discovery, e. g., the
TET enzyme based oxBS-seq [Booth 2012] or TAB-seq [Yu 2012]. Further, biologi-
cal challenges are to avoid incomplete conversion, where unmethylated cytosines
remain cytosines and will be mis-interpreted as methylated cytosines, and the
degradation of the DNA due to bisulfite treatment.
2.3.2 Computational methods
Alignment
The huge amounts of data produced by high-throughput technologies are pro-
cessed using computational methods. Beside the control of the data quality and
removal of adapter sequences, thefirst step in data analysis is the sequence align-
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ment or assembly. Downstream analysis include base calling, annotation, vari-
ation calling, copy number or gene expression analysis. The goal of an align-
ment is to map each read to the original position in the genome the fragment
was obtained from. This process is also called mapping. In principle, an align-
ment is a series of edit operations. Typically, edit operations are replacements,
i. e., matches and mismatches, or insertions and deletions. The edit operations
comewith a cost – these costs are the “prior knowledge”, given by a scoring func-
tion [Needleman 1970] or a distance metric [Sellers 1974], that are used to opti-
mize an alignment. Several kinds of problems during the alignment may occur,
e. g., the search space is huge (3.2 GB human reference genome), the reads contain
errors, e. g., errors from amplification or sequencing and the reference genome
is imperfect, i. e., missing regions, low complexity regions, single nucleotide vari-
ations (SNVs) and genome rearrangements. Furthermore, nucleotides in the
genome are non-randomly distributed and contain repetitive regions. Thus,
reads may map optimally to multiple loci. To tackle these problems alignment
heuristics are used. Typically, a database storing the location of substrings from
the reference genome is used to identify all regions where a substring (seed) of
a read may map. Subsequently, an alignment of the full read is only done at the
seed positions tominimize the search space. Different alignment tools use differ-
ent strategies to find the optimal alignment with respect to a scoring function,
thus the performance of these tools differ among each other and are subject to the
alignment. The choice of the alignment tool can significantly affect the results of
the alignment and should be well considered.
Alignment of bisulfite sequencing
A challenge for the alignment of bisulfite sequenced reads is the conversion of
unmethylated cytosines into thymines. Using a regular aligner would result in
a mismatch and consequently in a lower chance to find the true origin of the
read. Increasing the allowed number of mismatches is no appropriate solution,
as non bisulfite related errors would also be accepted and the results of the align-
ment would suffer. Therefore, this mapping should allow regular C to C and T
to T matches as in a regular alignment, in addition to T to C alignments, with-
out a penalty. Non bisulfite related C to T mismatches should still be penalized.
For reads mapping to the reverse strand, the alignment needs to allow A to G
mismatches without penalties. Three main strategies to tackle this problem are
used by the most popular aligners [Otto 2012]. First, a reduced three-letter al-
phabet consisting of A, G and T is used. Here, all Cs are converted into Ts, in the
reads as well as in the reference genome. Subsequently, a regular alignment is
done, but due to the lower complexity, post-processing is needed to avoid false
positive hits. Such a collapsed alphabet is used by Bismark, BRAT, BS Seeker,
MethylCoder [Bock 2012] and in the seed search of segemehl. A second strat-
24 2 The other layer: Epigenetics
egy is to enumerate all possible combinations of cytosines and thymines instead
of the sequenced thymines for each read. The main problem is the rapidly (expo-
nentially) growing number of reads with respect to the number of Ts in the reads,
resulting in unfeasible alignment times. Thus, enumeration is rarely used, e. g.,
in the seed search of BSMAP. The third main strategy is the use of an asymmet-
ric alignment rule. It allows for Ts in reads to map without penalty to reference
Cs while Cs are penalized when aligned to any other letter than Cs. This strat-
egy is less efficient with respect to to time and memory consumption but results
in the most accurate alignment. RMAP, RRBSMAP, GSNAP and after seed search
segemehl and BSMAP use an asymmetric alignment rule [Bock 2012].
Calling of DNA methylation rates
From the alignment of the bisulfite sequenced reads methylation rates are called
for each sufficiently covered cytosine of the reference genome. To obtain reliable
methylation rates a minimum coverage of at least 15 reads containing methyla-
tion information is recommended [Ziller 2015]. It is important to note, that infor-
mative reads for a cytosine methylation on the forward strand are not the reads
thatmap to the forward strand, but reads that are obtained from it. For the BS-seq
protocol that are the +RW and the +RC reads, even though the +RC reads map to
the reverse strand. Specifically, +RC reads map with a G to G match to the reverse
strand if the plus strand cytosinewasmethylated orwith anA toGmismatch if the
plus strand C was unmethylated. Correspondingly, the -FW and -RC reads yield
information about the methylation state on the reverse strand cytosines, respec-
tively. Typically, an estimate of the methylation rate of a forward strand cytosine
is the ratio of informative reads with a C to C mapping to the total number of in-
formative reads (methylation rate = #C#C+#T ). To avoid invalid methylation calls,
positions that are likely to be SNVs are discarded. A majority voting strategy can
be used to only consider positions where cytosine or thymine are the most fre-
quently sequenced bases [Otto 2012].
In a biological sense the methylation rate is the fraction of a methylated cy-
tosine in the sequenced sample at a specific position. The precise declaration
whether a cytosine is methylated or not is difficult. Assuming a single haploid
cell is sequenced, a fixed position x of the genome is eithermethylated or not, re-
sulting in amethylation rate of 1 and 0, respectively (Fig. 2.7 A). However, already
a diploid cell contains the position x twice (x1, x2), once on each chromosome.
This results in three possible methylation rates, i. e., 0, 0.5, or 1 (Fig. 2.7 B). A
methylation rate of 0 requires both positions x1, x2 to be unmethylated. Hemi-
methylation (∼ 0.5) results from either x1 or x2 to be methylated. A methylation
rate of 1, is only possible if x1, and x2 are methylated. The classification is dif-
ficult when considering a common sequencing experiment with millions of cells
being sequenced at once. In a simplified example, amethylation rate of 0.5 can be
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Figure 2.7: Schematic of biological composition of DNA methylation. (A) A specific cytosine
at a single chromosome is either methylated or not, resulting in a methylation rate of 0 (left) or
1 (right). (B) Considering a diploid cell, methylation rate would be 0, if both chromosomes are
unmethylated at a specific position (left), 0.5, if only one chromosome is methylated and the other
one is unmethylated (center) or 1, if both chromosomes aremethylated at the sameposition (right).
(C) In a common sample sequenced with todays technologies, a methylation rate of ∼ 0.5 could
result from a variety methylation distributions. Each cell could be either methylated or not (left),
each cell could be hemi-methylated (center) or some cells aremethylated, some unmethylated and
others are hemi-methylated (right).
explained either by (Fig. 2.7 C): all cells being hemi-methylated, or by half of the
cells being unmethylated and half fully methylated. In reality, the actual methy-
lation state of a CpG will be a superposition of these cases. Thus, the calculated
methylation rate is a measurement of the fraction of methylated cytosines found
at a positionx in a sample rather than a classification of cytosines intomethylated
or unmethylated positions.
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In the previous chapter key processes of epigenetic control have been intro-
duced. Cytosine DNA methylation has been shown to play an important
role in gene expression and cell di�erentiation. To analyze DNA methyla-
tion sequencing data accurately and reproducibly, we developed the mod-
ular bisulfite analysis toolkit BAT. It covers standard processing and anal-
ysis steps from raw read mapping up to annotation data integration and
calculation of correlating DMRs. This chapter is based on Kretzmer et
al. [Kretzmer ].
3.1 Introduction
Recently, a number of DNA methylation sequencing protocols like whole-
genome bisulfite sequencing (WGBS) and targeted bisulfite sequencing (e. g.,
RRBS) have made it possible to precisely and accurately capture this ma-
jor epigenetic modification. The impact of DNA methylation on several
processes like cell differentiation, gene expression, chromatin structure,
and cancerogenesis, raised the interest in sequencing and analyzing DNA
methylation on a genome-wide scale. Entire methylomes of a high number
of samples have been sequenced in a variety of cancer and developmen-
tal studies [International Cancer Genome Consortium 2010, Weinstein 2013,
ENCODE Project Consortium 2012a, Bernstein 2010, Martens 2013]. Further-
more, also studies about endemic disease, e. g., obesity, and neurodegenerative
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diseases, e. g., Alzheimer’s and Parkinson’s disease, begin to focus on DNAmethy-
lation analysis [van Dijk 2015, De Jager 2014, Schumacher 2006, Jowaed 2010].
Several steps of data analysis are required in virtually all projects and every
context, i. e., (quality) control, alignment, and methylation rate calculation.
Performing each single step by hand, however, is highly error prone, takes lots
of time, and reduces reproducibility. This means that consistent processing
of multiple samples in a study needs to be ensured, to avoid differences in
methylation patterns due to changes in processing. Specifically, analysis that
take multiple samples into account are required, since pooling of data leads to
loss of information. For 450k BeadChips data standardized workflows are already
established, but for bisulfite sequencing data no standards are set up until now.
Current tools and packages combine raw data processing steps, but analytical
steps are widely missing. Frequently covered analytical steps are simple DMR
calling methods, e. g., by QUMA [Kumaki 2008] and Methy-Pipe [Jiang 2014].
Even though some more pipelines were published, none of them cover the broad
variety of tasks that are needed for fundamental analysis.
One of the first DNA methylation analysis specific tools, BiQ
Analyzer [Bock 2005], focuses on quality control of the raw reads. In
brief, the mapping of raw data is carried out with a local version of
ClustalW [Thompson 1994] and visualizes the methylation of regions in a
web tool. While the mapping and visualization can be better tackled using
improved alignment and visualization software, the methylation data specific
quality control is up-to-date and still useful. Nevertheless, BiQ Analyzer
covers only a small part of a standard workflow needed and every single step
requires a user decision.
Another tool, QUMA, focuses on CpG methylation analysis. It covers the ma-
jor tasks of basic quality control, read mapping and DNA methylation rate call-
ing. In addition, it provides visual representations of local methylation patterns.
Conversion of called methylation rates or the coverage into convenient formats
is missing and resulst need to be extracted by hand from excel tables. As one
of the first pipelines, QUMA includes a statistical analysis between two samples.
Using Fisher’s exact test, single positions are tested for significant methylation
differences and the entire methylome is tested using the Mann-Whitney U-test.
In 2014, a more comprehensive tool, Methy-Pipe, was introduced.
Methy-Pipe covers the standard steps inmethylation data processing, e. g., read
alignment (BSAligner) and methylation rate calling, as well as calculation of
DMRs and visualizations. For DMR calculation, groups of samples can not be com-
pared, since DMRs are calculated between pairs of single samples using a sliding-
window approach. Statistics are plotted for easier interpretation of the data. For
example, methylation level averages and distributions are reported for user de-
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fined regions. Most importantly, however, integration of gene expression data
with annotated regions or DMR is not covered by Methy-Pipe.
Several other tools were published that focus on specific sub-tasks. The
minority takes annotation data into account and, to our knowledge, none of
them cover integration of gene expression.
BAT is a toolkit consisting of modular steps that facilitate an easy workflow
for analyzing bisulfite sequencing data. It covers the essential analysis steps of
read alignment, extraction ofmethylation information, and calling of differential
methylation as well as biologically relevant downstream analyses such as data in-
tegrationwith gene expression, histonemodification data, or transcription factor
binding site annotation.
The BAT workflow naturally follows a general guiding principle for analyz-
ing bisulfite sequencing data and enables fast and easy access to the topic. It
facilitates the analysis for biologists with the necessary biological background
but small bioinformatic knowledge as well as for bioinformaticians that already
worked on sequencing data but are not familiar with characteristics of bisulfite
sequencing data.
The default parameters for the tools included into the BAT pipeline are op-
timized to process bisulfite sequencing data for most applications. The smaller
number of parameters to be set by the user reduce potential errors and subse-
quently enhance the reproducibility of the entire analysis.
However, due to its modularity, the toolkit is flexible and can easily be
extended or customized to specific needs. For example, in contrast to WGBS
analyses, additional intermediate steps are necessary for RRBS data analyses.
To allow for workflow modifications and extensions, standardized formats
are used and interfaces to several other tools are facilitated. Basic steps, e. g.,
processing from raw reads to a single alignment file from multiple sequencing
runs, is split into its pre-, post-, and main processing steps, to allow for the
customized extension of the workflow. Error handling is eased by parameter and
file checks prior to the analysis and meaningful error messages support a fast
and straightforward trouble shooting.
A detailed documentation of all modules, including parameter description,
recommended additional tools, and data produced during the BAT workflow are
available at www.bioinf.uni-leipzig.de/Software/bat/. Moreover, all
automatically created visualizations are shown. These data and figures are de-
rived from a small example data set of two groups with four samples each, that
was adopted from Kretzmer et al. [Kretzmer 2015]. It consists of sequence and
methylation rate data from a small region of chromosome 19. They consist of
the raw FASTQ files of one sample, split into two smaller files, and the already
called methylation rate files of all eight samples. Furthermore, expression and
30 3 BAT - Bisulfite Analysis Toolkit
annotation data are integrated. This example data set, including the integrated
data, can be downloaded with the toolkit and all steps can be imitated in feasible
time. In addition, a run script, covering all modules of BAT, can be downloaded
and adopted to personal needs.
Usage information and options are given in section A.1.
3.2 BAT analysis workflow
Figure 3.1: Workflow of BAT. BAT comprises four modules covering (i) read mapping, (ii) methy-
lation rate calling, (iii) basic analysis, and (iv) DMR calling. The modules consist of a collection of
scripts that build up on one another, but easily single steps can be covered by alternative tools.
Several scripts plot graphics to visualize findings and statistics and standard formats, e. g., VCF,
BED, and BedGraph, are used as output format.
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Figure 3.2: Workflow of the mapping module. Themappingmodule consists of three scripts that
start from raw reads as initial input. The files, that are used for further analysis (blue), are the
mapped reads (single run) or merged mapped reads (multiple runs) files. In addition, statistics of
the mapping are calculated.
BAT consists of four main modules, i. e., alignment of bisulfite treated sequenc-
ing data (mapping module), extraction of DNA methylation information (calling
module), integration of groups of samples (grouping module), and investigation
of differential methylation (DMRs module) (Fig. 3.1).
In the following, the general workflow for analyzing bisulfite sequencing
data with BAT is described. The graphics, that are automatically generated dur-
ing the analysis, are used to illustrate the data visualization and quality check
ability of BAT. The data set used here was derived from a cancer WGBS data
set [Kretzmer 2015] and comprises two groups with 4 samples each.
3.2.1 Alignment of bisulfite treated sequencing data
The alignment of bisulfite treated sequencing data differs from the alignment
of untreated reads in a variety of characteristics. Even though the general tasks
are similar, there are bisulfite exclusive subtleties that also partly differ between
sequencing protocols. The alignment of bisulfite treated reads and subsequent
quality checks of the alignment are performed by the mapping module (Fig. 3.2).
Quality checks of the sequences are not included into BAT, since a variety of
specialized tools, such as FastQC [Andrews 2010] have been published. While
these tools are able to work with bisulfite sequenced data, one should keep in
mind that all statistics and quality evaluations are given with respect to whole-
genome sequencing. Themost crucial bisulfite specific deviation is the imbalance
in the “Per base sequence content” plot (Fig. 3.3 A). Due to the C-to-T conversion
of unmethylated cytosines, a very low fraction of Cs and a high fraction of Ts is
normal.
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Figure 3.3: Bisulfite specific quality control. A) Schematic representation of the imbalance in the
“Per base sequence content” plot showing an enrichment of sequences Ts and a reduction of se-
quenced Cs. This is due to the bisulfite induced C-to-T conversion. B) Digestion specific end-repair
bases at the end of the reads in RRBS. This artificial bases must be removed prior to methylation
rate calling. Figure adopted from Krueger et al. [Krueger 2013b]
To remove adapter sequences and trim for low quality bases tools like
cutadapt [Martin 2011] can be used. In case of RRBS sequencing protocol
specific characteristics must be considered. Due to the digestion process during
library preparation, bases (CG) are added to the sticky ends of the fragment
(Fig. 3.3 B). Alignment without removal of these artificial CpGs would lead to
misalignments and subsequent corruption of the methylation rates. Because of
these protocol specific characteristics all preprocessing of raw sequences has
to be left to the user and are therefore not covered by BAT. More sophisticated
tools, e. g., Trim Galore [Krueger 2013a], which is a wrapper tool around
cutadapt and FastQC, should be used for at least RRBS data. In addition to
adapter clipping and quality trimming, Trim Galore removes the artificial
bases at the ends of the reads.
After removal of potential quality issues, the read alignment is covered
by BAT_mapping. The supported tool, segemehl [Hoffmann 2009, Otto 2012],
is used in its specialized bisulfite mode to align bisulfite treated reads. This
mode ensures, that bisulfite-related mismatches are allowed without penaliza-
tion. Prior to the calling of segemehl, BAT_mapping checks for the presence of
the twobisulfite specific alignment indicies – onewith C-to-T and onewithG-to-A
conversions for alignment to the plus and theminus strand, respectively. If there
are no bisulfite indices of segemehl available, they will be built automatically.
segemehl runs two alignment routines, one for each conversion, andmerges
the two alignment runs afterwards. Since segemehl is capable of aligning reads
across regions of chromosomal strand breaks, post-processing of the alignment
is advisable. Alignments in such regions might show a high number of false-
stranded bisulfite mismatches, i. e., G-to-A mismatches during C-to-T mapping
run and vice versa. Those alignments cluster together and could lead to an fal-
sified methylation rate. BAT_mapping runs a post-alignment quality check and
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excludes those reads prior to further processing.
During the entire alignment process a log file keeping the working output
of segemehl is written to enable backtracking of possible errors. The final
alignment is in standard BAM format and can easily be used in other tools, e. g.,
the IGV [Robinson 2011] or UCSC genome browser [Karolchik 2014] for visual
inspections of coverage and read-distributions to enable early detection of
possible errors.
In addition, read alignment statistics are provided by BAT to allow the as-
sessment of alignment qualities, such as count statistics and frequency distribu-
tions. This allows to immediately check for contamination, low library complex-
ity, missed spike-ins, wrong or missed adapter clipping, or unfitting reference
genomes.
The quality reports are distinguished between single-end and paired-end
alignments as well as between reads aligned to one (unique) and multiple
locations. An alignment with 80% paired-end reads aligned to unique positions
indicates good quality of the data and the alignment. Lower numbers and
unusually high number of multiple hits indicate the enrichment of repetitive
or low complexity elements. When low percentages of unique mapped reads or
high percentages of multiple or single mate alignments are found, the data and
BAT parameters should be reviewed. The distribution of the e-distances of the
alignments are given for additional quality checks. The majority of the reads
should be mapped without non-bisulfite related mismatches. Thus, even though
a high number of reads was mapped, the e-distances are a good measurement for
possible errors, e. g., alignment to a wrong reference genome or contaminations.
In the case of replicates or multiplexing protocols that distribute samples
across multiple lanes using adapter sequences, it is common to pre-process
and align the samples separately. This strategy facilitates early detection of
sequencing or alignments problems and allows to exclude corrupted data sets
from methylation rate calling. BAT_merging covers this time-consuming step
of joining sequence alignments of multiple samples and enables the addition of
subsample-specific read group information, e. g., sample sequencing center. In
such a way, it is possible to subsequently trace putative batch effects or sequenc-
ing artifacts back to the original input file.
3.2.2 Extraction of DNA methylation information
Following mapping, the methylation information needs to be extracted from
the alignments (Fig. 3.4). Prior to this methylation calling it is, however,
recommended to exclude potential biases by clipping alignment overlaps of
paired-end reads, in particular when dealing with RRBS data. Again, due to the
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Figure 3.4: Workflow of the calling module. The methylation rate calling module consists of two
scripts that start from themerged or at least mapped reads as initial input. At first themethylation
rate for each cytosine of the reference genome are calculated. The files, that are used for further
analysis (blue), are the called methylation rates in VCF format and the filtered VCF.
the digestion process during library preparation, very short fragments might
be sequenced, such that mate alignments overlap [Krueger 2013b]. Methylation
rate calling without clipping of the potential overlaps, would lead to corruption
of the methylation rates since the same fragment was sequenced twice and thus
hold redundant information. To clip the overlaps of mates from the same frag-
ment, we recommend to use BamUtil’s clipOverlap [Wing 2015]. Incompletely
converted or artificially introduced cytosines can be detected with the M-bias
method, e. g., using BSeQC [Lin 2013]). These steps enhance the quality and the
certainty of the final methylation rates.
Subsequently, the methylation information can be extracted with
BAT_calling. Using the methylation rate caller haarz, BAT_calling re-
ports a VCF-like format that includes detailed information for each cytosine in
the reference genome and calculates the methylation rates as fraction of methy-
lated cytosines per position (#C/(#C+#T)). In addition to the raw methylation
rate, the sequence context, e. g., CG, the strand of the cytosine and, detailed
nucleotide composition of the position are given. Notably, the methylation rate
calling is not restricted to CpG positions.
To avoid corruption of the methylation rates due to SNVs, a majority voting
is performed to exclude positions with less than 50% aligned Cs or Ts. It is
also possible to additionally search for sequence variations during this step,
e. g., using Bis-SNP [Liu 2012] or BS-SNPer [Gao 2015]. These tools can easily
be integrated and provide a more sophisticated way to call SNVs in bisulfite
sequencing data and thus to exclude possible non-cytosine positions that would
otherwise possibly be called as unmethylated cytosines.
After methylation rate calling, it is highly recommended to restrict down-
stream analysis to sufficiently and reliably covered positions. This means a min-
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Figure 3.5: BAT_filter_vcf graphical output. A) Distribution of the coverage of all covered
cytosine positions of the reference genome. B) Distribution of the coverage of all covered cytosine
positions of the reference genome, restricted to the 0-90% quantile. C) Distribution of the coverage
of positions that passed the filters. D) Distribution of the methylation rate of all covered cytosine
positions of the reference genome. E) Distribution of the methylation rate of positions that passed
the filters.
imum coverage that avoids the loss of too many positions, but retains confident
methylation rates, e. g., 15 reads, as recommended in literature [Ziller 2015]. But
also a maximum coverage should be set, to exclude positions with an unusually
high coverage. At such positions, the methylation rates are error prone, since
there is a higher probability of either misaligned reads or a high read duplication
level than in other regions.
This step is automatized with the module BAT_filtering. It supports fil-
tering for genomic context as well as for minimum and maximum coverage, but
also for methylation rates, e. g., for nonCpG analysis. Along with the position fil-
tering, output files are provided for easy methylation rate inspection in IGV or
upload to the UCSC genome browser. This and automatically produced graph-
ics for coverage and methylation rate distributions, allow to check and possibly
finetune the filtering parameters. The graphics show the entire coverage distri-
bution (Fig. 3.5 A), the 0-90% quantile coverage distribution (Fig. 3.5 B) and the
coverage distribution of the filtered positions (Fig. 3.5 C). Issues with read cover-
age at the positions of interest can be detected at this stage. Re-sequencing of an
additional run should be considered if the coverage distribution is insufficient.
Similar figures are plotted for the methylation rate distribution of the initial po-
sitions (Fig. 3.5 D) and the filtered positions (Fig. 3.5 E). At an early state of the
analysis, this allows to easily compare different samples on a genome-wide level
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Figure 3.6: Workflow of the groupingmodule. The groupingmodule consists of three scripts that
start from the potentially filtered VCFmethylation rate files of several samples from two groups as
initial input. These files are summarized and coordinated into a set of files (blue). These files are
used for further analysis. In addition, several statistics and overview plots are created.
and allows for an additional library preparation and sequencing quality control,
e. g., insufficient bisulfite conversion are characterized by unusual highmethyla-
tion rates.
3.2.3 From single sample to group analysis
Usually, experiments investigate two or more groups of at least one sample each.
Thus, the single sample centered alignments andmethylation rate calls need to be
merged to analyze groups of multiple samples (Fig. 3.6). To ensure comparability,
the analysis of all samples must to be restricted to a subset of positions, that is
covered by a minimum number of samples per group. Moreover, this reduces the
risk of focusing on missing data based differences between the groups.
To combine and summarize the methylation information from individual
samples of two groups, BAT_summarize is used. It provides summary files for all
samples as well asmethylation ratefiles for each single sample. Furthermore, the
mean and difference methylation rates per group per position are provided. This
simplifies the merging step and offers several files and formats that are needed
for downstream analysis. Moreover, a single circos plot [Krzywinski 2009] con-
taining a genome-widemethylation rate heatmap for all samples is automatically
produced (average over bins, Fig. 3.7). Here, deviations in the homogeneity of
methylation rates in a single sample across the genome as well as genome-wide
trends between samples or groups are detectable. Extensive losses or gains in
a large region of either single samples or entire groups might also be already
visible at this level.
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Figure 3.7: Circos plot of BAT_summarize. Heatmap indicates the average methylation level of
bins for each sample. Here, 10MB bins were used. The colors indicate the methylation rate and
range from dark blue (0) via light blue (<0.5) and light red (>0.5) to dark red (1).
After reducing all samples to a joint set of positions, an overview of the
genome-wide similarities and differences of the two groups is useful to assess the
entire data set.
BAT_overview creates a panel of graphics to inspect the homogeneity
and difference between groups on single nucleotide level rather than in bins.
The strength and direction of methylation rate changes is evaluated in more
detail, which allows to detect the existence of rare changes. Rare changes are,
for example, changes contrary to the genome-wide change, or the methylation
level of CpGs that are subject to changes. First, boxplots of the genome-wide
average methylation level per sample are generated for each sample (Fig. 3.8 A).
These plots provide a graphical overview of the variability and difference on a
genome-wide scale of both groups. A second graphic visualizes a hierarchical
clustering based on all positions of all samples (Fig. 3.8 B). This plot represents
the similarities of the single samples and facilitates the identification of clusters
of samples as well as outliers. This also helps to detect errors in group or sample
classification, since group swaps of single samples or existing sub-groups can
be detected. This can lead to re-classification of samples or splitting of groups
to enhance the significance of the following analysis. Further plots are based
on the position-wise methylation rate averages of the two groups. The average
methylation rate distribution of the covered positions is binned into 5 bins
and the number of positions with the corresponding methylation average is
given (Fig. 3.8 C). The next plot shows the average methylation rate distribution
(Fig. 3.8 D). These two plots support more detailed detection of genome-wide
methylation rate shifts. Usually, the methylation rate is clearly bimodally
distributed in mammalian adult tissue, while for example in cancer tissue the
methylation rates frequently show an increase of intermediate methylation
rates [Hansen 2011]. Finally, two more plots provide a detailed view of the
change in methylation rates between the groups. This includes a smoothed
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Figure 3.8: BAT_overview graphical output. A) Boxplots of averagemethylation rate per sample.
B) Hierarchical clustering on the basis of the methylation rates of all positions in the summary or
metilene input file. C) Binned group-average methylation level indicating number of positions.
D) Distribution of group-average methylation rates. E) Smoothed scatter plot of the group-average
methylation rates. F) Counts of the difference of the group-average methylation rates.
scatter plot of the average methylation of the first group against the second
group (Fig. 3.8 E), for detection of methylation rate changes. In this example,
the majority of changes occurs at positions initially highly methylated in the
first group and lowly methylated in the second group. Only a small fraction
of positions that show a clear change in methylation rate are at positions that
were lowly methylated in the first group and hypermethylated in the second
group. The last plot provides count statistics of the difference of the average
methylation rates between the two groups (Fig. 3.8 F), to get an estimate of the
strength of hypo- and hypermethylation.
At this point the analysis frequently focuses on special regions (annotation
items). Especially, transcription factor binding sites (TFBS), CpG island-
s/shelves/shores, or chromatin annotations are often of interest in methylation
studies. This allows to investigate whether subsets of annotation items behave
different on a genome-wide scale, e. g., binding sites of transcription factor A are
differentially methylated between the two groups in contrast the the binding
sites of transcription factor B. This analysis indicates specific mechanisms that
are restricted to a group of annotation items. Additional data, like expression
values of the corresponding transcription factor, could also be considered in this
context.
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Figure 3.9: BAT_annotation graphical output. A) Length distribution of annotation items in
covered Cs. B) Length distribution of annotation items in nucleotides. C) Scatter plot of annotation
items length in nucleotides versus covered Cs (group A). D) Boxplots for each sample and the group
means showing the average methylation rate of group A annotation items (outliers are omitted).
E) Clustering heatmap showing the average methylation rate of group A annotation items for each
sample. F) Hierarchical clustering based both groups of annotation items.
Such analysis are facilitated by BAT_annotation. Here, average methyla-
tion rates in the annotation items are calculated and plotted for each group and
sample. A series of plots describes the length characteristics of the annotation
items. For each annotation item group the covered number of cytosines with as-
signed methylation rate [Cs] (Fig. 3.9 A) and nucleotides [nt] (Fig. 3.9 B) is plotted
separately. In addition, scatter plots of the length in nucleotides versus Cs of the
annotation items, separated by groups (Fig. 3.9 C), are plotted. This overview
helps to detect biases in length or number of covered Cs of the annotation items.
In addition, graphics showing the averagemethylation rate of all samples and the
group means are plotted per annotation item. The boxplots indicate the range of
average methylation rate per annotation item (Fig. 3.9 D). This enables the iden-
tification of items, that show unexpected or strong differences. Here only those
annotation items are considered, that cover at least one cytosinewith an assigned
methylation rate. The last series of plots are clustering heatmaps or hierarchical
clustering trees, depending on the number of annotation items. The heatmaps
or trees are separated by annotation item group (Fig. 3.9 E) and the final plot in-
tegrates the average methylation of all annotation items into a single heatmap
or clustering tree (Fig. 3.9 F). These plots can be employed to investigate the ho-
mogeneity of the samples in the annotation items. The clustering facilitates the
evaluation, whether changes in a group of annotation items are group specific or
occur throughout all samples.
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Figure 3.10: Workflow of the DMR module. The DMR module consists of two scripts that start
from the metilene input file. After DMR calling, the DMR annotation file is printed and are used
for further analysis (blue). In addition, statistics of the DMRs are plotted and in the second file
correlating DMRs are calculated.
3.2.4 Analyzing differential methylation
Finally, after the inspection of global methylation trends within the groups, dif-
ferential methylation between the groups needs to be detected and analyzed
(Fig. 3.10). Depending on the study, either identification of single differentially
methylated cytosines (DMCs) or differentially methylated regions (DMRs) is de-
sired. DMRs comprise de novo detected regions, that are predicted independently
of annotations, and predefined regions. Frequently used predefined regions are
annotation items like those that have been found to be of interest in the previous
analysis. The number, length, and methylation difference of the DMRs already
gives some idea about the severity of methylation rate changes. Furthermore,
DMRs/DMCs allow a comprehensive survey of the differences between groups of
samples and allows to identify affected genes and pathways.
The identification and characterization of differential methylation is done by
BAT_DMRcalling. It employs the DMR calling tool metilene [Jühling 2015],
that is introduced in chapter 4. The method is based on circular binary seg-
mentation of the group methylation difference signal in conjunction with a two-
dimensional non-parametric statistical test. metilene is able to detect DMCs,
work on predefined regions, or detect DMRs de novo. BAT_DMRcalling offers an
interface to filter metilene results accordingly to several criteria, e. g., length,
significance (i. e., q-value), and minimum mean methylation difference. In ad-
dition, characteristics of the detected differential methylation are visualized in
several plots and files for the visualization in the UCSC genome browser are pro-
vided.
The provided plots show the length distribution of the DMRs (Fig. 3.11 A, B)
and a scatter plot comparing the number of cytosines covered by a DMR with
its length (Fig. 3.11 C). These length distributions facilitate an evaluation of the
impact of the DMRs on gene expression and the length of affected regions allows
to get an estimate of the cytosine density of the DMRs. The distribution of the
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Figure 3.11: BAT_DMRcalling graphical output. A) Length distribution in nucleotides of the
DMRs. B) Length distribution in cytosines of the DMRs. C) Scatter plot of DMR length in cytosines
versus nucleotides. D) Distribution of the DMR differences. E) Scatter plot of the average methyla-
tion rate of the two groups. F) Scatter plot of DMR methylation difference versus DMR q-value.
significant methylation differences in a histogram (Fig. 3.11 D) provides a good
overview of the number of hypo- and hypermethylated regions or cytosines.
Also the mean methylation of the first group versus the mean methylation of
the second group is plotted (Fig. 3.11 E). From this plot it is easy to see whether
the initial methylation in the first group was high, intermediate, or already
low and whether those regions/cytosines are strongly or moderately hypo-
or hypermethylated. Finally, the methylation difference versus the q-value is
plotted (Fig. 3.11 F), to investigate differences in the significance level of hypo-
and hypermethylation.
Of course, the detection of differential methylation raises the question,
whether this influences the expression of associated genes. The association
between differential methylation and gene expression is commonly estimated
through spatial proximity. However, a more advanced method would be prefer-
able. This could be the integration of either Hi-C data, which shows interactions
between enhancer and promoter regions, or topologically associated domains. To
investigate the impact of the DMRs/DMCs on gene expression, their methylation
level can be correlated with the expression of associated genes.
The integration of methylation regions, e. g., DMRs or DMCs, with gene ex-
pression data is done byBAT_correlating. Given themethylation information,
the expression values of genes, and the association between regions (positions)
and genes, the correlation between both types of data can be examined in order
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Figure 3.12: BAT_correlating graphical output. cDMRplot showing the averagemethylation of
each sample in a scatter plot versus the expression of the corresponding gene. In addition, boxplots
indicate the variation in methylation (bottom) and expression (left) of the groups in boxplots.
to find correlating DMRs (cDMRs). For each DMR-gene pair, the linear pearson
correlation coefficient and the non-parametric, non-linear spearman correlation
coefficient are calculated. The non-linear correlation statistic should be used as
reference, since no linear dependency between the two entities can be assumed.
The correlation of each region is visualized as scatter plot that shows single
sample methylation rate - gene expression pairs for each sample (Fig. 3.12). Fur-
thermore, the variability in the methylation and expression values per group are
shown as boxplots.
These correlating regions are the optimal base for gene network or pathways
analyses. Inclusion of structural variation or mutation data can enhance these
analyses and allows for a comprehensive investigation of differences between
groups and deeper understanding of altered pathways and processes.
3.3 Summary
BAT has already successfully been applied in the framework of a large cancer
genome study, the ICGCMMML-Seq (chapter 5). Themain advantages, besides the
streamlined processing and analysis steps, are the reduction of user induced er-
rors and the acceleration of the data analysis. Its workflow represents a guideline
on bisulfite sequencing data handling. The modularity of BAT and its common
input and output formats are an important step towards a standardized analysis.
Furthermore, they allow the easy integration of alignment, rate calling or DMR
calculation tools as well as specialized tools for quality control.
The custom visualizations of the methylation data facilitate data mining and
allow to inspect the data quality at each step of the analysis. This is necessary to
increase the chance of an early detection of errors, e. g., in library preparation
and data handling. Therefore, quality control statistics and graphics are pro-
duced continually throughout the entire pipeline.
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Furthermore, BAT comes in a handy Docker [Merkel 2014] image as well as in
single scripts. Using the docker images, almost any hardware can be used inde-
pendently of the platform. Existing hard drives are mounted to avoid time con-
suming translocation or upload of the frequently huge data. All software depen-
dencies are secured and software used by BAT is already installed in the Docker
image. Thus, the user is not distracted by time consuming management of sys-
tem structure, installations and error management and can focus on the analysis
itself. The toolkit itself is written in Perl and calls software components mainly
written in C and R to ensure fast handling of time consuming tasks.
Taken together, BAT is a collection of modular steps for analyzing bisulfite
sequencing data that (i) can easily be run on various platforms due to the vir-
tualization via Docker, (ii) can be combined or extended by other software tools
(e. g., BSeQC for M-bias analyses) due to the use of standardized file formats, (iii)
automatically generates publication-ready graphics, and (iv) supports data inte-
gration, e. g., annotation or gene expression data.
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Whole genome bisulfite sequencing experiments (WGBS) and reduced rep-
resentation bisulfite sequencing (RRBS) protocolsmade it possible to study
cytosine methylation landscapes at single CpG resolution. Falling costs
and a high availability of next generation sequencing facilities have made
it feasible for a rapidly growing research community to study this impor-
tant epigenetic layer. The detection of di�erentially methylated regions
(DMRs) between di�erent conditions in large groups of samples requires
accurate and e�icient algorithms. At present this is a serious bo�leneck
in methylome analyses. In this chapter, a highly e�icient segmentation
algorithm to detect DMRs between single samples as well as in large sets
of biological replicates is presented. In contrast to other methods, the al-
gorithm proposed does not make assumptions on underlying distributions
or background models. Instead, we propose the use of a scoring model to
optimize inter-group methylation di�erences within a minimum interval
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of CpGs in conjunction with non-parametric tests. This approach is fast
and memory-e�icient enough to finish within minutes on a typical work-
station. The algorithm is fully parallelized, thus its computing time can be
reduced to a minimum using multiple cores. This chapter largely follows
Jühling and Kretzmer et al. [Jühling 2015].
4.1 Introduction
As one of the most important mechanisms of epigenetic control, localized dif-
ferential methylation has been associated with a wide variety of phenotypes
and conditions. These include cell differentiation [Cortese 2011, Sheaffer 2014],
tissue type and age [Day 2013] as well as pain sensitivity [Bell 2014]. Differ-
ences in DNA methylation levels have also been connected to many differ-
ent diseases like diabetes [Nilsson 2014], Alzheimer’s disease [De Jager 2014]
and coronary artery. Furthermore, differential DNA methylation plays a role
in many cancers, such as medulloblastoma [Hovestadt 2014] and B-cell lym-
phoma [Kretzmer 2015], and connects risk factors like age [Teschendorff 2010]
and smoking [Teschendorff 2015] with cancer. These studies show, that the
methylation of DNA is an an important regulatorymechanism and the loss or gain
of methylation proximal to transcription start sites, for example, is often associ-
ated with altered transcription. Spatially confined changes of methylation levels
can indicate binding or dissociation of transcription factors (TFs) to their tran-
scription factor binding sites (TFBS) or changes in the chromatin structure. Thus,
methylation levels can reflect protein-DNA interaction. Whole genomemethyla-
tion studies have shown that methylation landscapes are highly tissue specific
and allow to determine the differentiation status of cells. On the other hand,
global loss of methylation, common to many neoplastic diseases [Ehrlich 2009],
is frequently interpreted as a loss of epigenetic control.
To better grasp the methylation differences between different cell types or
tissues it becomes imperative to compare groups of individual samples, i. e., to
identify confined genomic regions where two or more groups of individuals sig-
nificantly differ in their methylation level (differentially methylated regions,
DMRs). Therefore, it is necessary to account for the methylation differences
among the groups as well as for the intra-group variances caused by individual
differences. This can be an important obstacle, especially for small sample sizes.
Furthermore, DMRs vary in length, making correct identification of DMR borders
an important task. The objective problem of finding DMRs has two dimensions:
the first dimension is to find a genomic region such that, in the second dimen-
sion, the individuals of two groups are significantly distinct in their methylation
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Figure 4.1: Dimensions of the problem. A DMR is defined as genomic region (1. dimension), in
that the methylation rates of two groups are significantly different (2. dimension).
levels (Fig. 4.1).
To tackle this important problem several algorithmical and statistical solu-
tions have been proposed so far. Typically, the methylation rates of single CpGs
are modeled using specific distribution. After testing for differential CpGs, DMRs
are inferred using a sliding window of fixed size or by clustering and trimming
algorithms. In summary, these methods rely on statistical models such as the bi-
nomial distribution or regression models to discover single differentially methy-
lated CpGs (DMC) that are later merged to longer DMRs. Furthermore, several
methods are restricted to “target regions”. BiSeq [Hebestreit 2013], is by de-
sign restricted to regions with a high density of sufficiently covered CpGs. After
smoothing the data, a beta regression model is fitted to each CpG site and a Wald
test is carried out to determine the group effects. Finally, the CpG clusters are
trimmed to remove non-differentially methylated CpGs. For regions with a low
CpG density, e. g., in vincity to transcription factor binding sites, accurate DMR
detection might suffer from local smoothing approaches [Sun 2014]. A smooth-
ing approach is also used in BSmooth [Hansen 2012]. MOABS [Sun 2014] also relies
on an extensive parameter fitting step and clusters the DMCs. For whole genome
bisulfite sequencing data, DMAP [Stockwell 2014] uses windows of fixed size to
carry out an ANOVA and F ratio test to assess differential methylation. Thus,
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DMAP requires the groups to have homogeneous variance and the size of DMRs
is constant. Similarly, methylkit [Akalin 2012] uses predefined regions that are
tested either with a logistic regressionmodel that requires fitting or a fisher’s ex-
act test. Predefined regions are also tested in MethylSig [Park 2014]. It is based
on a beta-binomial distribution. To fit this distribution, Park et al. employ a max-
imum likelihood estimation (MLE). The authors point out that the distribution
asymptotically approaches a χ2 distribution for large sample sizes. Because of
the fact that the sample size might not be sufficiently large, they propose to per-
form a t-test instead. DSS [Feng 2014] also uses afitted binomial beta-distribution
for testing single CpGs. In a subsequent step DMCs are clustered into DMRs given
“a number of user specified parameters” such as the length of the DMR,minimum
number of CpGs and the percentage of CpGs with a minimum p-value.
4.2 Method
We developed a segmentation algorithm to detect DMRs between single sam-
ples as well as in groups of samples (Fig. 4.2). As a distinguishing feature it does
not make assumptions on underlying distributions or background models, and
is applicable to WGBS as well as RRBS data without further parameter adjust-
ments. In contrast to other approaches, we propose a scoringmodel to findmaxi-
mum inter-groupmethylation differences within a genomic interval ofminimum
length in combination with a non-parametric test. Our approach, based on a cir-
cular binary segmentation (CBS) [Siegmund 1986, Olshen 2004], scans for pairs of
change points within the mean difference signal (MDS, difference of CpG-wise
mean methylation level in the groups), delimiting a region with homogeneous
methylation difference. Subsequently, intervals are tested for similarity using a
two-dimensional Kolmogorov-Smirnov-Test (2D-KS test) [Fasano 1987]. Initially,
the genome is pre-segmented to avoid calling DMRs containing long stretches
without methylation information. These regions are recursively segmented until
(i) a region contains less than a user-definednumber of CpGs, or (ii) no p-value im-
provement is achieved. Briefly, within a region [s, t] a window [a,b] is sought us-
ing the scoring function Zs,t(a,b), such that the MDS attains a maximal change.
The algorithm takes care of situations where regions of differential up- and
down-methylation are spatially adjacent, and checks for the existence of short
methylation valleys embedded into longer differentially methylated regions.
Therefore, a cutoff factor for the methylation difference when comparing global
and regional methylation differences is set. Thus forces to segment further until
no more valleys are found. Its influence can be reduced by decreasing the cutoff,
or it can be turned off. The effect of the valley filter on resulting DMR calls at dif-
ferent valley length and depths within the meanmethylation signal is illustrated
in Fig. 4.3. Depending on the cutoff, the methylation inside the valley, and its
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Figure 4.2: Workflow of metilene. After a pre-segmentation step to exclude non-informative
regions, the circular binary segmentation is used to identify regions with significant differential
methylation. The segmentation algorithm is applied recursively identify a window [a,b] with the
maximum difference of the cumulative sum of the mean methylation difference, indicating a po-
tential DMR.
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Figure 4.3: Valley filter. The effect of different cutoffs on the prediction of DMRs.
length, either a single DMR is called, or three DMRs of different length are called,
or two DMRs to the right and to the left of the valley are called while the valley is
not predicted as differentially methylated.
For a detailed usage information, input and output wrappers and an explana-
tion of further parameters see section A.2.
4.2.1 Foundations
The segmentation is based on a circular binary segmentation [Olshen 2004] in
conjunction with a scoring function similar to the function of Siegmund et
al. [Siegmund 1986], and Zhang and Siegmund [Zhang 2012]. In a first step, the
mean difference signal for each CpG (MDS):
MDS =
1
|A|
�
γ∈A
pγ −
1
|B|
�
δ∈B
pδ (4.1)
is calculated. Here, A,B are the sample groups that are to be compared and pγ
(pδ) is the methylation level of the given CpG position in sample γ (δ).
We use a slightly modified scoring function to account for decreasing values
in the MDS:
Zs,t(a,b) =
[|S(a,b)|− (b− a) · |S(s, t)|/(t− s)]2
(b− a)[1− (b− a)/(t− s)]
(4.2)
where Zs,t(a,b) denotes the score of window [a,b] in segment [s, t], and S(i, j)
4.2. METHOD 51
the sum of the MDS for the interval [i, j].
S(i, j) =
j�
0
MDS−
i�
0
MDS
Thewindow [amax,bmax]with themaximal increase or decrease in theMDS
within segment [s, t] is given by
Zmax(a,b) = max
s�a<b�t
|Zs,t(a,b)| (4.3)
Since we consider all samples of both groups, we have slightly modified the orig-
inally proposed formula [Siegmund 1986]. By maximizing we find the window in
[s, t] that shows the maximal possible change in the MDS. This window is marked
as a potential DMR.
The statistical significance of potential DMRs is assessed by a two-
dimensional version of the Kolmogorov-Smirnov-Test [Fasano 1987] to calculate
p-values during segmentation and to use it as termination criterion during re-
cursive segmentations. The output of metilene provides the adjusted and un-
adjusted p-value for the 2DKS-Test and additionally the results of an independent
Mann-Whitney-U test.
4.2.2 Algorithm
The pseudocode of the algorithm is shown in the appendix (Alg. 1). Initially, the
genome is pre-segmented into regions that do not have subintervals longer than
tdist (default: 300 nt) without methylation information. The pre-segmented re-
gions are recursively segmented. First, the window [a,b] with the maximal ab-
solute change in the MDS in a region [s, t] is identified via Zmax (Equation 4.3).
This results in three sub-regions: [s,a− 1], [a,b], and [b+ 1, t].
Second, termination criteria are checked for all three sub-regions. Every sub-
region that fulfills none of the termination criteria is further segmented, starting
with the first step. We use two distinct termination criteria: (i) number of CpGs
< tmin (default: 10), and (ii) a p-value based termination criterion, i. e., the p-
value of a sub-region must be larger than the p-value of the parental region. To
save computational time, the p-value of a region is not calculated, if (i) the seg-
ment contains awindow of tmin consecutive CpGswith amuchweakerMDS than
the total segment, or if (ii) the signs of MDS have no major trend, i. e., we find a
balanced number of both positive and negative values. In such regions segmen-
tation is directly continued.
Please note, that except for the tmin criteria, there are no additional con-
straints or parameters for the minimum length of an interval [a,b] or [s, t]. The
effect of different tmin settings is shown in Tab. A.12. The parameter does affect
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the performance of metilene only in WGBS data when it is set to large window
sizes.
Third, after the termination of the recursion, the sub-region associated with
the lowest p-value is flagged as a potential DMR. All surrounding sub-regions are
merged and recursively segmented again.
Missing data estimation
Methylation rates of missing data (pmis) are estimated from a beta distribution
pmis ∼ Beta(α,β). The parameters α and β are calculated from the mean (µr)
and variance (σ2r ) of the remaining methylation rates at the corresponding CpG
position:
α = (
µr(1− µr)
σ2r
− 1)µr
β = (1− µr)(
µr(1− µr)
σ2r
− 1)
Positions with more than a user defined number of missing values are omitted.
4.3 Evaluation
A DMR caller should detect significant differences between groups of sam-
ples independently of the background, and with the exact genomic bound-
aries. metilene was compared to three of the frequently used DMR detec-
tion tools, i. e., MOABS (v1.2.9) [Sun 2014], BSmooth (v.1.0.0) [Hansen 2012] and
BiSeq [Hebestreit 2013] (v1.2.5), using artificial and real-life data.
4.3.1 Artificial data simulation
All DNA methylation simulations were performed on the human chromosome 10
using a Beta-Binomial approach implemented inR [R Core Team 2014] to simulate
both, biological methylation and the sequencing step. The script for the DMR
simulation as well as the data that was used for the benchmarks is available at
www.bioinf.uni-leipzig.de/Software/metilene/.
4.3.1.1 Background
We simulated two different backgrounds to account for promoter and non-
promoter differences. Since the overall sequence composition in promoters is
expected to be different to non-promoter regions, and to do the simulation in
a more realistic fashion, we used the ENCODE chromatin state segmentation of a
lymphoblastoid cell line (GM12878) [Ernst 2011, Ernst 2010, Raney 2011] to obtain
a set of real promoter and non-promoter regions on chromosome 10.
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non-promoter promoter
α β α β
background 1 40 3 3 40
background 2 15 5 5 15
Table 4.1: Parameters for the beta distributions to simulate background methylation rates.
For the 20 simulated samples, methylation rates pwere drawn from beta dis-
tributions (Beta) with parameters α and β to obtain p ∼ Beta(α,β). The dis-
tributions of the two simulatedmethylation backgrounds (Tab. 4.1) are visualized
in Fig. 4.4 A.
Junctions between the non-promoter and the promoter backgrounds were
blurred using a weighted, local polynomial regression fitting (loess; span value
of 0.2). Specifically, the methylation rate of 25-50 CpGs (uniform sample) around
each junction was smoothed by setting it to the average of the raw and the fitted
value.
Subsequently, an artificial read coverage n was assigned to the CpGs by sam-
pling from a normal distribution (N) with mean µ = 30 and standard deviation
σ = 5. The minimum required coverage was set to ε = 15 reads. For the simulation
of lowly methylated data, the parameters were set to µ = 7, σ = 2 and ε = 3:
n∗ ∼ N(µ,σ2)
n = min(n∗, ε)
To determine the number of these reads with CpGs indicating methylation
m ∼ B(n,p) was drawn from a binomial distribution (B) with parameters n and
p for coverage and methylation rate, respectively.
4.3.1.2 Foreground (DMRs)
To simulate the foreground, i. e., the DMRs, the 20 samples were split into two
groups of 10 samples. A total of 1,000 DMRs were introduced into the simulated
background of each group. We introduced an equal number of hypermethylated
DMRs into promoter (n=500) and hypomethylated DMRs into non-promoter re-
gions (n=500). To generate the DMRs, the parameters α and β of the background
where swapped, i. e., a DMR within a promoter region was simulated using the
beta-distribution for the non-promoter regions and vice versa. To account for
DMRs of different intensities, the values were mixed from both beta distributions
and multiplied with different mixing factors c
p ∼ Beta(α,β) · c+Beta(β,α) · (1− c)
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Figure 4.4: Distributions of methylation rates for backgrounds and DMRs. A) Two different
background distributions were used to simulate non-promoter (top) and promoter (bottom) re-
gions. B) The distributions of meanmethylation differences in DMR regions for the combination of
the two simulated backgrounds with four different mixture ratios. This allows to simulate a com-
prehensive grading set of DMRs between easily (class 1 DMRs – background 1, top – yellow) and
difficultly (class 4 DMR on background 2, bottom – red) distinguishable.
to generate a total of 4 different DMR sets. The mixture factors c are given in
Table 4.2, all resulting distributions of DMR classes 1-4 are visualized in Fig. 4.4 B.
Again, the number of reads without conversion was drawn from the binomial dis-
tribution.
Reduced bisulfite sequencing datawas simulated in a similar fashion. Weused
the regions covered by the publicly available RRBS data set of GM12878. In total,
200 DMRs, 100 DMRs in promoters and 100 DMRs in non-promoters, with a max-
imum length of 40 nt were place inside these regions using the same parameters
as for the WGBS simulations.
DMR class Mixture factors c
1 1
2 0.87
3 0.73
4 0.60
Table 4.2: Mixture factors of random variables sampled from beta distributions for the simulation.
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4.3.1.3 Noise
To investigate the robustness of our DMR detection method, in one of the artifi-
cial data sets (background 1 and class 1 DMRs) methylation rate outliers (noise)
were introduced. This results in a less homogeneous data set with single posi-
tions representing random errors that for example might result from an SNV in a
single sample. Therefore, all DMRs were gradually distorted by replacing 10-90%
of themethylation rates with uniformly distributedmethylation rates pr ∈ [0, 1]
for all samples.
4.3.1.4 Low coverage
A low-coverage artificial data set was simulated containing 10 vs. 10 samples of
class 1-4 DMRs on background 1. All samples had a mean coverage of only µ = 7
with a standard deviation of σ = 2 and a minimum coverage of ε = 3.
4.3.1.5 Missing data
The data set containing 10 vs. 10 samples of class 1 DMRs on background 1 was
simulated and methylation values were removed at a probability of 10-90% to
resemble data sets with different degrees of missing values.
4.3.2 Performance evaluation
4.3.2.1 Artificial data
All segmentation tools were run in their default settings and for MOABS the
maximal distance between two consecutive DMCs to be considered in a DMR
(maxDistConsDmcs option) was set to 300 nt to be comparable to metilene
and BSmooth. Because BSmooth terminated with a runtime error, local correc-
tions were switched off for the RRBS data analysis (local.correct=F). Pre-
dicted DMRs were filtered to a minimal absolute methylation difference (avg.
MDS) larger than 0.1 which is in accordance with the cutoff recommended also
by BSmooth. By default BSmooth only reports significant DMRs. The output of
MOABS and metilene was filtered for DMRs with an (adjusted) p-value � 0.05.
The performance was evaluated in terms of CpG-wise and DMR-wise true positive
rates (TPR) and positive predictive values (PPV). In the following we distinguish
between sets of CpGs (C) and sets of CpGs within DMRs (D). A set of DMRs is
denoted by (D). The sets of simulated and predicted CpGs inside simulated and
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predicted DMRs are defined by
Csim = {c ∈
�
D∈Dsim
D}
Cpred = {c ∈
�
D∈Dpred
D}
Furthermore, we define true positive (TP) CpGs (CTP) as those CpGs in simulated
DMRs that were correctly predicted by the segmentation tool. This definition
includes all those CpGs that are in the overlap between simulated and predicted
DMRs. Thus,
CTP = Csim ∩Cpred
is the set of true positive CpGs. We calculate
PPVCpG = |CTP |/|Cpred|
TPRCpG = |CTP |/|Csim|
to obtain the benchmarks on the CpG resolution level. For the region-wise evalu-
ationDTP is the set of predicted DMRs where more than 50% of the DMRs’ CpGs
are simulated to be differential, i. e., elements ofDsim. On the other hand,DTP�
is the set of simulated DMRs wheremore than 50% of the DMRs’ CpGs are inDTP.
Given
DTP =
�
D ∈ Dpred
���� |CTP ∩D||D| > 0.5
�
C�TP =
�
D∈DTP
D
DTP� =
�
D ∈ Dsim
���� |C�TP ∩D||D| > 0.5
�
we calculate
PPVDMR = |DTP |/|Dpred|
TPRDMR = |DTP� |/|Dsim|
to obtain the benchmarks for the region-wise comparison analogously. Note,
that the distinction betweenDTP andDTP� is necessary due to a possible m-to-n
rather than an 1-to-1 association between simulated and predicted DMRs.
Accuracy of DMR boundaries
Boundaries of predicted DMRs were compared to simulated DMRs. More pre-
cisely, the distance (in CpGs) between the boundaries of each simulated DMR and
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its closest predictedTPDMRwas calculated. To analyze and compare the accuracy
regarding the boundary detection of the different segmentation tools, the empir-
ical cumulative distribution function of the absolute values of these distanceswas
used.
4.3.3 Evaluation of runtime and memory requirements
The running time of all tools was measured using the unix time command while
the maximal residual memory consumption (RAM) was tracked by the unix ps
command. The evaluation was done separately with ten cores and one core of a
clusterwith the following specifications: Intel®XEON™ E7540 CPU@ 2.00GHz× 24,
520 GB RAM. To measure memory and runtime requirements for the WGBS data
set we used 10 cores of the same clustermachine. To evaluate metilene’s perfor-
mance in a environment with restricted computational resources, theWGBS data
set was additionally processed on a desktop machine with the following specifi-
cations: Intel®Core™ i5-4570 CPU@ 3.20GHz× 4, and 7.8 GB RAM.
4.4 Results
4.4.1 Performance tests on artificial data
4.4.1.1 WGBS
The simulated 8 data sets of different levels of complexity (Fig. 4.4) were used for
performance tests. Two groups with 10 samples each were simulated. A perfor-
mance evaluation in terms of the true positive rate (TPR) and positive predictive
value (PPV)was carried out for CpGswithin simulated and predicted DMRs aswell
as for predicted DMRs overlapping with� 50% of simulated DMRs.
Almost all DMRswith largermethylation differences (DMR classes 1 & 2) were
correctly predicted by metilene and MOABS on both, the CpG (Tab. A.13) and the
DMR level (Tab. A.14). With a TPR below 0.5 BSmooth had difficulties identifying
simulated DMRs (Fig. 4.5 A). For DMRswith smallermethylation differences (DMR
class 3) in regions with difficult background methylation (background 2) the ad-
vantage of metilene was more apparent: While the TPR of MOABS dropped be-
low 40%, metilene still reported 99.8% of the DMRs. A similar TPRwas achieved
by metilene for the most challenging DMR class 4 in background 1. A drop in
sensitivity of metilene (TPR≈ 0.5) was only observed for the complicated back-
ground. MOABS did not predict any class 4 DMRs. metilene showed a PPV �
0.989 in all scenarios.
metilene predicted the starts and ends of DMRs (Fig. 4.5 B, Fig. A.2) within
a very small margin of error, independent of the background type and the DMR
class. MOABS performed less accurately for the simple data. Likely due to the
efficient smoothing step, BSmooth improvedwithmore complicated background
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Figure 4.5: Evaluation of artificial data. A) The performance of metilene, MOABS, and BSmooth
was assessed in terms of true positive rates and positive predictive values (PPVs) for different
classes of DMRs. The evaluation was performed in terms of the fraction of correctly predicted
CpGs within simulated DMRs (top) as well as in terms of simulated and predicted DMR segments
with an overlap of at least 50% (bottom). B) Boundary detection analysis for strong (left) and weak
(right) differences in the background methylation level. See stabtime memory and stabtime mem-
ory real for details. C) Results for metilene, MOABS, and BSmooth on a the low coverage data sets.
D) Runtime and memory consumption on a single core and 10 cores.
methylation. To verify the robustness of predictions we simulated low coverage
data. Here, metilene came up top in both, PPV and TPR (Fig. 4.5 C). In addition,
different levels of noise were introduced. Except for very high noise, MOABS and
metilene performed comparably (Fig. A.3).
Runtime and memory consumption.
On a single core metilene used approximately four minutes to analyze the sim-
ulated data set (chromosome 10) with 2×10 samples. The runner up with re-
spect to the results, MOABS, neededmore than 65 hours to perform the same task,
while BSmooth took 2.3 hours. The memory consumption of metilene was be-
low 1GB, while MOABS (5.4 GB) and BSmooth (10.7 GB) used substantially more
RAM. When running the tools on 10 cores, MOABS used approximately 9 hours,
BSmooth 23 minutes and metilene around one minute. The memory consump-
tion of metilene and MOABS increased only slightly while BSmooth used more
than 90GB in the multi-threaded mode (Fig. 4.5 D).
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4.4.1.2 RRBS
We explored the performance of metilene on RRBS data and found similar
results without further parameter adjustments. We added another specialized
RRBS tool, i. e., BiSeq, and showed that metilene still performs favorably re-
garding the prediction power (Tab. A.15, Tab. A.16, Fig. A.4), boundary detec-
tion (Fig. A.5) as well as runtime and memory requirements (Tab. A.17). In
some test scenarios, BiSeq and metilene showed comparable results regard-
ing TPRs. However, BiSeq did not reach metilene’s PPV. The results of MOABS
and BSmooth on RRBS data are comparable to the results on WGBS data.
4.4.2 DMR calling on biological data
DNA methylation data of 12 human medulloblastoma tumors (subgroup 4) and 8
human normal controls were taken from Hovestadt et al. [Hovestadt 2014]. The
qualitative analysis of the WGBS data set with 12 vs. 8 samples (22,524,970 data
points without missing values) was restricted to chromosome 10 with a total
of 1,111,583 methylation data points. All DMR calling tools were run in their
default settings and for MOABS the maximal distance between two consecutive
DMCs to be considered in a DMR (maxDistConsDmcs option) was set to 300 nt to
be comparable to metilene and BSmooth. DMRs were required to contain at
least 10 informative CpGs, i. e., CpGs with an associated methylation rate, and an
absolute methylation difference (avg. MDS) larger than 0.1. Outputs of MOABS
and metilene were filtered with the critical p-value 0.05.
For the genome-wide analysis of the WGBS data set, our tool used 10 minutes
on 10 cores, the peak memory usage was 88.3MB. Because of the memory
and runtime requirements of MOABS and BSmooth (Tab. A.18) the qualitative
comparison of the results had to be restricted to chromosome 10.
Among the tools tested, metilene found the highest number of DMRs
(n = 4,602) followed by MOABS (n = 2,108) and BSmooth (n = 1,935; Fig. 4.6 A). This
observation is in line with the observed advantages in sensitivity in the simula-
tions. The distribution of additional DMRs detected by metilene peaks around
mean methylation differences between 0.2 and 0.3 (Fig. 4.6 B). MOABS has diffi-
culties to report DMRs with smaller differences while BSmooth only reports a
rather small number of DMRs with higher differences. Using an independent
non-parametric test (Wilcoxon) confirms that the DMRs exclusively reported by
metilene are significantly differential. In general, metilene’s unique DMRs
tend to have lower p-values than MOABS or BSmooth (Fig. 4.6 C). We found that
some of metilene’s unique DMRs do not only show a high absolute methyla-
tion difference but are also long (Fig. 4.7 A). To test whether the DMRs exclu-
sively reported by metilene can be confirmed with respect to the estimated
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Figure 4.6: Evaluation of real data. A) Venn diagram of DMRs found by metilene, BSmooth and
MOABS in theWGBSmedulloblastomadata onhuman chromosome10. B) Count of DMRs exclusively
found by metilene, BSmooth and MOABS, binned into methylation difference classes. C) Boxplots
of p-values of exclusive DMRs using an independent Wilcoxon-Test.
mean methylation difference and thus the homogeneity inside the predicted
boundaries, we compared the WGBS results to matched 450k methylation arrays.
The high correlation coefficient (r = 0.96) indicates the good reproducibility of
metilene predictions (Fig. 4.7 B). An example of a DMR only found by metilene
is shown in Fig. 4.7 C. It is located intragenic and shows a strong difference level.
The original publication reported 39 promoter downstream correlating re-
gions (pdcR) on chromosome 10, i. e., differential methylated regions correlating
with gene expressions. Of these 39 pcdRs 29 were retrieved by metilene, while
MOABS reported only 21 and BSmooth 12. Most pdcRs (7 of 10) not reported by
metilene contain large stretches of more than 300 nt between CpG sites while
the remaining 3 showhighly heterogeneous intra-groupmethylation levels. With
the exception of a single BSmooth prediction, all pdcRs reported by BSmooth and
MOABS were also detected by metilene.
4.4.3 Summary
In summary, metilene does not rely on any assumptions on underlying distri-
butions or backgroundmodels, nor on joining DMCs. Thus it is able, in contrast to
MOABS and BSmooth, to analyze sample pairs without replicates (Fig. A.6). Fur-
thermore, it can estimate missing methylation data (Fig. A.7) to include CpG po-
sitions not fully covered in all samples. Additionally, it features modes for testing
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Figure 4.7: Evaluation of real data. A) Scatterplot of length and mean methylation differences of
DMRs exclusively reported by metilene. Isoclines indicate their distribution while labels denote
the fraction of DMRs found inside the respective area. Note theminimummethylation cutoff at 0.1
(gray line). B) Correlation of mean difference of exclusive metilene DMRs and 450k methylation
beta values. The plot shows all DMRs covered by at least two probes on the array. C) Figure of
the DLG5 gene containing a DMR (red line) exclusively found by metilene. Methylation rates of
control (top) and medulloblastoma (below) are heatmap color-coded, indicating low methylation
rates in blue and high methylation rates in yellow. The MDS signal is shown between the DMR
annotation and the gene annotation (bottom).
differential methylation in user-defined regions, and finding DMCs.
Despite its superior performance in terms of sensitivity, specificity and ac-
curacy on simulated data, metilene achieved a speedup of nearly 1,000 x on a
single core cluster machine compared to MOABS, the only remaining competitor
after analyzing the DMR prediction results of all tools. (Tab. A.19). On a single
core desktop machine, metilene was able to process the human WGBS set with
8 vs. 12 human samples in≈15 minutes. Speed and memory requirements are an
important issue concerning future studies. We compared all tools and found only
metilene to be prepared for larger samples sizes (Tab. A.20).
While metilene still performed as well as for small group sizes, MOABS
and BSmooth took already 4.5 and 18.75 days, respectively, to finish the 8 vs. 8
run. Furthermore, while metilene’s memory consumption was constantly low
(<150MB) and independent of the number of samples, MOABS and BSmooth con-
sumed between 17–300GB RAM for the same tasks. Both, the 16 vs. 16 and the
50 vs.50 run could be performed only for metilene due to time and memory
issues of both other tools. The results demonstrated the future-proof design
of metilene that is capable of dealing with large sample sizes without a large
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loss of performance. While metilene works well on lowly covered data (7-fold,
Fig. 4.5 C), we still recommend to provide our tool with methylation rates calcu-
lated from 15 reads or more [Ziller 2015].
The non-parametric test at the heart of the strategy integrates two dimen-
sions, i. e., for each given genomic interval (1st dimension) the methylation sig-
nal of all samples (2nd dimension). Our simulations show that this strategy is
advantageous when group-wise methylation differences are subtle and/or the
methylation background is variant. This feature comes in handy when dealing
with contaminated or heterogeneous samples. Therefore, metilene seems to be
especially suitable for DMR prediction in cancer samples or other samples where
a superposition of different methylation signals can be expected.
Chapter 5
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In the context of this thesis and in the framework of the ICGCMMML-seq
project a dataset of 33 whole genome bisulfite sequencing (WGBS) sam-
ples was analyzed. The methods and algorithms described in the previous
two chapters were used for this analysis. This chapter starts with back-
ground information on the development of germinal-center B-cell derived
lymphoma.
The WGBS data were derived from three types of lymphoma, i. e., Burki�
lymphoma (BL), follicular lymphoma (FL) and di�use large B-cell lym-
phoma (DLBCL).While lymphomas share features with their proposed cell
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of origin, the germinal center (GC) B-cells, they are still biologically, epi-
demiological and clinically quite diverse. This data set o�ers the unique
opportunity to study to the epigenomic architecture of neoplasms derived
from the same cell of origin. Here, WGBS data paired with genome and
transcriptome sequencing from 13 IG-MYC-translocation positive Burki�
lymphoma, 9 BCL2-translocation positive follicular lymphoma, 7 DLBCL
samples and four normal GC-B-cell samples are analyzed. In the final sec-
tion, the most relevant findings are shown. In brief, our results demon-
strate a tight connection between somatic mutations, DNA methylation
and transcriptional control in key B-cell pathways deregulated di�eren-
tially between Burki� and follicular lymphomas. This chapter is based on
Kretzmer et al. [Kretzmer 2015].
5.1 Biological background
5.1.1 B-cell development
B cells are generated from hematopoietic stem cells (HSCs) in a primary lym-
phoid organ, the bone marrow. HSCs develop through pro-B-cell and several
pre-B-cell stages into immature B cells. This process is characterized by the re-
arrangement of the three immunoglobulin (Ig) loci. The immunoglobulin heavy
chain (IgH\Ig@) is encoded on chromosome 14 and the two immunoglobulin light
chains (IgL), kappa (Igκ) and lambda (Igλ), are encoded on chromosome 2 and 22,
respectively. The Ig genes consist of multiple, so called constant (C), variable (V)
and joining (J) segments. The heavy chain contains additional diversity (D) seg-
ments. Rearrangement of the V, D and J segments of the IgH locus and the V and J
segments of th IgL loci, called V(D)J recombination, result in a high antibody (im-
munoglobulin) diversity [Janeway 2001]. An antibody consists of two identical
heavy chains and two identical light chains [Nemazee 2006]. The type of heavy
chain (γ, δ, α, µ, ε), which depends on combination of IgH segments, defines the
class of the antibody (IgG, IgD, IgA, IgM and IgE) [Janeway 2001]. If the V(D)J re-
combination processwas successful, i. e., the antibody is not self-reactive, thema-
ture, antigen-specific B-cell receptor (BCR) is expressed on the cell surface. The
BCR is built from an isoform of the immuoglobulin molecules (IgD, IgM, IgA or
IgE) and the transmembrane protein CD79. Immature B cells leave the bone mar-
rowwhere they becomemature naïve B cells, expressingmainly IgM and IgD, and
travel through the blood stream to the secondary lymphoid organs, e. g., lymph
nodes, tonsils and spleen. Upon antigen stimulation through the BCR and co-
receptors [Rajewsky 1996] the naïve B cells collect in the germinal center (GC).
5.1. BIOLOGICAL BACKGROUND 65
Figure 5.1: Schematic of the germinal center reaction. The germinal center reaction consists of
rapid cellular division of B cells and somatic hypermutation in the dark zone and immunoglobulin
class switch recombination and a selection process in the light zone. This can result in either pro-
grammed cell death or the differentiation into plasma B cells or memory B cells. Figure taken from
Klein et al. [Klein 2008].
5.1.2 Germinal Center Reaction
In the GC the cells undergo the germinal center reaction, comprising somatic
hypermutation (SHM), immunoglobulin class switch recombination (CSR) and
a selection process, which can result in the differentiation into plasma B cells
or memory B cells [Natkunam 2007] (Fig. 5.1). The GC consists of three major
histopathologically distinct compartments, the dark and the light zone, and the
mantle zone, which surrounds the dark and light zone and consists of resting B
cells [Gatto 2010].
Dark zone
The B cells located in the dark zone (DZ), called centroblasts, are highly prolif-
erative and replicate every 6-7 hours [Hess 1998]. At this stage, high numbers
of mutations (10−3-10−4 per base per generation) accumulate in the antibody
coding regions [Gatto 2010], which is an 105-106 fold enriched compared to the
normal genome-wide mutation rate [Oprea 1999]. This process is called somatic
hypermutation (SHM). The target region of the SHM is non-random, but directed
to the variable region genes of the light and heavy chain immunoglobulins, which
is responsible for antigen recognition. Due to the Activation-Induced Deaminase
(AID) dependent SHM mechanism, the most frequent type of mutation are nu-
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cleotide changes, rather than deletions or insertions [Klein 2008]. The AID deam-
inates a cytosine to uracil, leading to a mismatch with the guanosine on the com-
plementary strand. Thesemismatches are removed by Base Excision Repair (BER)
enzymes and the missing bases are replaced by error-prone DNA polymerases,
which frequently introduce errors (mutations) at the removed position itself or
at neighboring positions. Through the high mutation rate combined with rapid
cell division, a diverse set antibodies, and subsequently a massive amount of B-
cells with different affinities for antigens emerges. After several rounds of pro-
liferative expansion and SHM, the B cells migrate from the dark to the light zone
of the GC.
Light zone
The B cells located in the light zone (LZ), called centrocytes, are non-dividing, and
smaller thanDZ B cells. They express their previouslymodified immunoglobulins
to the cell surface [Gatto 2010]. The light zone is less densely populated by B cells
due to interspersion with follicular dendritic cells (FDC), follicular T helper (TFH)
cells and macrophages [Klein 2008]. As the first of three processes in this zone, a
selection process takes place, enriching B cells with an improved antigen affinity.
This is regulated by interaction and upon signals from FDC and TFH [Basso 2015].
B cells with a low antigen affinity may re-cycle to the DZ and undergo further
waves of SHM, while self-reactive B cells, are killed through apoptosis and are
removed by the macrophages [Gatto 2010, Basso 2015]. Secondly, B cells selected
for survival and non-reentry into the DZ might undergo immunoglobulin class
switch recombination [Stavnezer 2008]. This irreversible recombination involves
double strand breaks at the switch region, located upstream of the heavy chain
immunoglobulin genes, by AID and BER enzymes. These double strand breaks
are repaired with the side effect of intrachromosomal deletion of some repeated
regions, resulting in a switch of expression from IgMand IgD to other classes (G, A,
E) of immunoglobulin molecules. This does not affect the affinity of the antigen,
but determines which constant region of the heavy chain is expressed. Finally,
upon not fully understood signals, B cells differentiate into post-GC cells, namely
memory B cells or plasma cells [Klein 2008].
5.1.3 GC B-cell lymphomas
This highly complex process is crucial for an effective immune system, but is
also risky. Some mutations might also occur in non target regions or auto-
reactive antibodies may arise [Klein 2008, Gatto 2010]. The fact that almost all
B-cell non-Hodgkin lymphomas (B-NHL) show modifications at the variable im-
munoglobulin genes, gives reason to assume that the malignant B cells already
underwent at least parts of the germinal center reaction [Klein 2008, Gatto 2010,
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Küppers 1999]. The most frequent B-NHL are Burkitt Lymphomas (BL), which
are the most common lymphomas in childhood, follicular lymphomas (FL), and
diffuse large B-cell lymphomas (DLBCL), which are the two most common lym-
phomas of adulthood. Together they account for approximately 80% of all lym-
phoma cases [Basso 2015].
5.1.3.1 Burkitt Lymphoma
BL are a very aggressive type of GC B-cell lymphomas [Basso 2015] and, on the
basis of gene expression profiles, they are assumed to develop from the DZ B-
cells [Victora 2012]. Just like DZ B-cells, BL show a high proliferation rate with a
Ki-67 above 90%, which gives the percent of tumor cells with a positive immuno-
histochemical staining for the antigen of the Ki-67 protein. The Ki-67 protein is
a marker for cell proliferation, meaning that in BL more than 90% of the cells
are in the active phase of the cell cycle [Bellan 2003]. Thus, it is the fastest grow-
ing human tumor. The characteristic of BL is a t(8;14) translocation, affecting
the proto-oncogene MYC [Gatto 2010]. This translocation brings MYC in close
proximity of the immunoglobulin heavy chain locus. Thereby, it gets under the
control of the immunoglobulin control structures [Schmitz 2014]. Subsequently,
MYC is overexpressed in BL in contrast to regular DZ B-cells, where MYC is re-
pressed by BCL6 [Dominguez-Sola 2012]. In addition to the translocation, recur-
rently mutated genes were identified to be enriched in BL [Schmitz 2012]. MYC
was found to be not only translocated but also affected by the SHM machinery,
gaining mutations that led MYC act as an oncogene. Two other recurrently mu-
tated genes in about 70%of BL cases are TCF3 and ID3 [Schmitz 2012, Richter 2012,
Schmitz 2014]. Overexpression of TCF3 results in antigen independent BCR ex-
pression and, subsequently, PI3K signaling, which is important for cell cycle reg-
ulation. ID3 is the negative regulator of TCF3, and regulation of TCF3 is either
disturbed by inactivating mutations in ID3 or by mutations in TCF3 affecting the
ID3 binding site.
5.1.3.2 Follicular Lymphoma
FL are the secondmost frequent B-NHL of adulthood and an indolent form of lym-
phoma [Morin 2011]. The gene expression profiles resembles the gene expression
profile of LZ B-cells [Victora 2012], suggesting that FL lymphoma are derived from
LZ B-cells. FL are characterized by a t(14;18) translocation that brings the BCL2
oncogene into the immunoglobulin heavy chain locus. Due to this translocation,
BCL2 is no longer suppressed by BCL6, but shows aberrantly increased expres-
sion [Klein 2008]. BCL2 is a negative regulator of apoptosis and its overexpression
is an important component of the pro-survival program of FL cells. The second
hallmark of FL is the inactivation of histonemethyltransferaseMLL2 [Basso 2015].
Early in FL development MLL2 is inactivated in about 80% of FL cases. MLL2 is a
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H3K4 methyltransferase and its inactivation may contribute to dysregulation of
the epigenome in FL.
5.1.3.3 Diffuse Large B-Cell Lymphoma
DLBCL are an aggressive, fast growing type of lymphoma and the most frequent
B-NHL in adults [Pasqualucci 2011]. Usually, DLBCL arise de novo but can also de-
velop out of other types of lymphomas or leukemias, e. g., FL. Therefore, DLBCL
are quite diverse and it is hard to sub-classify this entity. They can for example
show features similar to BL, which are developed in the dark zone, however the
subtypes originate fromdifferent non-dark zoneB cells [Ahn 2012]. Currently, the
two major subclassifications are germinal center B-cell-like DLBCL (GCB-DLBCL)
and activated B-cell-like DLBCL (ABC-DLBCL) [Morin 2011]. Both types were re-
ported to show LZ specific expression profiles [Victora 2012]. This is in line with
the LZB-cell origin of theGCB-DLBCL, but is in contrast to the origin ofABC-DLBCL
(post-germinal center B-cells) [Basso 2015]. Subtypes without subclassification
are called ”diffuse large B-cell lymphoma, not otherwise specified” [Jaffe 2009].
In addition to alterations to epigenetic modifiers like CREBBP, EP300 and MLL2,
DLBCL are chracterised by t(3;14) BCL6 translocations into the heavy chain im-
munoglobulin loci [Pasqualucci 2011, Morin 2011, Ye 1995]. Alterations that dis-
tinguish GCB- and ABC-DLBCL are frequent t(8;14) MYC and t(14;18) BLC2 translo-
cations in GCB-DLBCL akin to BL and FL. ABC-DLBCL recurrently show a third copy
of chromosome 3 and NFκB pathway activation [Pasqualucci 2011, Lenz 2008].
5.2 Material and methods
5.2.1 Data
The sequencing cohort consists of pre-treatment tumor tissue and correspond-
ing germline material from peripheral blood, that was shown to be tumor-free
by clonality analyses. In all cases, histopathologic diagnosis was confirmed by
a panel of reference hematopathologists. The tumor cell content in the cryo-
preserved sample material was estimated to be at least 60% in all cases. Whole
genome bisulfite (WGBS), whole genome and transcriptome sequencing of 13 IG-
MYC-translocation positive BL, 9 BCL2-translocation positive FL (including 8 FL
grade 1/2 and one FL 3a/DLBCL) and 7 DLBCL samples (3 ABC, 3 GCB and 1 un-
specified) samples was performed in several sequencing centers. In addition,
FACS-sorted GC-B-cells from non-neoplastic tonsils of four donors were analyzed
as control reference.
For all samples Infinium HumanMethylation450 450k BeadChips (450k Bead-
Chips) were analyzed and array based gene expression analysis from a previous
cohort was used for validation. For 935 validation cohort samples, comprising
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primary lymphomas (BL (mBL) n = 84, FL n = 144, DLBCL ABC n = 106, DLBCL GCB
n = 176, DLBCL unclassified n = 80), lymphoma cell lines (n = 32) and normal B-cell
controls (tonsils n = 10, naïve B-cells n = 8, GC-B-cells n = 13, postGC-B-cells n = 9),
array-based gene expression data from Affymetrix Gene Chip U133A (array) were
available.
Chromatin segmentations of several B-cell lymphoma cell lines were used to
represent the chromatin state of BL and FL samples. These included BL-2 and DG-
75 BL cell lines, showing the IG-MYC fusion, as well as the KARPAS-422, which
is actually a DLBCL cell line, but with a FL typical BCL2 translocation, was used
to represent FL. The GM12878 cell line was used as normal control. ChIP-Seq
of H3K4me1, H3K4me3, H3K27ac, H3K9me3, H3K36me3, H3K27me3 modification
sensitive sites was done for the BL-2, DG-75 and KARPAS-422 cell lines using the
standard protocols generated within the Blueprint Consortium [Martens 2013].
For the compilation of homogeneous groups of lymphomas we defined pro-
totypic groups of lymphomas. Prototypic follicular lymphomas (pFL) included
FL with chromosomal breaks affecting the BCL2 locus detected by FISH. Proto-
typic Burkitt lymphomas (pBL) included all Burkitt lymphomas (excludingBurkitt
leukemia cells from the bone marrow/peripheral blood) with FISH-proven IG-
MYC fusion and devoid of BCL2 or BCL6 breakpoints. Because of the heterogene-
ity of themolecular characteristics, the DLBCL were omitted completely from the
analysis. Instead, we focus on the comparison of themolecularly andmorpholog-
ically well-defined cases of BL and FL.
5.2.2 Mapping and DNA methylation rate calling
Strand-specific MethylC-seq libraries were prepared using the approach de-
scribed by Lister et al. with the some modifications. Adaptor-ligated DNA frag-
ments with 200-250 bp insert lengths were isolated and bisulfite conversion was
performed. PCR amplification of the fragments was performed in six parallel re-
actions per sample, pooled per sample and sequenced on a Illumina HiSeq2000
platform, yielding an average of 835 million (±81 million s.d.) 101 bp paired-
end reads per sample. This resulted in a total of 25 billion read pairs, with at
least 0.7 billion read pairs per sample (Tab. A.21). The mapping was done using
segemehl [Hoffmann 2009, Otto 2012] in its bisulfite methyl-C seq mode with
default parameters and hg19 reference genome. On average, 92% of the reads
were mapped, of which 86% mapped uniquely and 7% were multiple mappings.
Multiple lanes belonging to a single patient were mapped independently and
merged together prior tomethylation calling, resulting in amean coverage of 54x
(Tab. A.21). Themethylation callingwas doneusingBAT [Kretzmer ], which calcu-
lates the methylation rate, #C/(#C+#T), for each cytosine. We restricted our anal-
ysis to cytosine positions that showed a strand-informative coverage between
15 and 150 reads in all samples of our study. 25 million CpG positions met our
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Figure 5.2: Verification of DNA methylation rate calls. Correlation of WGBS methylation rates
with Illumina 450k BeadChip beta rates, calculated for n = 26 sample pairs. Linear model resulted
in mean adjusted R2 of 0.921.
coverage criteria. Only reference CpG positions were taken into account in the
main analyses, while reference nonCpG positions were analyzed separately. 450k
BeadChips were used for verification of theWGBSmethylation rate calls. A linear
model of the 450k BeadChip beta values and theWGBSmethylation rates resulted
in an average adjusted R2 value of 0.921 (n = 26, p-value < 0.05, Pearson correla-
tion test, Tab. A.21, Fig. 5.2). The linear model analysis was performed using the
stats package for R (3.1.0) [R Core Team 2014].
The transcriptome data were mapped with segemehl allowing for spliced
alignments and using a minimum accuracy of 90%. An average of 150 million
reads were obtained per case, of which 89% concordant pairs and 94.5% sin-
gle ends were mapped (Tab. A.22). Differential expression was analyzed using
DESeq [Anders 2010b]with default parameters and a significance criterion of 0.05
(p-value adjusted for multiple testing).
The analyses were complemented by 30x deep whole genome sequencing of
tumors and matched controls from the same patients, and the GC-B-cell popula-
tions, as well as 8 additional BL.
5.2.3 DMR calling and cDMR calculation
To obtain genome wide differentially methylated regions (DMRs) between the
three entities BL, FL and GC-B-cells, the previously algorithm metilene was
used [Jühling 2015]. Methylation gaps (e. g., centromeres) were excluded through
the requirement of at least one CpG that was sufficiently covered by the bisulfite
5.2. MATERIAL AND METHODS 71
Figure 5.3: cDMRs. A) A DMR is assigned to a gene, if it overlaps with the a gene itself (blue) or its
promoter region (1500 nt upstreamof its TSS, red). B) Four classes of cDMRs are defined. Depending
on delta methylation and delta expression, cDMRs are classified into one of the four quadrants Q1-
Q4.
sequencing each 500 nt. Furthermore, a DMR was required to have a minimum
of 10 CpGs. These constraints are intended to prohibit the extension of a DMR
into low complexity regions or loci with a low coverage of bisulfite treated reads.
Thus, the detection of DMRs as well as their sizes are influenced by the mapabil-
ity of a genomic locus and the density of CpGs. In other words, the exclusion of
methylation gaps and the length constraints focus the DMRs to regions of strong
and constant differential methylation. In addition, we did not impose further
size constraints. As differentially methylated regions the top 10% and the bot-
tom 10% segments were taken (ranked by p-value). A total of 90,350 DMRs be-
tween all pairs of BL, FL and GC-B-cells were found. The comparison of only BL
(FL) and GC-B-cell yielded 36,775 (27,607) DMRs. The average length of DMRs was
about 520 bp, intragenic (515 bp) and intergenic DMRs (522 bp) also did not signif-
icantly differ and their length distributions were close to congruent (Fig. 5.4 A).
Almost 50% of the DMRs that were not associated with a gene (coding and non-
coding) are located in repetitive regions or heterochromatin. Furthermore, 10%
were located in repressed regions and another 10%were related to transcription.
The second largest fraction (25%) were mapped to enhancers not in the vicinity
of annotated genes.
The correlating DMR (cDMR) analysis was performed on all pBL-pFL DMRs
using all BL and FL samples. To obtain DMRs correlating with the expression of
nearby genes (DMR overlapping a gene or at most 1500 nt upstream of its TSS,
Fig. 5.3 A), no linear relation was assumed and a correlation test was performed.
To increase robustness and to avoid the violation of assumptions (e. g., variance
homogeneity, normal distribution) thenon-parametric spearman correlation test
was used. The GENCODE [Harrow 2012] version 14 gene annotation was used for
correlation analysis, including protein coding genes and other biotypes like an-
tisense, lincRNA, miRNA and other non coding genes. DMRs with a significant
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Figure 5.4: DMR and cDMRs length and position distribution. A) The length distribution of
DMRs in the vicinity or inside genes (red) shows no apparent differences to inter-genic DMRs. B)
The length distribution of DMRs (blue line) and cDMRs (red line) are virtually identical. C) Den-
sity distribution of cDMRs in gene regions. Positively correlated DMRs (blue) have a peak density
upstream of a TSS, while negatively correlating DMRs (red) are most frequently found just down-
stream of the TSS within the gene body.
correlation test (p<0.05) were declared cDMRs. This analysis naturally gives rise
to the four classes/quadrants of correlations (Fig. 5.3 B). The first and the sec-
ond quadrant (Q1, Q2) indicate cDMRs that are hypermethylated correlate with
genes that are up and down regulation, respectively. Correspondingly, the third
and fourth quadrant (Q3, Q4) indicate hypomethylated cDMRs correlating with
down and up regulated genes, respectively. Here, the change in methylation and
expression of BL with respect to FL is given, e. g., Q1 holds cDMRs where BL are
hypermethylated and upregulated with respect to FL. Quadrants Q1 and Q3 hold
cDMRs with positive correlation, Q2 and Q4 hold cDMRs with negative correla-
tion.
Furthermore, we computed the length distributions of DMRs and cDMRs. The
distributions were very similar, with typical DMRs as well as cDMRs lengths in the
range of 100 to 1,000 bp (Fig. 5.4 B). Indeed, we found differences between the dis-
tributions of positive and negative cDMRs across gene regions. Specifically, neg-
ative correlating DMRs have a peak density just downstream of the transcription
start sites, while positively correlated DMRs are more evenly distributed across
gene regions, with a peak in the promoter region (Fig. 5.4 C).
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5.2.4 TFBS enrichment analysis
For all transcription factor binding sites (TFBS) annotated for
GM12878 [ENCODE Project Consortium 2012b] we checked whether they are sig-
nificantly enriched in one of the four classes of cDMRs between BL and FL. TFBS
data was accessed under http://hgdownload.cse.ucsc.edu/goldenPath/
hg19/encodeDCC/wgEncodeHaibTfbs/ [Flicek 2014, Karolchik 2014]. If avail-
able, replicates were merged. For significance testing bootstrapping was used as
described below. As a backgroundmodel for the enrichment we used the set of all
pBL-pFL DMRs that were associated with a gene, i. e., including non-correlating
DMRs. For each quadrant i we randomly selected #cDMRi from the whole
set of gene associated DMRs (#cDMRi = number cDMRs in the quadrant i).
These random DMRs were intersected with the binding sites of all transcription
factors (TFs) and the number of intersecting TFBS per TF was recorded. After
1,000 iterations, a TF was defined to be enriched if less than 5% of the iterations
showed a higher number of binding sites in random DMRs than in cDMRs of the
corresponding quadrant.
For all 40 enriched TFBS an activity plot was calculated to integrate the corre-
lation of the cDMR-gene pair and the expression of the transcription factor. For
each cDMR-gene pair an activation score y (y = ρ ∗ log2FCTF) was calculated. ρ
is the spearman correlation coefficient of the cDMR-gene pair and log2FCTF is the
delta expression of the TF between the two entities. These activation scores were
assigned to TFs with a binding site in the cDMR. For TFs withmore than one bind-
ing site in different cDMRs belonging to the same gene themean of the activation
scores was used.
Furthermore, the correlation of the TF expression with the expression of the
cDMR-gene in the corresponding quadrant with a TFBS in the cDMR was calcu-
lated (rpkmTF ∼ rpkmcDMR-gene). The spearman correlation was calculated for all
enriched TFs and their associated genes (Tab. A.23).
5.2.5 DNA methylation profiles
The DNA methylation profiles of genes and TFBS were calculated using a sliding
window approach. The annotation of each itemwas extended by 15% of the gene
length or 5,000 nt for TFBS. Awindow size dependent on the extended annotation
length was chosen to ensure an equal number of k windows per item. In each
window for each item the average methylation rate is calculated, if the window
contained at least methylation rates for 5 CpGs. Finally, the methylation of each
bin i, i = 1, . . . , k, is averaged and plotted.
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5.2.6 Control of confounding factors
Control of confounding factors was performed for (i) age bias in in DMR detec-
tion, (ii) tumor cell content on genome-wide methylation, (iii) proliferation rate
as measured in Ki67 expression on TF expression and genome-wide methylation
and (iv) homogeneity of DMRs and cDMRs.
Age bias
To control for an age bias in the DMRs, all loci located in DMRs or cDMRs were
extracted from the 450k BeadChip data. This includes 37 BL samples of an age be-
tween 4 and 57 years, among them 450k BeadChip data of the 13 whole-genome
bisulfite sequenced BL. The samples were sorted the samples according to the
donor’s age (x axis, Fig. A.8 A) and a hierarchical cluster analysis of the beta values
was performed. The data showed no relevant (continuous) change in the methy-
lation pattern according to the donors’ age in both data sets.
Tumor cell content
Based on the cryostat sections adjacent to selections used for nucleic acid
extractions, tumor cell content was estimated for all specimen by a single
hematopathologists. We investigated a potential relationship of tumor content
and average per sample genome-wide methylation rate. No apparent tumor con-
tent related biases were observed (Fig. A.8 B).
Proliferation rate
To test the hypothesis that TF expression is biased by the proliferation status, all
expression valuesmeasured by arrays of the TF genes (Fig. A.8 C) and their targets
(Fig. A.8 D) were pooled. These gene expression values were correlated to the Ki-
67 staining in germinal center DLBCL (GCB DLBCL; n = 160). In both cases (spear-
man correlation coefficient = 0.02 and spearman correlation coefficient = 0.043)
no meaningful correlation was found. In addition, we analyzed whether the pro-
liferation rate correlates with the average genome-wide level of methylation and
again, no significant correlation (spearman correlation) was found (Fig. A.8 E).
DMR homogeneity
In order to support that theWGBSdata fromamore limited number of BL/FL sam-
ples is representative, 450k BeadChips of a larger number of BL and FL samples
were used to investigate whether the DNAmethylation profiles are homogeneous
(or heterogeneous)within each lymphoma entity. We therefore performed anun-
supervised cluster analysis of 450k BeadChip data obtained from 37 BL and 52 FL
samples (Fig. A.8 F). Analyses based on all CpGs located within either DMRs or
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cDMRs revealed homogeneous, entity-specific methylation patterns. These data
confirm that BL and FL have distinct and characteristic DNAmethylation patterns
that are amenable to analysis by either WGBS or 450k BeadChips.
5.2.7 nonCpG analysis
nonCpG analysis was separated from CpG analysis, since at least in human adult
tissue almost only cytosines in CpG context are methylated, while nonCpG are
predominantly unmethylated [Lister 2009]. An exception is brain tissue, where
considerable amounts of nonCpG methylation were reported [Guo 2014b]. Usu-
ally, the methylation of cytosines not followed by a guanosine can not be up-
held during replication. Nevertheless, it could be a side effect of a mis-regulated
methylation machinery. For all candidate nonCpGs a two-step approach was per-
formed.
Assessment of the methylation rate on highly trustable mappings only
In order to get high confidence nonCpG methylation candidates, reads were fil-
tered extensively using rather strict thresholds. For this, reads were discarded if
only one mate was mapped, the read pair was mapped multiple times, its edit-
distance was above 6, the alignment contained more than 3 indels or (e) a read
contained more than two unconverted Cs in a non G context. This reduced the
number of reads by 32% to about 1.5 billion per sample. Based on the remaining
reads, the methylation rate of all nonCpG positions was calculated analogous to
the CpGmethylation analysis, i. e., coverage of 15-150 andmethylation rate is the
fraction of unconverted to converted and unconverted cytosines.
Reduction of false positives
All reference nonCpGswith amethylation rate� 0.3 were taken into account. For
positions passing these filtering step, the sequence of single reads was examined
with respect to the nonCpG position and the numbers of reads containing CpGs
and nonCpGs were counted separately. Only nonCpG positions covered by at least
5 nonCpG reads and a proportion of nonCpGs-to-CpGs above or equal to 0.3 were
labeled as methylated nonCpG positions. This resulted on average in 250,000
candidate nonCpG positions. To further reduce the number of false positives,
reads were filtered that had an alternative explanation for the methylation of
the cytosine. The most frequent alternative explanation were mutations to a G
at the 3� end of the C. Other explanations were deletions in the read of the base
3� of the C which was followed by a G as well as insertions of a G, represented
by a mismatch in the alignment. On average 4,800 nonCpGs (0.2%) without an
alternative explanation were found. No enrichment of nonCpG methylation
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Figure 5.5: Sequence motif of nonCpGs. An average of 4,500 methylated nonCpGs war found per
sample. A sequence motif search using MEME in a window 50 bp around the methylated nonCpGs
revealed this very strong motif. The motif was identified as belonging to and ALU repeat.
in the cancer samples was foundwith respect to to the normal GC-B-cell controls.
In downstream analysis MEME [Bailey 2006] was used for sequencemotifs en-
richment around the methylated nonCpGs. In a window of 50 bases centered
around the methylated cytosine MEME revealed a strong motif (Fig. 5.5) which
is part of an ALU repeat. The high GC content of the ALUs may be a reason for
this finding. As expected, nonCpG and CpGmethylation rates show a distinct dis-
tributions. nonCpGs have only relatively low methylation levels, and only very
few are highly methylated. This is consistent with the fact that nonCpG methy-
lation can not easily be kept up during cell replication. nonCpG methylation fol-
lows the genomic cytosine distribution, with the exception of a significant en-
richment in repetitive regions. It has not been ruled out that this effect is en-
hanced or even caused by misalignments. Furthermore, the 5% of the nonCpG
that were highly methylated, were tested against the whole nonCpG set to find
out whether there was an enrichment for highly methylated nonCpGs for regu-
latory segments. However, no significant difference was found.
5.3 Results
5.3.1 DNA methylation
5.3.1.1 Loss of methylation
Analysis of average genome-wide CpG methylation revealed all lymphoma en-
tities to be hypomethylated compared to non-neoplastic GC-B-cells (Fig. 5.6 a).
However, considerable differences were seen in extent and variability of DNA
methylation between the BL and FL groups – despite their common ori-
gin (Fig. 5.6 b). In addition to global hypomethylation, considerable DNA-
methylation gains were observed in BL and FL samples at CpGs with low-level
methylation in GC-B-cells (GC-B-cell<0.3; Fig. 5.6 c). To determine whether DNA
methylation patterns vary between genome segmentswith different function, we
compared methylation differences (average of BL and FL vs. GC-B-cell) for the 15
ENCODE chromatin states (Tab. A.1) defined in the GM12878 lymphoblastoid cell
5.3. RESULTS 77
Figure 5.6: Genome-wide alterations. Loss of methylation in lymphoma. (a) Circular plot for
genome-wide group-average DNA methylation signals. A gradual loss of methylation in compari-
son to normal GC-B-cells can be observed (1: GC-B-cells, n = 4; 2: FL, n = 9; 3: BL, n = 13). (b) Boxplot
of average methylation levels for lymphoma and normal controls. Methylation differences are sig-
nificant (<0.05) for all pairwise comparisons except for FL vs. BL (p = 0.13). (c) Correlation of DNA
methylation levels in BL, FL and GC-B-cells at CpG resolution. (d) Average differential methyla-
tion (average of BL and FL vs. GC-B-cell) of GM12878 chromatin segments. (e) Scatter plots of DNA
methylation of poised promoters versus RNA expression of the associated genes.
line [Ernst 2011]. For most chromatin states, individual segments showed either
hyper- or hypomethylation largely neutralizing each other in this global analy-
sis. However, changes in heterochromatin were mostly unidirectional, resulting
in the greatest relative reduction of DNAmethylation levels of any chromatin seg-
ment in the lymphoma samples. In stark contrast, poised promoters showed the
strongest, but nevertheless small, increase in DNA methylation levels at a global
level (Fig. 5.6 d). The observed gains in poised promoter methylation were at
times associated with increases in RNA expression of the associated genes in BL
and FL samples (Fig. 5.6 e).
5.3.1.2 Differentially methylated regions
Gene-centered analysis, including coding and non-coding genes, showed in-
creased levels of gene body methylation for highly expressed genes, which re-
turned to background levels at transcription end sites (TES). High transcription
levels were typically associated with the presence of large hypomethylated re-
gions downstream of the transcription start sites (TSS), suggesting regulatory
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Figure 5.7: Differentially methylated regions (DMRs). (a) Interdependence of DNA methylation
and RNA expression levels across gene regions (mean of GC-B-cell, FL and BL is shown). Genes were
grouped by expression level (not: RPKM<0.1; low: 0.1�RPKM<1; medium: 1�RPKM<10; high:
10�RPKM) (b) Proportion of DMRs in promoters, transcribed- and intergenic regions. (c) Density
plot of DMRs with respect to distance from the TSS (n = 22 samples). (d) Proportion of DMRs in
intragenic regions (1,500 nt upstreams of TSS to TES) that showed no, positive or negative correla-
tions of DMRmethylation and expression of the associated gene containing the DMR. (e) Types and
distribution of correlating DMRs (cDMRs). Degrees of methylation are correlated (p<0.05; Spear-
man) with the RNA expression of associated genes for about one-third of DMRs (n = 8,207; upper
panel). Of these cDMR-gene pairs, 67% showed negative correlation (Q2 and Q4).
relevance for these regions (Fig. 5.7 a). The great majority of DMRs were lo-
cated within transcribed (TSS to TES) rather than in promoter (1,500 nt upstream
of TSS) or intergenic regions (Fig. 5.7 b), with a strong enrichment of DMRs
immediately downstream of the TSS (Fig. 5.7 c), analogously to the so-called
“promoter downstream correlated regions” recently described for medulloblas-
toma [Hovestadt 2014].
To define the role of these potential regulatory regions in BL and FL, we corre-
latedmethylation levels of intragenic DMRs (contained in the transcribed regions
and up to 1,500 nt upstream of the TSS) with expression levels of the associated
genes containing these DMRs. 40% of the intragenic DMRs showed significant
(p<0.05) correlations between methylation and RNA expression (Fig. 5.7 d), with
themajority (64%) showing negative correlations (Fig. 5.7 e). Overall, 85% of cor-
relating DMRs (cDMRs) were located downstream of TSS.
5.3.1.3 Dark and light zone
To ascertain the biological relevance of cDMR methylation, genes that previ-
ously had been reported as preferentially expressed in B-cells of the dark zone
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Figure 5.8: DMRs in dark and light zone genes. (a) Proportion of GC dark zone (DZ) and light zone
(LZ) genes with negatively correlating DMR-gene pairs in BL and in FL. (b, c) Scatter and box plots
of negatively correlating DMRmethylation and RNA expression affecting the DZ and LZ-associated
genes MDM1 and JAK3, respectively.
(DZ) or light zone (LZ) of the GC [Victora 2012] were examined; around 22%
of DZ- and 28% of LZ-specific genes possessed cDMRs. DZ-specific genes were
predominantly hypomethylated and upregulated in BL, while hypermethylated
and downregulated in FL samples (p<0.001; Fisher’s exact test, Figs. 5.8 a, b);
LZ-specific genes showed the opposite pattern (p<0.001; Fisher’s exact test,
Figs. 5.8 a, c). These data are in line with the view that the majority of BL are
frozen in the DZ cell state while the majority of FL are frozen in the LZ cell state;
moreover, they suggest that methylation at cDMRs could act to fix the other-
wise physiologically transient functional states of DZ and LZ B-cells in BL and FL
samples, respectively. Examples include high expression of TCF3 and SMARCA4,
higher expressed in DZ than in LZ B-cells and in BL than in FL, as well as NFκB
and TNFAIP3, showing the opposite expression pattern.
5.3.2 Pathway analysis
The observed association between LZ- and DZ-specific gene expression prompted
us to more fully evaluate cDMR involvement in differential gene expression be-
tween BL and FL. Ingenuity pathway analysis (IPA) was performed based on (i)
all genes differentially expressed between BL and FL and (ii) the subset of differ-
entially expressed genes with negatively correlating DMRs. Genes with positive
correlations of methylation and expression were used as negative control. The
first gene set identified 60 pathways showing significant enrichment of differen-
tially expressed genes. The pathways were assigned scores indicating pathway
activation. Analysis of genes with negatively correlating DMRs identified 58 of
the 60 pathways, all with comparable ratios of gene enrichment and activation
scores. Pathway analysis based on positively correlating DMRs identified signifi-
cantly fewer pathways (17/60; p<0.001; Fisher’s exact test). These data strongly
indicate that modulation of DNA methylation levels is a common mechanism in
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the regulation of differential gene expression in BL and FL.
Next, we sought to define the molecular mechanisms deregulated by DNA
methylation, particularly in BL using FL as a contrasting group. Thiswas achieved
by directly comparing BLwith FL rather thanwithGC-B-cells since the latter anal-
ysis would have been underpowered and potentially biased due to the smaller
number of available GC-B-cell samples (n = 3). We identified 23 pathways with
IPA that were differentially activated in BL and FL. To determine the directions
of gene expression changes in those activated pathways relative to GC-B-cells,
we visualized gene expression in BL, FL and GC-B-cells for all 23 pathways. Spe-
cific downregulation occurred in inflammation and immunity pathways in BL,
and cell cycle and DNA repair pathways in FL (Fig. A.9). Remarkably, one of
the few genes that, relative to GC-B-cells, were upregulated in BL and down-
regulated in FL was IGF2BP1 (Fig. A.10), an RNA-binding protein that stabilizes
MYC [Weidensdorfer 2009], underscoring its central importance inGC-B-cell lym-
phoma biology.
Detailed pathway-based analyses showed that, e. g.,, DNA methylation was
significantly associated with the downregulation of NFκB signaling and the up-
regulation of cell cycle control genes in BL (Figs. A.11 A.12). This finding is
concurrent with the proliferation rates of close to 100%, typical for BL (Ki-67
staining), and in line with previous reports on the molecular pathogenesis of
BL [Dave 2006, Richter 2012, Schmitz 2012, Hummel 2006, Love 2012]. The ob-
served aberrant signaling was linked to differential methylation of key path-
way genes in BL, including the hypermethylation and downregulation of JAK3
(Fig. 5.8 c) and STAT3 [Dave 2006] (Figs. 5.9 a, b) in linewith low JAK-STAT-pathway
activity in BL. Another example of differential methylation of key regulatory
genes in BL was hypomethylation and overexpression of the transcription fac-
tor TCF3 (Figs. 5.9 c, d, e). Remarkably, the TCF3 gene even harbors two cDMRs of
which cDMR1 contains a TCF3 binding site that is occupied in B-cells [Ernst 2011],
suggesting the possibility of a positive-feedback loop amplifying TCF3 transcrip-
tion (Fig. 5.9 d). Analysis of published TCF3 ChIP-Seq data of the BL cell lines
BL-41 and NAMALWA [Schmitz 2012] confirmed TCF3 binding within cDMR1 that
overlapped a common TCF3 binding motif, and methylation levels of the CpGs
surrounding thismotif were inversely correlatedwith TCF3 expression in a larger
set of 39 samples (Fig. A.13). These results indicate that, in addition tomutational
mechanisms [Richter 2012, Schmitz 2012, Love 2012], TCF3-cDMR hypomethyla-
tion contributes to TCF3 activation.
Pathway analysis also revealed deregulation of sphingosine-1-phosphate sig-
naling in both BL and FL when compared to GC-B-cells (Fig. 5.10 a). Sphingosine-
1-phosphate receptor 2 (S1PR2) is frequently affected by loss-of-function mu-
tations in BL and DLBCL, leading to increased AKT and migratory activ-
ity [Muppidi 2014]. In our analysiswe additionally identified cDMRs in several key
pathway genes including PDGFRB, which is strongly upregulated in both BL and
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Figure 5.9: DMRs in JAK-STAT-pathway. (a) DNA methylation plot for STAT3, showing a cDMR
in intron 6; red, methylated; blue, unmethylated. (b) Correlations of cDMR methylation and ex-
pression for STAT3. (c) DNA methylation plot for TCF3, showing two cDMRs within the gene body.
cDMR1 in intron 2 contains a TCF3 binding site. (d, e) Correlations of cDMR methylation and ex-
pression for TCF3.
FL relative to GC-B-cells (Fig. 5.10 b), the stimulatory G-alpha-q protein GNA11,
upregulated in BL (Fig. 5.10 c), and S1PR1 and the G-alpha-protein complex
G(12/13)-member GNA12, which are overexpressed in FL (Figs. 5.10 d, e). Analysis
of whole genome sequencing data detected mutually exclusive mutations in sev-
eral G(12/13)-complex genes in 14 of 21 BL samples analyzed (Fig. 5.10 f). These
findings were corroborated by our previous description of RHOA mutations in
8.5% of BL samples in an extended cohort of 82 cases [Rohde 2014] and by a recent
study functionally implicating G(12/13) mutations in the development of GC-B
lymphomas [Muppidi 2014]. Interestingly, 3 of the remaining 7 samples were af-
fected by somatic mutations in two genes of the Gαi complex, GNAI1 and GNAI2,
in 5 BL samples, including recurrent (n = 3) GNAI2 R179H substitutions. The Gαi
complex can regulate several signaling pathways including AKT, ERK and pro-
tein kinase A (PKA). Inhibition of PKA in BL cell lines did not affect cell viability
(Fig. A.14), suggesting that this pathway might not be essential in BL; however,
mutations of the Gαs protein GNAS at the position homologous to GNAI2 R179H
are known to cause upregulation of AKT signaling and cellmigration in pancreatic
adenocarcinoma and pituitary tumors [O’Hayre 2013, Takuwa 2011]. Recently, it
was proposed that, in addition to G(12/13) mutations, GNAI2 R179H mutations
might increase proliferation and migration of DLBCL cells [Morin 2013]. Our ob-
servations on sphingosine-phosphate and G-protein signaling suggest that mu-
tation and DNA methylation of genes involved in these pathways might comple-
ment each other in suppressing G(12/13) and activating AKT signaling in BL.
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Figure 5.10: Sphingosine-1-phosphate signaling is affected by complementary DNA mutation
and methylation in GC-B-lymphomas. (a) Pathway of sphingosine-1-phosphate and related G-
protein-coupled signaling. RNA expression of genes differentially expressed between lymphoma
(BL and FL) and GC-B-cells are indicated in red and green for up- and downregulation, respectively.
Genes marked with blue outlines are associated with cDMRs. (b-e) Scatter and box plots of nega-
tively correlating DMR methylation and RNA expression affecting genes involved in sphingosine-
1-phosphate and G-protein signaling. (b) PDGFRB (c) GNA11 (d) S1PR1 (e) GNA12 (f) Mutations
identified in BL samples affecting the G12/13 (above dashed line) and Gαi (below dashed line) com-
plexes.
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5.3.3 Transcription factor binding sites
Since cDMRs could be used to identify pathways contributing to the pathogenesis
of BL through genomic mutation or deregulation by DNAmethylation, we sought
to identify sets of transcription factors (TFs) driving expression of genes with
cDMRs. We intersected the cDMR dataset with TF binding sites (TFBS) data for
46 TF [Ernst 2011, Abraham 2013]. Significant enrichment of TFBS was observed
for genes that were expressed at lower levels in BL than in FL samples, and were
associated with hypermethylated (BL vs. FL) cDMRs in quadrant 2 (Q2) of the
radar plot (Fig. 5.11 a). We selected the ten TFs displaying the highest correlation
of TF and target gene expression (Tab. A.23) for subsequent analyses. Differential
methylation of the corresponding TFBS typically was restricted to the TFBS itself
and rapidly returned to background levels outside of it (Fig. A.15).
To understand how cDMR-methylationmodulates TF-target gene expression,
we plotted average methylation levels of cDMRs against average RNA expression
of the associated genes for all 10 TFs (Fig. 5.11 b). Target genes of STAT5A and
BCL3, both enriched in Q2 (Fig. 5.11 a), displayed hypermethylation and reduced
RNA expression in BL when compared to GC-B-cell and FL samples, in agreement
with the low level activity of the NFκB and JAK/STAT pathways previously re-
ported in BL [Dave 2006]. Similar patterns were observed for the target genes
of other TFs in Q2. In Q4, we observed hypomethylation and activation of TCF3
target genes in BL when compared to FL samples. GC-B-cell samples displayed
intermediate methylation levels, more similar to FL methylation levels than BL.
As previously noted, mutations affecting TCF3, or its negative regulator ID3, de-
tected by us and others [Richter 2012, Love 2012] in more than two-third of all
sporadic BL have been proposed to foster TCF3-dependent gene expression driv-
ing BL-cell proliferation [Schmitz 2012]. Taken together, these findings suggest
that both BL- and FL-specific gene expression programs are subject to regulation
through DNA-methylation of TFBS.
To assess the impact of these TFs on target gene expression at a single gene
level, we generated activity plots integrating and visualizing the correlation of
target gene expression with cDMR methylation and the level of TF expression
(Fig. 5.12 a). Individual genes displaying the strongest activation in FL as com-
pared to BL included the hallmark gene of follicular lymphomagenesis, BCL2, as
well as CBX7, encoding a chromobox protein of the polycomb repressive com-
plex 1, which was previously shown to be functionally involved in lymphoma-
genesis with high expression in FL [Scott 2007]. Notably, strong activation in
FL was also observed for a set of genes typically expressed in T-cells, includ-
ing CD3E, CD2, GIMAP1 and ITK, in line with the differential role of bystander
T-lymphocytes [Dave 2006] in follicular, in contrast to Burkitt, lymphomagen-
esis. TCF3 was among the genes strongly activated in BL, in line with the al-
ready above proposed auto-activation loop of its expression (Fig. 5.12 a, b). Other
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Figure 5.11: Enrichment of transcription factor binding sites (TFBS) in cDMRs. (a) Radar plot
showing the enrichment of binding sites of 46 transcription factors in cDMRs. Quadrants (Q1-Q4)
classify cDMRs by correlation type (positive or negative) and direction of methylation and expres-
sion in BL vs. FL. Negatively and positively correlating DMR-gene pairs are located in Q2/Q4, and
Q1/Q3, respectively. Concentric circles indicate levels of TFBS enrichment measured as percent
binding sites of a particular TF found in cDMRs relative to all binding sites of this TF found in DMRs.
Stars indicate TFBS that are significantly enriched in cDMRs. Red stars indicate the 10 TFs show-
ing the best correlation of TF and average target gene expression. (b) Correlations of sample-wise
average cDMRmethylation and average target gene expression for the 9 of the top 10 TFs showing
negative correlations.
strongly activated genes included the E2F family member E2F1, the POLD1 gene,
which encodes the MYC-interacting polymerase D1, the TERT gene, which en-
codes telomerase as well as the SMARCA4 gene (Fig. 5.12 a, c) encoding a mem-
ber of the SWI/SNF nucleosome remodeling complex. Consistent with previ-
ous findings [Hummel 2006], we could independently confirm overexpression of
SMARCA4 RNA in BL using array-based analysis.
Unexpectedly, the observed strong SMARCA4 transcriptional activation did
not result in the upregulation of SMARCA4 target genes in BL, despite the fact
that SMARCA4 binding sites were hypomethylated (Fig. 5.11 a, Fig. 5.12 d). These
data suggest that suppression of SMARCA4-dependent expression does not occur
through hypermethylation of its binding sites in the target genes, but rather is
deregulated by DNA-methylation independent mechanisms in BL.
5.3.4 Integrative analysis
To elucidate the role of SMARCA4 in Burkitt lymphomagenesis, we performed an
integrative data analysis (Fig. 5.13 a) that showed high expression of SMARCA4 in
BL associated with both decreased DNA methylation and chromatin reprogram-
ming to active promoters (Chr19: 11.07-11.09 Mb) and enhancers to promoters
(Chr19: 11.15-11.16 Mb). Immunohistochemical staining found strong SMARCA4
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Figure 5.12: Activity of TF in cDMRs. (a) Activitymap integrating the correlation of TFBSmethyla-
tion and differential expression of target genes. Color and hue indicate the strength of inactivation
(red) or activation (blue) in BL compared to FL samples. The top 40 target genes are shown for quad-
rants Q2 and Q4, each. (b,c) RNA expression of TCF3 (b) and SMARCA4 (c) in BL, FL and GC-B-cell
determined by array analysis in an extended lymphoma cohort. (d) Correlations of sample-wise
average cDMR methylation and average target gene expression for SMARCA4.
protein (BRG1) expression in normal GC-B-cells, butmuch less pronounced signal
was seen in GC mantle and other B-cell compartments of the tonsils (Fig. 5.13 b);
in contrast, BL samples showed ubiquitous, high SMARCA4 protein expression in
(Fig. 5.13 c).
Whole-genome sequencing of the cohort identified SMARCA4
mutations in 9 out of 21 BL samples. In line with previous re-
ports [Dykhuizen 2013, Klapper 2012], these SMARCA4 mutations clustered
in the helicase domain (Fig. 5.13 d), revealing a mutation pattern that stands
in strong contrast to the germline nonsense mutations predisposing to can-
cer syndromes [Hasselblatt 2011, Hasselblatt 2014, Schneppenheim 2010,
Witkowski 2014]. Further investigation of the SMARCA4 mutational landscape
from bona fide BL samples, including data from cell lines and published data,
confirmed these observations. In the BL samples, mutant and wildtype SMARCA4
transcripts had similar expression levels and immunohistochemistry and im-
munofluorescence analyses of BL samples showed constant co-expression of
SMARCA4 and MYC proteins in BL, regardless of the presence or absence of
SMARCA4 mutations (Fig. 5.13 c).
Intriguingly, genomic mutations of other members of the SWI/SNF complex,
including ARID1A, ARID1B and SMARCB1 were present in a subset of BL samples
lacking SMARCA4 mutation (Fig. 5.13 e), and, moreover, SWI/SNF complex genes
showed increased expression levels in BL samples (Fig. 5.13 f). Protein model-
ing [Betts 2015] suggests that SMARCA4 mutations likely do not obstruct binding
of themutant protein to DNA, but somemutationsmight ablate helicase function
directly, through interference with ATP-binding, or indirectly or by obstructing
the interaction of the helicase N and C-terminal domains. It has recently been
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Figure 5.13: SMARCA4 genome architecture and protein expression. (a) Integrative genome
browser view of the SMARCA4 locus. Top: chromatin segmentations of GM12878, BL2, DG-75 and
KARPAS-422 cell lines; middle: average CpG methylation of BL, FL and GC-B-cell samples; bottom:
average RNA expression of BL, FL and GC-B-cell samples. (b, c) Staining of SMARCA4 (BRG1) by con-
ventional immunohistochemistry in (b) a normal reactive follicle (reactive tonsil, original magni-
fication 400x), and (c) in a BL case with SMARCA4 R973W mutation (infiltrated lymph node, origi-
nal magnification 400x). (d) Accumulation of missense mutations in the SMARCA4 DEXDc helicase
(cyan) and helicase conserved C-terminal (grey) domains in BL samples. Lollipops indicate posi-
tions of mutations, with height proportional to number of mutations at that position. Red squares
indicate severe changes in physico-chemical properties (score<0); yellow: 0<score<4. (e) Sub-
units of the SWI/SNF complex are affected by somatic mutations (SNVs or indels) in 17/21 BL ana-
lyzed bywhole-genome sequencing. The distribution ofmutations in the samples suggestmutually
exclusive occurrence of different mechanisms of inactivation the SWI/SNF complex. (f) Unsuper-
vised analysis of SWI/SNF complex RNA-expression data (Affymetrix hgu133a) segregates BL and
FL. (g) Model of SMARCA4 mutations in BL, showing that they probably do not directly obstruct
binding of the mutant protein to DNA, but that some are likely to ablate helicase function by in-
terfering with ATP-binding, either directly or by obstructing the interaction of the helicase N and
C-terminal domains. The N-terminal helicase domain (DEXDc) is shown in cyan and the conserved
C-terminal helicase domain is shown in grey, as in panel.
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suggested, that such oncogenic SMARCA4 mutations like those observed herein
in BL compromise TOP2A chromatin binding which is dependent on the ATPase
activity of SMARCA4. Through our integrated analysis we now add a model for
a potential dominant function of mutated SMARCA4 (Fig. A.16). In this model,
overexpression of TCF3, initiated by the combination of cDMR hypomethylation
and mutation of TCF3 or its inhibitor ID3, leads to high expression of the inactive
SMARCA4 protein which prevents methylation of its binding site and expression
of its target genes due to its maintained binding competence in the absence of
helicase activity.
5.3.5 Comparison to progenitor cells
Finally, we aimed at comparing the DNA methylation patterns in BL and FL with
the DNA methylome changes observed during human B-cell differentiation re-
cently described by Kulis et al. [Kulis 2015] Comparison of the DNA methylation
levels determined by WGBS in the sorted GC-B-cells in both studies showed an
excellent agreement (correlation of means = 0.9799; Fig. 5.14 a). Principal com-
ponent analysis of the lymphomas analyzed herein together with the recently
investigated normal B-cell populations showed the BL and FL to cluster together
but are distinct from the normal B-cell subsets (Fig. 5.14 b). This separation of the
FL and BL cases from the physiologic GC-B-cells is caused most likely by the neo-
plastic process. To further investigate this, we analyzed the differences in DNA
methylation between BL and FL, respectively, as compared to normal GC-B-cells
for the 20majormodules of dynamic CpGmethylation during B-cell development
defined by Kulis et al. using both WGBS and array-based data (Figs. 5.14 c, d). In
linewithwhat has been described for diffuse large B-cell lymphoma by Kulis et al.,
we observe strongly increased DNA methylation of CpGs related to polycomb re-
pressed regions (modules 17-20) and decreased DNAmethylation of CpGs related
to heterochromatin (modules 8 and 9) in both FL and BL as compared to GC-B-
cells. This extends the previous findings to the fact that also BL and FL frequently
acquire methylation changes in regions already undergoing dynamic methyla-
tion during normal B-cell differentiation. Remarkably, when directly comparing
the DNA methylation of BL and FL for the 20 modules, we hardly observed any
differences. This suggests, that the DNA methylation differences between these
two GCB-lymphoma subtypes indeed reflect the separate oncogenic paths driv-
ing these lymphomas rather than DNA methylation dynamics of normal B-cell
differentiation. The only notable exception is module 11, which tends to lower
DNA methylation in BL than in FL. Remarkably, the CpGs of this module, which
are strongly enriched for enhancer sites, are characterized by DNA methylation
state switches from the naïve B-cell to the GC-B-cell stage. The difference in the
methylation rate as well as the enrichment for TCF3 binding sites in this module
might relate to a certain extent to the above described freezing of the functional
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states of GC-B-cells in BL and FL (Fig. 5.14 e), which is also supported by the dif-
ferential activation of oncogenic pathways in these lymphomas.
5.3.6 Summary
Here, we studied the epigenomic architecture of two neoplasms, BL and FL, de-
rived from the same cell of origin but showing considerably divergent genomic
evolution. In common, we found the global loss of DNA methylation of the
samples of both lymphoma subtypes and the contrasting gain of methylation at
poised promoter chromatin regions. Furthermore, comparison of BL and FL sam-
ples revealed differential methylation of intragenic regions where methylation
strongly correlated with expression of associated genes, e. g., genes active in GC
dark zone and light zone B-cells. Integrative pathway analyses of regions differ-
entially methylated between BL and FL implicated DNAmethylation to cooperate
with somaticmutation of sphingosine-phosphate and G-protein signaling, as well
as the TCF3/ID3 and the SWI/SNF complexes in a large fraction of BL lymphomas.
These findings support the concept of BL and FL being caught in different states
of GC-B-cell development.
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Figure 5.14: DNA methylation patterns of lymphomas and in normal B-cell differentiation.
A)Correlation of DNA methylation levels in GC-B-cell from Kulis et al. and the current study at
CpG resolution (blue: low density, orange: high density). B) Unsupervised principle component
analysis (PCA) of 450k BeadChip methylation data for all lymphoma and GC-B-cell samples used
in the current study and all normal B-cell samples of Kulis et al.. PCA was performed as described
in [Kulis 2015]. SHPCs, hematopoietic progenitor cells; preB1Cs, pre-BI cells; preB2Cs, pre-BII cells;
iBCs, immature B cells; naiBCs, naïve B cells from peripheral blood; t-naiBCs, naïve B cells from
tonsil; gcBCs, germinal center B cells; t-PCs, plasma cells from tonsil; memBCs, memory B cells
from peripheral blood; bm-PCs, plasma cells from bone marrow. C) WGBS methylation differences
of all CpGs of the modules defined by Kulis et al.. Top: BL against GC-B-cell, center: BL against FL,
bottom: FL against GC-B-cell. D) 450k BeadChip methylation differences of all CpGs of the modules
defined by Kulis et al.. Top: BL against GC-B-cell, center: BL against FL, bottom: FL against GC-B-cell.
E) Enrichment or depletion of cDMRs in the modules defined in Kulis et al. for the four quadrants
defined in the cDMR analysis. All DMRs were used as background.
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In the previous chapter contrasting findings of the DNA methylation
change at poised promoter chromatin segments with respect to to the
global loss of methylation were mentioned. Unexpectedly, poised pro-
moter associated genes were found to be frequently upregulated in the
analyzed lymphoma. In this chapter, we re-analyze combined expression
and methylation data sets, comprising over 5,000 samples, and demon-
strate that the hypermethylation of poised chromatin in conjunction with
up-regulation of the corresponding genes is a general phenomenon in can-
cer. This upregulation a�ects developmental genes and transcription fac-
tors, including many genes implicated in cancer. In addition, the analy-
sis of 7,000 methylation data sets shows that a universal classifier built
from poised chromatin data can identify cancer samples solely from the
hypermethylation status of poised chromatin. We reason that the alter-
ation of the epigenetic status of poised chromatin is intimately linked
to tumorigenesis. This chapter largely follows Bernhart and Kretzmer et
al. [Bernhart ].
6.1 Introduction
In recent years, a considerable amount of money and work has been spent
to investigate cancer using modern high throughput sequencing experi-
ments. However, especially when not only considering genomic, but also
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transcriptomic or epigenomic data, the evaluation and integration of the
data is often missing. We here integrate thousands of methylation exper-
iments and expression data from the International Cancer Genome Con-
sortium (ICGC) [International Cancer Genome Consortium 2010] and The
Cancer Genome Atlas (TCGA) [Cancer Genome Atlas Research Network 2008]
with chromatin segmentations from the NIH Roadmap Epigenomics
Project [Roadmap Epigenomics Consortium 2015] to assess the impact of
poised chromatin in cancer.
Poised promoters and enhancers are abundant chromatin states in both, stem
cells and differentiated cells [Mikkelsen 2007]. They are characterized by the si-
multaneous enrichment of activating (e. g., H3K4me1 or H3K4me3) and repress-
ing (e. g., H3K27me3) chromatin modifications [Voigt 2013]. While the associated
genes are repressed, poised promoters are preloaded with poised polymerase II
(Pol II) to prepare genes for rapid activation [Margaritis 2008, Mikkelsen 2007,
Gaertner 2012]. Poised chromatin is frequently found within the promoter re-
gion of developmentally important genes [Bernstein 2006, Lesch 2013]. These re-
gions have been suggested to “safeguard differentiation” [Voigt 2013], and their
malfunction might have a profound impact on the cell.
While DNA at poised promoters carries low levels of methylation in nor-
mal cells [Roadmap Epigenomics Consortium 2015, Meissner 2008], in cancer
cells they were reported to be hypermethylated [Hinoue 2012, Gal-Yam 2008,
Ohm 2007, Rodriguez 2008, Easwaran 2012]. Accordingly, we showed in the pre-
vious chapter that the mean methylation change at poised promoters in Burkitt
and follicular lymphoma is up to three times higher than in other chromatin seg-
ments [Kretzmer 2015]. Unexpectedly, we found themajority of genes controlled
by suchhypermethylated poised promoters to show simultaneously increased ex-
pression levels. An up-regulation of genes controlled by poised promoters was
recently shown in colorectal cancers [Hahn 2014]. In this study, however, it was
reported that hypermethylation led to the continued repression of genes. The
vast amount of publicly available data allowed us to investigate in this chapter
whether the positive statistical dependence, or more informally positive correla-
tion, of methylation and gene expression is a common feature to different cancer
types, or whether it is a lymphoma-specific phenomenon. We also were able to
fathom which types of genes are affected.
6.2 Material and methods
Material
In total, 127 15-state chromatin segmentation annotations (n=122 nor-
mal, n=5 cancer) were retrieved from the NIH Roadmap Epigenomics
Project [Roadmap Epigenomics Consortium 2015], including 16 chromatin
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segmentations generated from ENCODE [Harrow 2012] data. In addition,
ChIPseq data of cancer cell lines generated in the framework of the BLUEPRINT
consortium [Martens 2013] were used for chromatin segmentation.
RNAseq data sets (n=390 normal, n=5,389 cancer) were re-
trieved from ICGC [International Cancer Genome Consortium 2010] and
TCGA [Cancer Genome Atlas Research Network 2008]. 450k BeadChip methyla-
tion data (n=1,691 normal, n=7,870 cancer) are taken from ICGC, TCGA, ENCODE,
and GEO [Barrett 2013]. The BL, FL, GC-B-cell and BLUEPRINT data were pub-
lished in [Kretzmer 2015]. Combined 450k BeadChip and RNAseq data for normal
and cancerous tissue were available for a subset of 18 ICGC and one TCGA data
set.
From GEO additional array-based expression data were downloaded.
Chromatin segmentation
We genrated chromatin segmentations from the BLUEPRINT ChIPseq data
(H3K27me3, H3K36me3, H3K4me1, H3K4me3 and H3K9me3) of seven different
blood cancer cell lines (BL2, DG-75, JVM2, Karpas-422, SU-DHL5, U-266, Z-138).
To compare these chromatin segmentations to the Roadmap chromatin segmen-
tations, we used Roadmap’s 15 state HMMmodel and ChromHMM [Ernst 2012].
Poised, ESC and active intervals
We generated poised, embryonic stem cell (ESC) derived, and active promoter
intervals. These intervals are based on the 122 normal cell chromatin segmenta-
tions from Roadmap.
To gain poised enhancer and poised promoter intervals, the annotated poised
chromatin segments were merged separately. The number of distinct chromatin
segmentations contributing to each merged interval was counted. Poised seg-
ments, that are supported by� 80% (n=97) of the chromatin segmentations, are
called frequently poised segments (FPSs).
The ESC derived poised intervalswere defined asmerged poised intervals that
were poised in at least three ESC chromatin segmentations, but in less than 12
normal cell chromatin segmentations.
The active promoter intervals were calculated in a similar way. All normal
cell active promoter segments were merged. The active promoter intervals was
defined as those that are supported by� 50% of the normal cell segmentations,
but are not overlapping a FPS. For comparison of length distributions, we also
generated data sets derived frommerged active promoter and promoter flanking
regions as well as from genic and normal enhancers in the same way.
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Methods
Stability of poised segments in cancer
To assess the fate of poised segments in cancer, the types of 15 chromatin seg-
ments were subclassified into 8 main categories. The stability of these chromatin
categories in 11 cancer cell lines with respect to cells of origin was computed.
Therefore, the fraction of nucleotides that did not change their chromatin cate-
gory compared to the cell of origin segmentation was calculated. These numbers
were compared to the stability of chromatin segments in related normal cells.
Methylation values from 450k BeadChips and WGBS data sets
Themeanmethylation (β-values) anddifference inmeanmethylation for all CpGs
were calculated for each cancer and control group. These methylation differ-
ences were intersected with the respective chromatin segmentations and aver-
agedwithin the segments. Only segments with at least 3 covered CpGswere taken
into account.
Methylation changes of poised segments in cancer data
The cancer (cell line or fresh tissue) chromatin segmentations were paired with
their presumed cell of origin chromatin segmentation (A549:Lung, K562:Primary
B from cord blood, HepG2:Liver, BL:Primary B from periph blood, FL:Primary B
from periph blood). All segments where either the cancer or the cell of ori-
gin chromatin segmentation showed poised chromatin were taken into account.
The segments were classified as “stable” when both, normal and cancer, showed
poised chromatin, “lost” where only the cell of origin chromatin was poised, and
“new” where only cancer showed poised chromatin. For methylation analyses,
methylation rates were restricted to positions that were covered in WGBS (n=2)
and RRBS (n=4) data sets and for each pair only CpGs covered in both, cancer and
cell of origin, were taken into account.
Methylation classifier
For the main classifier only those FPS were used, that had contributions from
least 120 Roadmap single chromatin segmentation data sets (n=14 FPS, 163 CpGs
on 450k BeadChips). Two other classifiers were based on poised promoters (en-
hancers) and consists of the 9 (12) most frequently poised segments supported by
more than 97 (115) chromatin segmentations. Classifier segments that cover less
than three CpGs were discarded. For methylation rate calculation of the classifier
segments, data sets that hold methylation information for less than 3 segments
were discarded. About 6,090 cancer and 1,300 control data sets met these criteria.
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For a classification of samples into cancer and healthy tissue, the mean methyla-
tion over all CpGs was used for normalization.
For comparison, the analysis was repeated using a data set comprising seg-
ments that are poised in all ESC and iPSC chromatin segmentations, but in less
than three other more differentiated cells (n=47). All CpGs (n=92) present in any
of the 47 segments were used for classification. In addition the analysis was re-
peated on a merged polycomb repressed (ReprPC) data from which all regions
that overlap an FPS were subtracted.
Methylation vs. expression analysis of ICGC/TCGA data
To integrate changes in methylation and changes in gene expression, the aver-
age methylation differences for the FPS genes were plotted against the edgeR-
derived log2fold change expression of the associated genes. As a control gene set
all non-FPS genes with an active promoter chromatin segment in at least 50%
of all chromatin segmentations were taken. An additional control gene set was
defined as genes that overlapped with poised chromatin in at least 3 embryonal
stem cell, but in no more than 10 other segmentations. We used subsets of genes
significantly differentially expressed, lowly expressed (negative logCPM for the
normal cells), and the overlap between the two subsets.
Cell lines
For lymphoma cell line analysis, we plotted expression vs. methylation changes
of between BL, FL, GC-B-cell data and lymphoma cell lines, i. e., BL values were
compared to the mean of BL-2 and DG75 values, FL values to KARPAS-422 val-
ues, and GC-B-cell values were compared to the mean values of BL-2, DG75 and
KARPAS-422.
To compare changes in expression of FPS and not FPS associated genes dur-
ing the first stages of a newly created cell line, array based expression data from
glioblastoma were used. Average expression values of fresh tumor tissue, cancer
cell lines after a number of passages grown in serum, and of a commonly used cell
line were calculated. Log2fold changes were computed comparing the neoplastic
cells and the control cells.
Statistical dependence and correlation
By statistical dependence we refer to the situation were the differential expres-
sion of a gene (first variable X) is not statistically independent from differential
methylation of the poised segment (second variable Y). Specifically, this associa-
tion is positive if P(X > x,Y > y) � P(X > x)P(Y > y) is satisfied. Thus, the
positive correlation of two random variables is formally a special case of the posi-
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tive dependence. However, in everyday language statistical dependence is often
referred to as correlation.
6.3 Results
6.3.1 Poised segments in normal and cancer tissues
6.3.1.1 Distribution of poised chromatin in human cells
We analyzed 127 publicly available human chromatin segmentations from
the NIH Roadmap Epigenomics Project [Roadmap Epigenomics Consortium 2015]
and 7 cancer cell line chromatin segmentations from the BLUEPRINT consor-
tium [Martens 2013]. We could confirm that poised segments, i. e., poised pro-
moters and poised enhancers, are present in all analyzed tissues. However, the
total numbers differed strongly (Fig. 6.1 A). As expected, embryonic stem cells
(ESC) and induced pluripotent stem cells (iPSC) contained about twice as many
poised segments on average compared to other tissues. Cancer cell lines, on the
other hand, had the smallest number of poised segments.
Restricting the analysis to the non-cancer chromatin segmentations
(n = 122), and intersecting them with the Gencode version 19 gene annota-
tion [Harrow 2012], we confirmed that genes associated with poised chromatin
have a highly significant enrichment of the gene ontology (GO)-terms related to
transcriptional activity and developmental processes, but also e. g., to metabolic
processes (Fig. 6.1 B).
6.3.1.2 Frequently poised segments
To compare cancers of different tissues, we were interested in those genomic
regions that are under bivalent control in the majority of cell types. We thus
merged all non-cancer chromatin segmentations of the NIH Roadmap, and iden-
tified 918 genomic regions that were poised in more than 80% (n>97, frequently
poised segments, FPS, section A.4) of normal cells. On average, 25% of the poised
elements within a single data set overlapped FPS (Fig. 6.1 C). Recent publica-
tions used segments poised in ESC to investigate bivalent marks [Hinoue 2012,
Ohm 2007, Charlton 2015, Teschendorff 2015, Bartlett 2013]. Since ESCs and iP-
SCs have a much higher number of poised segments than differentiated cells, we
expect our conservative FPS approach to have a lower false positive rate. How-
ever, all FPS overlap a poised region in at least one ESC. The 80% requirement
makes FPS relatively robust against single erroneous segmentations. In themean,
FPS span 9,300 nucleotides, which puts them between active promoter (mean
length = 5,000 nt) and enhancer (mean length = 20,000 nt) segments. Some FPS
spanning gene clusters such as the HOXA, HOXB and HOXC clusters, are up to
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Figure 6.1: Poised segments in normal and cancer tissues. A) Number of poised segments in
cancer cell lines (red), normal tissues or cells (grey), embryonic stem cells (ESC, blue) and induced
pluripotent stem cells (iPSC, light blue). Stem cells on average have the highest number of poised
segments, while cancer cell lines have low numbers of poised segments. B) GO-term enrichment
for genes associated to poised segments. Light grey: genes associated to any poised segment; dark
grey: Genes associated to a FPS. The enrichment ofmetabolic process genes is lost in FPSs, while the
FPS genes are stronger enriched in the GO-terms developmental processes, anatomical structure
morphogenesis, sequence-specific DNA binding RNA polymerase II transcription factor activity (∗)
and signaling. C) Left: Fraction of poised chromatin segments that are part of a frequently poised
segment (FPS) in cancer cell lines (red), normal tissues or cells (grey), ESC (blue) and iPSC (light
blue). On average, cancer cells are depleted in FPS poised chromatin. Right: Fraction of FPS that
are poised in cancer cell lines (red), normal tissues or cells (grey), ESC (blue) and iPSC (light blue).
FPS are infrequently poised in cancer cell lines compared to normal cells. D) Length distribution
of FPS (black) and segments based on active promoters (red) and enhancers (blue).
93,000 nt long (Fig. 6.1 D). Amonggenes associatedwith FPS (n = 1,406), the enrich-
ment of GO-terms related to transcriptional activity, developmental processes
and signaling was even stronger than among all poised segments. (cf. Fig. 6.1 B).
The enrichment of metabolic processes was no longer significant.
6.3.2 Chromatin poising is disrupted in cancer
Analyzing poised segments in cancer cells shows that there is a difference in the
number and the location of poised segments as compared to normal cells. Can-
cer cells show less poised segments. Conversely, only an average of 28% of FPS
segments are poised in cancer, compared to 87% in normal cells (Fig. 6.1 D). This
suggests a disruption of chromatin poising in cancer cells. To analyze whether
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Figure 6.2: Cancer cell lines lose poised chromatin. Comparison of stability of chromatin seg-
ments between related normal cells and cancer cells and their cells of origin. Poised segments (Biv)
are the least stable chromatin segments in cancer, while they show average stability in normal cells.
Biv: Bivalent chromatin, Enh: Enhancer, Hetchr: heterochromatin, Quies: quiescent, TssA: active
promoter, Tx: transcribed, ZNF: zinc-finger/insulator.
the loss of poised chromatin in cancer cells is only part of a general restructur-
ing of the chromatin, we paired the segmentations of cancer cell lines (n = 11)
with segmentations of their tissues of origin. As a control, we created pairs of
closely related normal cells (n = 9). In the control, stability of poised segments
was similar to that of other chromatin types. In contrast, the stability of poised
segments in cancer cell lines was significantly lower when compared to all other
states (wilcoxon p<10−4, Fig. 6.2). Recently, Hahn et al. also described a “high
instability or variability of bivalent promoters in colorectal cancer” [Hahn 2014].
In summary, these findings suggest that tumorigenesis is accompanied by a sys-
tematic disruption of bivalent marks in cancer.
6.3.3 Hypermethylation and upregulation
6.3.3.1 Hypermethylation of poised chromatin in bisulfite sequencing data
As poised chromatin is mostly very lowly methylated, we suspected that the hy-
permethylation of chromatin poised in normal cells is accompanying the loss of
poising. To test this hypothesis, we compared the methylation changes of chro-
matin segments that lost their bivalent state in cancer cells to those that stayed
bivalent orwere only bivalent in cancer data of 5 different cancers. In all data sets,
hypermethylation of regions that lost their poising was stronger than for stably
poised regions. On average, newly poised regions did not showhypermethylation
(Fig. 6.3 A). We also re-analyzed the whole-genome bisulfite sequencing (WGBS)
data of BL and FL, presented in chapter 5, using a chromatin segmentation of
fresh primary B cells and confirmed poised chromatin hypermethylation in lym-
phomas compared to GC-B-cell. This was in contrast to the genome-wide loss of
methylation in BL (mean = -0.06) and FL (mean = -0.04) (Fig. 6.3 B). Similar results
were found for the WGBS data of acute lymphoblastic leukemia (ALL) [Lee 2015]
and Medulloblastoma [Hovestadt 2014]).
About a third of all FPS are longer than 10,000 nt. In contrast, poised regions in
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Figure 6.3: Hypermethylation of poised chromatin in cancer tissues. A) Methylation change
of poised segments in relation to their stability. Methylation change for fresh cancer (right) and
cancer cell lines (right) is shown for all elements in the cells of origin. Violet: chromatin poised
in cancer and cell of origin, blue: chromatin no longer poised in cancer, grey: chromatin poised
in cancer but not in cell of origin. B) Methylation difference for the 15 NIH Roadmap chromatin
states in BL. Poised states (grey box) show the strongest hypermethylation. C) Methylation differ-
ence in BL at (grey marked area) and around FPS, shown for FPS>10,000 nt (black), FPS<10,000 nt,
FPS subsegments poised in primary B cells (red) and segments poised in primary B cells but not
overlapping FPS (brown). D) ROC curve of FPS (orange), poised enhancer (black), poised promoters
(green), polycomb repressed regions without FPS (ocher) and ESC derived classifier (blue).
single segmentations aremuch shorter, with 96% below 2,000 nt. We investigated
whether the hypermethylation in cancer spans the entire FPS or is restricted to
the shorter subsegments that are poised in the cells of origin. We could show that
on average, poised chromatin in single segmentations is embedded in hyperme-
thylated regions. In contrast, hypermethylation is spanning the entire FPS,with a
quite sharp decrease to the background level at the borders of the FPS (Fig. 6.3 C).
Thus, FPS describe the regions of hypermethylation better than single poised re-
gions do.
6.3.3.2 Poised chromatin methylation as a universal cancer marker
To find out whether poised segment methylation is stable enough to distinguish
cancer samples from controls, we designed a methylation array based classifier.
In a similar approach, Nejman et al. have shown that the level of H3K4me3 and
H3K27me3 histone modification can be used to predict a CpG island’s susceptibil-
ity to hypermethylation in cancer, however without considering poised or biva-
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lent chromatin [Nejman 2014].
To construct a simple FPS-based classifier, we selected those FPS that were
poised in the maximum number of chromatin segmentations. Since only one FPS
was poised in 121 segmentations, we included all 13 additional FPS with 120 con-
tributors (98% of data sets). Evaluating 450k BeadChips data from 6,347 cancers
and 1,361 controls from various tissues, we found that the relative methylation
of these segments separated cancer and normal samples already with high sen-
sitivity and specificity (AUC = 0.926; Fig. 6.3C). Despite the high heterogeneity of
cancer types and the relatively small number of CpGs (n = 1,163), this classifier
was a robust predictor of cancer. The performance increased only slightly using
subsets of the 14 FPS regions.
Our classifier overlapped with 24 protein coding genes, including 14 home-
obox genes among which are seven HOX genes, two PAX genes (PAX3 and PAX6),
LBX1, and DBX1. Additionally, it contained nine other genes involved in develop-
mental processes, e. g., TBR1, ZIC2 and ZIC5. Many of these genes were frequently
upregulated in the ICGC cancer data (Fig. 6.5).
To disentangle the impact exerted by poised enhancers and promoters, we
repeated the classification with the most frequently poised promoters and en-
hancers, separately. These classifiers showed comparable performances, provid-
ing evidence that hypermethylation in cancer is a general phenomenon of poised
chromatin and is not restricted to promoters or enhancers (Fig. 6.3 C).
For all three classifiers, the lowest sensitivities and specificitieswere observed
for renal carcinomas, stomach adenocarcinoma and thyroid carcinoma, however,
still with AUC�0.73. 16 cancers could be classified with high sensitivities and
specificities (AUC>0.9). Most of them, including lung and rectum carcinomas,
even showed AUC>0.95 (Tab. A.25).
These results are in line with those obtained by other, less universal cancer
classifiers that were trained on CpG methylation, which showed enrichment of
bivalent genes in predictive areas [Teschendorff 2015, Bartlett 2013]. In striking
contrast, a classifier based on the relative methylation of chromatin segments
poised in all ESC and iPSC cells but not in more than 2 other cell types achieved
an AUC = 0.51.
6.3.3.3 Hypermethylation and up-regulation of genes as a global phe-
nomenon in cancer
To test whether the association of poised segment hypermethylation with in-
creased expression at the corresponding gene loci is a ubiquitous phenomenon in
cancer, we evaluated the mean expression values of RNAseq data sets (n = 6,092)
and methylation rates from 450k BeadChips (n = 6,246) of 19 cancer types and
their respective controls published by ICGC or TCGA. As some (9 of 19) cancer
sets lack a chromatin segmentation for their tissues of origin, we used FPS for
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Figure 6.4: Up-regulation of poised chromatin genes in cancer tissues. A) Scatter plots of
methylation change versus expression change for significantly differentially expressed genes in
FPS (left) and controls (active promoter background (center) and chromatin poised in ESC ex-
clusively (ESC, right). B) Cumulative plot of the number of cancers and the relative number of
gene/promoter tuples in quadrant 1 of the scatter plot (hypermethylation and up-regulation) for
FPS genes (blue), ESC genes (grey) and background (red). Top: Only significantly differentially
expressed genes are considered. Bottom: Only lowly and differentially expressed genes are con-
sidered. FPS has the highest fraction in Q1 in 16 cancer data sets. Q1 has the highest fraction of
tuples in 13 FPS data sets. C) Boxplot showing the expression change of significantly differentially
expressed genes controlled by FPS (blue), genes poised in ESC (grey) and other genes (red). Signif-
icance (wilcoxon) of comparisons: ∗ ∗ ∗: p<2.2×10−9, ∗∗: p<10−3, ∗: p<0.05. For abbreviations
of cancer names see Tab. A.24.
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our analysis.
We first restricted our analysis to genes that were significantly differentially
expressed. We found a large degree of positive dependence between increased
methylation and expression of genes associated with FPS (Fig. 6.4 A, Fig. 6.4 B):
For example, 15 of 19 cancers show an upregulation (mean log2fold change: 0.94)
and hypermethylation (mean change 0.07) in more than 40% of the genes. There
will be a bias introduced by the low baseline expression of most poised genes.
Therefore, we also compared the subset of lowly expressed FPS genes to other
lowly expressed genes. In 17 of the 19 cancer data sets, FPS genes showed a higher
enrichment of hypermethylated and up-regulated genes. Compared to genes as-
sociated to genomic regions that are poised in embryonic stem cells but not in
more differentiated cells, FPS genes again showed a higher proportion of hyper-
methylated and up-regulated genes in all but two cancer types.
Many RNAseq experiments show a bias towards upregulation of genes in can-
cer. To compensate for this effect, we separately compared the change in ex-
pression of FPS genes to all genes. Using one-sided wilcoxon tests, we found that
12 of 19 cancers showed stronger upregulation in FPS than in the background,
while only one showed significantly weaker upregulation. When restricting the
analysis to lowly expressed genes, 17 cancer types showed significantly stronger
upregulation in FPS genes than in the background, while none showed the oppo-
site behavior. Comparisons to the genes poised in ESC did closely resemble these
results.
6.3.3.4 Analysis of upregulated genes
To analyze what type of genes were among themost strongly affected by upregu-
lation, we chose the FPS genes that were significantly up-regulated in more than
50% of all cancers we investigated (n = 172), and compared them to the FPS genes
that showed significant downregulation in more than half of the cancer data sets
(n = 68). We found that even compared to all FPS genes, the upregulated genes are
enriched in genes containing homeobox domains (n = 37, 1.6 fold enrichment) as
well as in genes for transcription regulation (n = 55, enrichment 1.3 fold) and de-
velopmental proteins (n = 45, enrichment 1.3 fold). In contrast, downregulated
genes showed a depletion of homeobox containing genes (n = 2, enrichment 0.22
fold), developmental genes (n = 7, enrichment factor 0.5) and transcription regu-
lation genes (15, enrichment factor 0.87).
Unsupervised clustering of the expression fold changes of the FPS genes for all
19 cancer entities revealed similarities between cancers that come from similar
organs such as lung squamous cell carcinoma (LUSC) and lung adenocarcinoma
(LUAD) or rectum and colon adenocarcinoma (READ and COAD) (Fig. 6.5 B). For
the former pair a particularly high expression of HOXC13 was observed, while
the latter showed upregulation of SOX14. In addition, several members of the
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Figure 6.5: Expression heatmaps of FPS controlled genes A) Heatmap of the expression log2fold
changes of selected FPS associated genes. Unsupervised clustering reveals expression similarities
of FPS associated genes in related tissues. For abbreviations of cancer names see Tab. A.24. B)
Heatmap of expression changes for all FPS genes significantly upregulated in more than 50% of
the cancer data sets.
NKX homeobox family were frequently upregulated. In particular, the cervix car-
cinoma produced high levels of NKX2-1, NKX2-2 and NKX2-5.
As homeobox genes have been shown to play an important role in both, onco-
genesis and tumor suppression [Shah 2010], we further investigated the upreg-
ulated genes of this gene family. In our analysis HOXB13, previously associ-
ated with ovarian [Miao 2007] and breast carcinoma [Wang 2007, Jerevall 2008],
was strongly upregulated in lung, skin, breast and gynecologic malignancies.
OTX1, which has been connected to colon oncogenesis and to non-Hodgkin lym-
phoma [Yu 2014], was most strongly upregulated in cervical carcinoma, but also
very strongly upregulated in rectal and colon adenocarcinoma.
The rectal and colon adenocarcinoma both produced increased amounts of
the forebrain embryonic zinc finger protein 1 (FEZF1), which has been implicated
in the development of gastric cancers [Song 2009]. Among the highly upregulated
genes, TBX15 showed the strongest hypermethylation across all cancer entities
(median = 0.228). In the context of prostate carcinoma the hypermethylation of
TBX15 as well as HOXD3 has been associated, via a positive correlation with ERG
expression, to the histone deacetylase HDAC1 and a global epigenetic reprogram-
ming [Kron 2012, Iljin 2006].
Interestingly, the polycomb group genes CBX4 and CBX8 are also among the
genes that often show significant upregulation and hypermethylation. CBX8 has
been connected to leukemogenesis [Tan 2011], while CBX4 potentiates angiogen-
esis in hepatocellular carcinoma [Li 2014].
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Figure 6.6: Expression and methylation of cancer cell lines. A) Methylation an expression
changes of FPS in BL cell lines against BL fresh tissues (top left), KARPAS-422 against FL fresh tis-
sues (top right), lymphoma cell lines against normal GC-B-cells (bottom left) and GCB against FL
fresh tissues. Changes are shown relative to the cell lines. The number of tuples in each quadrant is
shown. B) Expression change of FPS genes (blue) and other genes against normal cells in glioblas-
toma fresh tissue (left) and in cancer cell lines after a number of passages grown in serum. At the
right, the value for commonly used cell lines is shown. C) Relative methylation of classifier FPS in
cancer cell lines, fresh cancer tissue, normal cell lines and normal tissue.
Naturally, this set of genes is determined by the types of cancers we investi-
gated. The degree of differential expression of these 172 genes, varies from can-
cer to cancer. However, in 17 cancer types, there is an enrichment of homeobox
genes in the significantly upregulated genes. The two exceptions show very little
significantly differentially expressed genes, mostly due to the small number of
control experiments. The genes that overlapped with the methylation classifier
mostly showed strong upregulation and hypermethylation, while the genes over-
lapping with the stem cell based classifier showed a much weaker upregulation
(p<2.2×10−16).
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6.3.3.5 Evidence for lower expression of FPS genes in cell lines
Earlier cell line based studies of hypermethylation in bivalent regions did not
report an upregulation of associated genes [Easwaran 2012]. To investigate this
discrepancy, we compared DNA methylation [Kretzmer 2015] and gene expres-
sion [Klapper 2008, Hummel 2006, Klapper 2012, Rosolowski 2013] of lymphoma
cell lines to fresh cancers and controls. Indeed, our comparison revealed a hy-
permethylation of poised regions and a downregulation of associated genes in
the cell lines when compared to fresh cancer tissues (Fig. 6.6 A). An analysis of
cell line expression data from Glioblastoma [Lee 2006] confirmed that FPS genes
are upregulated in fresh cancer tissue, but much less in commonly used cell lines
(Fig. 6.6 B). Analysis of the expression data of cell lines newly generated by Lee
et al. indicated that FPS genes are gradually silenced with each passage. After a
couple of passages, FPS genes show an expression close to that in control cells
(Fig. 6.6 B). We could confirm the repression of FPS genes in data from cervix car-
cinoma cell lines [Scotto 2008] and found a small but significant (p<0.008) reduc-
tion of FPS gene expression in freshly generated cell lines from lung carcinoma
metastasis [Gottschling 2012].
We also investigated whether the relative classifier CpG methylation of cell
lines is different to the one of primary tissues. Cancer cell lines (but not nor-
mal cell lines) showed a significantly higher relative descriptor methylation than
fresh cancer tissues (p<10−13, Fig. 6.6 C).
6.4 Summary
In an attempt to reconcile our seemingly controversial findings we recall that:
(i) hypermethylation of poised elements is a frequent event in fresh cancer tis-
sues. Our data indicates that (ii) this effect is even more pronounced in several
cancer cell lines and that chromatin poising is frequently lost in cancer cell lines.
While we see (iii) an upregulation of associated genes in fresh cancers, (iv) the
repression seems to be largely intact in the cell lines.
We propose that the hypermethylation, the up-regulation, and the loss of
poised chromatin might have a common cause, namely the genome-wide “ac-
tivation” of poised Pol II followed by a transient gene expression. Subsequently,
methylation could gradually re-silence the genes, leading to a signal mixture of
both elevated expression and methylation in fresh cancer tissues. The fact that
cancer cell lines have a significantly higher methylation and an intact repres-
sion suggests that these cell lines have managed to re-establish the silencing via
methylation. In fact, our results suggest that a quick repression of FPS genes oc-
curs during the creation of cell lines. Although our data indicates that the bi-
valent marks are frequently lost in cancer, we have found no rule to predict the
fate of poised elements in neoplastic diseases, and we have no data on the chain
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of events that leads to this loss. Likewise, the mechanism that would lead to the
activation of the Pol II remains speculative. One possible trigger for the activa-
tion of poised Pol II is the proto-oncogeneMYC.MYC is frequently over-expressed
in cancer [Beroukhim 2010] and facilitates Pol II pause release by recruiting the
positive transcription elongation factor (P-TEFb), a pause release factor, to the
paused Pol II [Rahl 2010]. Therefore, MYC has been predicted to cause expression
of formerly poised genes in cancer [Rahl 2010]. However, the described phenom-
ena are not limited to cancers over-expressing MYC.
The DNA hypermethylation may be explained by the enrichment of two DNA
methyltransferases (DNMT1 and DNMT3b) surrounding poised promoters in can-
cer cell lines [Jin 2012]. It is tempting to speculate that poised chromatin methy-
lation is a backup to re-enforce repression in case of a disruption of poising, em-
phasizing the importance of keeping the respective genes under tight control.
The tight control on the epigenetic level coincides with selective pres-
sures on the genomic level. The NIH Roadmap project showed that
poised chromatin tends to be enriched in non-exonic conserved elements
(GERP) [Davydov 2010] compared to its respective active chromatin counter-
part [Roadmap Epigenomics Consortium 2015]. This is another hint for the func-
tional importance of poised chromatin.
A change of chromatin state is essential for hypermethylation, since the pres-
ence of H3K4me3 would still protect the DNA from methylation.
Effect of genes up-regulated
Poised chromatin is known to play an important role in normal tissue develop-
ment, but also seems to be crucial for keeping cells in their differentiated states.
The enichment of FPS associated homeobox genes is indicative of this function.
Homeobox genes such as the HOX family have been implicated to play an impor-
tant role in both, oncogenesis and tumor suppression [Shah 2010]. Abate-Shen
described that homeobox genes exert their oncogenic effect via a strong over-
expression or a temporospatially different expression pattern [Abate-Shen 2002].
It has been shown that cancer risk factors such as smoking or age are
correlated with the hypermethylation of CpGs at bivalent regions in the
genome [Teschendorff 2015, Teschendorff 2010]. For dysplasia cells, however,
also an age independent component was shown. Furthermore, the BL investi-
gated here are pediatric cancers (median age 11 years), while the FL are mostly
geriatric (median age 62 years). The fact that we see only little difference regard-
ing poised chromatin methylation and expression indicates that non age-related
causes contribute to this effect.
Taken together, we show that the aberrant expression of developmental genes
effectively no longer under poised chromatin control is present in various cancer
types. In principle, such a runaway expression could lead to a de-differentiation
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of cells, much like the over-expression of the Yamanaka factors used to gener-
ate induced pluripotent stem cells [Takahashi 2006]. As an example, three out of
four transcription factors (SOX2, POU3F2, and OLIG2) recently shown to be able
to reprogram differentiated Glioblastoma cells to stem-like tumor-propagating
cells [Suvà 2014] are associated to a FPS. The three poised segments correspond-
ing to these genes showed hypermethylation across all cancer types (median
methylation difference 0.13, 0.09 and 0.09, respectively), and the genes’ expres-
sion showed a median log2fold change of 1.7, 1.8, and 1.2, respectively.
Hence, some of the hypermethylated and upregulated FPS genes may well
have contributed to the reprogramming of cancer cells. If apoptosis or prolifer-
ation related genes are damaged, de-differentiated cells might develop into can-
cer cells. The fact that poised segments accumulate in genes associated to HDAC1
and SOX2 provides further evidence that the disturbance of poised genes causes
a global epigenetic reprogramming.

Chapter 7
Conclusion
The regulation of gene expression is an essential process in all cells. Rather com-
plex and specialized mechanisms cooperate to ensure the expression of a specific
subset of genes. Intricately interwoven levels of control and feed-back coordi-
nate the reaction to external or internal triggers. The time point of gene expres-
sion, the number of copies, as well as the specific regions that are transcribed are
all regulated by this machinery. Disturbances of these highly orchestrated pro-
cesses are sometimes tolerated and mitigation strategies are activated, e. g., the
expression of an wild type allele compensates for the expression of an mutated
allele [Rossi 2015]. However, severe disruptions may not be compensated and ul-
timately lead to serious consequences, including diseases and all types of cancer.
Thus, a comprehensive view and a deeper understanding of this regulatory
network, with all its interactions and dependencies, is of great interest. A
better knowledge would allow for regulatory intervention on the system. In
the so-called personalized medicine it might be possible to correct such disturbed
systems more precisely. Unfortunately, it is not possible to uncover the entire
regulatory system at once, since the degree of complexity and interaction is
inextricable. Today the different key players of gene expression regulation are
initially investigated individually. Subsequently, the knowledge of mechanisms
are integrated and the effect on transcription is evaluated.
Next-generation sequencing technologiesmade it possible to investigate sev-
eral regulatory layers, including the epigenome, in great detail and resolution.
While the costs of the experiments are decreasing, the throughput, and conse-
quently the amount of produced data, increases. Due to the role of epigenetic
mechanisms in several key processes, e. g., in normal cell and disease develop-
ment or the response to external influences, the analysis of the epigenome will
become more important. However, huge amounts of data demand efficient and
accuratemethods and pipelines. In particular, for large studies comprising a high
number of samples it is essential to establish a standardized, well-benchmarked,
and performant pipeline to ensure comparable results.
To achieve this, the versatile toolkit BAT for bisulfite-treated sequencing data
processing and analysis was developed in the context of this work. The basic pro-
cessing ofWGBSdata, startingwith the read alignment, and post-processing steps
are streamlined to ensure reproducibility. This noticeably enhances the conve-
nience, reduces hands-on time and random human error. The methylation rates
reported by BAT can easily be filtered, visually inspected and compared using
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various plots and statistics, and conversions to standard formats are provided.
Moreover, BAT offers the first steps in data analysis of groups of samples, i. e.,
provides statistics on genome-wide methylation levels. The reported graphics
are concise, easy to interpret, and give a first impression of the underlying data
and differences of groups and samples. A more advanced analysis is the detec-
tion of differentially methylated regions (DMRs) with our newly developed tool
metilene, including pre- and post-processing steps. Finally, BAT allows for inte-
gration of gene expression and DNA methylation data by the calculation of cor-
relating DMRs.
metilene identifies DMRs in whole-genome and targeted bisulfite sequenc-
ing data with unrivaled specificity and sensitivity. metilene was tested on 12
types of artificial data sets that vary in the degree of background heterogene-
ity, complexity (difference) of the simulated DMRs, and density of CpGs. None of
the competing tools, i. e., BSmooth, MOABS, and BiSeq, could detect DMRs com-
parably good across all artificial data sets. The binary segmentation algorithm
combined with a two-dimensional statistical test allows to detect DMRs in large
methylation experiments with two groups of multiple samples in minutes rather
than days using off-the-shelf hardware. While all tested tools at least finished
their DMR calling runs for a low number of samples per group (up to 8 vs. 8 sam-
ples), only metilene called DMRs in groups of up to 50 vs. 50 samples in less than
one hour using 10 cores. In contrast to other tools, no pooling of data is done,
such that the full intra-regional and intra-group variation is taken into account.
Furthermore, metilene performs favorably on low coverage data, and can esti-
mate missing data. In summary, metilene’s sensitivity and speed in detecting
changes in DNA methylation on a global, genome-wide level, make it possible to
use it in projectswith dozens of samples per group. But even in situationswithout
biological replicates, metilene produces highly significant and reliable results.
None of the other tools available today are able to analyze such data without the
consumption of huge computational resources. Currently, metilene is also be-
ing integrated to the Galaxy platform [Giardine 2005] to make it accessible to a
broader group of researchers. Taken together, the ability to handle a high num-
ber of samples, the very short running time and its high specificity and sensitivity
qualifies metilene to be suitable for DMR calling in future.
The tools developedwithin this thesis, i. e., BAT and metilene, were success-
fully applied to the bisulfite sequencing data of ICGCMMML-seq project. The pre-
sented DNA methylation analyses of BL, FL, and GC-B-cell, identified substantial
differences in DNAmethylation patterns between the three entities. By combina-
tionwith genomeand transcriptome analyses the differences inDNAmethylation
could be linked to transcription factor activity and showed that these differences
are critical determinants of FL- and BL-specific gene expression patterns. In ad-
dition, lymphoma subtype-specific patterns of DNAmethylation, integrated with
mutation analysis, helped to identify complementary aberrant regulation of the
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SWI/SNF, TCF3/ID3 and Gαi complexes as important contributors to Burkitt lym-
phomagenesis. These findings are important steps for the deeper understanding
of lymphoma specific altered genes and pathways. Due to the already shown per-
formance of the developed tools, BAT and metilene, they will also be used in
consecutive projects. The findings and tools presented here will be a good start-
ing point for integration of the DLBCL data to further elucidate the trigger of the
very diverse phenotypes of lymphoma from the same cell of origin.
In addition to the lymphoma specific alterations in the methylome and
transcriptome, we detected a molecular alteration that is common to a greater
number of cancer types. First, we showed, that the loss of the poised chro-
matin state is a common phenomenon in a variety of cancers. This finding
has the potential to reveal mechanisms frequent in cancer. In brief, already
the methylation rate of a small set of loci located in frequently poised chro-
matin could be the basis for a cost-effective and efficient universal cancer
descriptor for diagnostic purposes. This test could be used globally to identify
cancer of all types irrespective of their cells of origin. Since poised marks
are usually inferred from independent ChIPseq experiments, it can not be
ruled out that several bivalent marks annotated by NIH Roadmap are artificial
juxtapositions of H3K4me and H3K27me3 histone modifications. ChIP-reChIP
experiments [Voigt 2012, Bernstein 2006] will help to improve the annotation of
poised promoters and other chromatin segments in the future.
Taken together, the realization of the impact of epigenetic modifications and
the ability to sequence them, allows the analysis of a variety of cells, diseases, and
developmental stages from a new point of view. The methods presented here fo-
cus on the bioinformatical analysis of one of the two major epigenetic modifica-
tions. We demonstrated the demand and potential of our newmethods and tools
to improve the analysis of DNA methylation data.
In the future, it will be necessary to integrate genetic and epigenetic infor-
mation more closely, e. g., DNA methylation and histone modifications, with the
transcriptomic data to obtain a better understanding of the crosstalk between
these components and their influence in physiological and pathological mecha-
nisms. Changes in the epigenetic components can work together to transcrip-
tionally silence genes, fine tune the expression level, or maintain the present
state. The nature of these interactions is highly complex and multifaceted. Sev-
eral components influence another and most regulations are not unidirectional.
The accessibility of the chromatin regulates the expression of genes, which in
turn may shape the chromatin by encoding for histone modifying enzymes or
non-coding RNAs [Wang 2011]. These relations become more complex the more
levels are considered – transcription factors, chromatin conformation, protein
levels, and clinical data are only some examples. Consequently, the interactions
among various mechanisms form a highly interconnected network. Neverthe-
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less, the focus of such multi-dimensional data analyses lies mainly on the effect
on gene expression [Gomez-Cabrero 2014].To carry out such analyses, it has to
be ensured that single components are evaluated in a proper way. This applies
in particular when multidimensional data with multiple samples and groups are
considered. For a simplified representation some kind of summary or consensus
information is valuable. However, for differential analysis all observations should
be considered, since biological replicates capture biological variation. Simplifica-
tions, dimensionality reductions and location measures, like means or medians,
might diminish these variations. Thus it is better to incorporate this during dif-
ferential analysis.
The definition of a location measure is comparably simple for metric data,
e. g., DNA methylation or gene expression levels, since the average of the nor-
malized sample levels is commonly used. This is complicated if the signal is on an
ordinal or nominal scale. Examples are chromatin accessibility, transcription fac-
tor binding sites, or chromatin states. Especially for chromatin state data better
methods are needed to integrate it with gene expression data. During the analy-
sis of the lymphoma data set in chapter 5, the definition of an average chromatin
state per region was circumvented. Instead of ChIPseq data for each sample, cell
line data was used to represent the stable states of the lymphoma and control
cells. In chapter 6 we took it a step further and integrated the chromatin states
of several samples and cell lines. First of all, we assured that all chromatin seg-
mentations were generated using the samemodel, to ensure comparability. Since
we were interested in a specific subset of chromatin states, i. e., poised states, we
centered the analysis on those states. All poised states were merged and, based
on the support level, regions were classified as poised or not. Without a rank-
ing of chromatin states, however, this approach is not suitable for whole genome
analyses and more sophisticated methods are needed.
Recently, a lot of progress has beenmade in differential gene expression anal-
ysis. For RNAseqdata several tools exist that consider values of all samples and ac-
cordingly also intra-group variances [Robinson 2010, Reyes 2012, Anders 2010a,
Law 2014]. Calling of differential methylation in bisulfite sequencing data was
largely based on approaches that either disregard biological variation inside
groups or regional variation [Akalin 2012, Park 2014, Feng 2014, Stockwell 2014,
Sun 2014, Hebestreit 2013, Hansen 2012]. We coped with this problem by the de-
velopment of metilene (chapter 4). These improvements now need to be ex-
tended to ordinal or nominal data. In chromatin state data the difference prob-
lem grows from a two-dimensional to a multi-dimensional problem. Chromatin
states are encoded in categories that show different degrees of similarity but can
not be linearly ordered with respect to their similarity. Depending on the under-
lying chromatin modifications and their location, the impact on gene expression
varies. Consequently, the detection and classification of differential chromatin
regions is challenging and needs to take the multiple dimensions of the problem
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into account.
Following characterization and proper measurement of changes in each the
regulatory mechanisms, one approach is to evaluate each mechanisms with re-
spect to the changes in the level of expression or sequence alterations of specific
genes. Subsequently, these gene-centric evaluations could linked to explain sev-
eral facets and parts of alterations in pathways that are not explainable by the
single observations. In chapter 5 this has been done on a local scale for the ex-
pression of genes regulated by the SWI/SNF complex. Changes in the DNAmethy-
lation level, chromatin state modifications, transcription factor expression, and
genomicmutations were integrated to explain the altered expression of SWI/SNF
complex target genes. With more sophisticated analyses of the different mech-
anisms and the extension of this kind of data integration an important step to-
wards a better understanding of this complex regulatory network could bemade.
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A.1 BAT - Parameter and basic usage
BAT_mapping
Basic usage
$ perl BAT_mapping -g <string> -p <string>
Parameter
parameter description
-g path/filename of reference genome FASTA.
-p path/filename of query sequence. File containing single ended reads
or first mate if paired end reads in FASTA or FASTQ format. May be
gezipped.
-q path/filename of mate sequences. Default is none and -p option reads
will bemapped. If -qmates are provided the reads aremapped as paired
end reads. Please take care, that first reads and mates are in the same
order.
-i path/prefix of database indices. segemehl needs two types of indices
for bisulfite mapping. If no segemehl indices exist, the indices will
be built under the given path with the given prefix. This is time con-
suming, but need only to be done once. Indices can be used for further
mapping of bisulfite data using segemehl.
-o path/prefix of out files. By default, all out files are written to path di-
rectory, named with the given prefix. Using the –stdout option, the
sorted BAM will be printed to standard out. No index files .bam.bai and
no excluded.bam will be written. By default this directory is also the
temporary directory, if no temporary directory is specified.
- -tmp path/prefix of temporary directory. segemehl produces several tem-
porary files during mapping. All temporary files, e. g., segemehl files,
SAM files and temporary files produced by samtools are written to the
temporary directory. If a non-existent directory is specified, the direc-
tory will be build and removed afterwards. Make sure that enough disk
space is available.
-t start <num_threads> threads (default: 1). Increase of number of threads
decreases mapping time.
-F bisulfite mapping with methylC-seq/Lister et al. (=1) or bs-seq/Cokus
et al. protocol (=2) (default: 1). The type of protocol that has been used
for library preparation.
-a additional segemehl parameters (default: none). Do not give already
set options! This option is recommended only for advanced users who
are familiar with mapping/segemehl.
- -stdout flag for output to stdout. Pipeline ends with output of sorted BAM. No
indexed BAM, excluded mappings are discarded and no log file will be
written. Not recommended.
- -exclude if XF_flag>number, mapping is excluded from regular BAM file (default:
3). This option is recommended only for advanced users who are famil-
iar with segemehlmapping of bisulfite data.
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- -segemehl path/filename of segemehl executable. Required if segemehl exe-
cutable is not in PATH. For installation, manual or problems please view
the segemehl website.
- -samtools path/filename of samtools. Required if samtools is not in PATH. For
installation, manual or problems please view the samtools website.
BAT_mapping_stat
Basic usage
$ perl BAT_mapping_stat --bam <string>
or
$ samtools view <bam> | BAT_mapping_stat
Parameter
parameter description
- -bam path/filename of input file (default: stdin)
- -excluded path/filename of input file
-p path/filename of output file for multiple hits frequencies paired end
(default: stdout)
-m path/filename of output file for multiple hits frequenstringcies one
mate (default: stdout)
-s path/filename of output file for multiple hits frequencies single ends
(default: stdout)
-e path/filename of outputfile for e-distance distribution (default: stdout)
- -brief flag to summarize important information in one line
- -fastq path/filename to FASTQ file (first read pair if paired end), to calculate
percentages in addition to total numbers
BAT_merging
Basic usage
$ perl BAT_merging -o <string> --bam <string>
Parameter
parameter description
- -bam comma-separated list of path/filename of BAMs to be merged
-o path/filename of merged output BAM file
- -cn comma separated list of names of sequencing centers produced the
reads, one for each BAM file (default: none)
- -ds comma separated list of descriptions, one for each BAM file (default:
none)
- -dt comma separated list of dates (ISO8601 date or date/time) the runswere
produced, one for each BAM file (default: none)
- -fo comma separated list of flow orders, one for each BAM file (default:
none), Format: ’/*|[ACMGRSVTWYHKDBN]+/’
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- -ks comma separated list of arrays of nucleotide bases that correspond to
the key sequence of each read, one for each BAM file (default: none)
- -lb comma separated list of libraries, one for each BAM file (default: none)
- -pi comma separated list of predicted median insert sizes, one for each BAM
file (default: none)
- -pl comma separated list of platforms/technologies used to produce the
reads, one for each BAM file (default: none), valid values: CAPILLARY,
LS454, ILLUMINA, SOLID, HELICOS, IONTORRENT, PACBIO
- -pu comma separated list of platform units, one for each BAM file (default:
none)
- -sm comma separated list of samples, one for each BAM file (default: none)
- -id comma separated list of read group identifiers, one for each BAMfile (de-
fault: determined by the file name the read is coming from andmatches
RG tag of the reads)
- -samtools path/filename of samtools. Required if samtools is not in PATH. For
installation, manual or problems please view the samtools website.
BAT_calling
Basic usage
$ perl BAT_calling -d <string> -q <string>
Parameter
parameter description
-d path/filename of reference genome fasta
-q path/filename of query sequences (BAM (path/query_prefix.bam) or
gzipped SAM file (path/query_prefix.sam.gz))
-o path for outfiles (default: query_path)
-i path/filename of query index (default: path/query_prefix.sam.idx)
- -haarz path/filename of haarz executable. Required if haarz executable
is not in PATH. For installation, manual or problems please view the
segemehl website.
- -samtools path/filename of samtools. Required if samtools is not in PATH. For
installation, manual or problems please view the samtools website.
BAT_filter_vcf
Basic usage
$ perl BAT_filter_vcf --vcf <string> --out <string>
Parameter
parameter description
- -vcf path/filename of gezipped vcf file containing methylation calling in-
formation
- -out path/filename of filtered outfiles (gezipped vcf file, bedgraph, pdf)
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- -context comma seperated list of context
- -MDP_min minimumnumber of reads afterfiltering by bisulfite conversion strand
in all samples
- -MDP_max maximum number of reads after filtering by bisulfite conversion
strand in all samples
- -NS minimal number of samples
- -MR_min Minimum sample methylation rate
- -MR_max Maximum sample methylation rate
- -MR flag ifMRfilter should be applied only tomeanmethylation/difference
in methylation rate
-R path/filename of R. Required if R is not in PATH. For installation, man-
ual or problems please view the R website.
BAT_summarize
Basic usage
$ perl BAT_summarize --g1 <string> --g2 <string> --out <string>
Parameter
parameter description
- -in1 comma-seperated list of bedgraph input files of group 1
- -in2 comma-seperated list of bedgraph input files of group 2
- -out path/prefix of out files (mean methylation rates, difference in mean
methylation rates, all samples bedgraphs and metilene input)
- -cs path/file of chrom.sizes file of the corresponding genome
- -NA string how missing values are coded (default: NA)
- -NA1 number of max. missing values in group 1 allowed (else discard position,
default: 0)
- -NA2 number of max. missing values in group 2 allowed (else discard position,
default: 0)
- -h1 comma-seperated list of sample identifiers of group 1 (default: prefix
bedgraphs)
- -h2 comma-seperated list of sample identifiers of group 2 (default: prefix
bedgraphs)
- -cir path of circos folder, if defined, a circos plot (heatmap) containing all
samples will be plotted. Needs to contain “bin” bed files
-l comma-seperated group ids (one for each group, default: group1,
group2)
-c path/filename of circos. Required if circos is not in PATH. For instal-
lation, manual or problems please view the circos website.
- -b path/filename of bedtools. Required if bedtools is not in PATH. For
installation, manual or problems please view the bedtools website.
- -bgbw path/filename of UCSCtools bedGraphToBigWig. Required if
UCSCtools bedGraphToBigWig is not in PATH. For installation,
manual or problems please view the UCSCtools website.
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BAT_overview
Basic usage
$ perl BAT_overview -i <string> -o <string> -p <string> -q
<string>
Parameter
parameter description
-i input file, e. g., summary file, with methylation rates for all samples.
-p identifier of first group. Column names need to start with the group
identifier.
-q identifier of second group. Column names need to start with the group
identifier.
- -o path/filename.pdf of pdf out file
- -m string to indicate missing values, (default NA)
BAT_annotation
Basic usage
$ perl BAT_annotation -b <string> -i <string> -g <string>
Parameter
parameter description
-b bedgraph file containing annotation of regions, e.g. TFBS, hy-
po/hypermethylated regions, genes, CpG islands/shores (format:
chr<tab>start<tab>end<tab>identifier<tab>grouping_label)
-i summary file for methylation rates, bed-like (format:
chr<tab>start<tab>end<tab>sample1<tab>sample2<tab>...<tab>samplej)
-g comma-separated group assignment for samples in summaryfile (option
-i), e. g., group1,group1,...,group2,group2,...
- -o path/prefix for output (default: current directory/annotation)
- -cs path/file of chrom.sizes file of the corresponding genome
- -NA string how missing values are coded (default: NA)
- -NA1 number of max. missing values in group 1 allowed (else discard position,
default: 0)
- -NA2 number of max. missing values in group 2 allowed (else discard position,
default: 0)
- -h1 comma-seperated list of sample identifiers of group 1 (default: prefix
bedgraphs)
- -h2 comma-seperated list of sample identifiers of group 2 (default: prefix
bedgraphs)
- -cir path of circos folder, if defined, a circos plot (heatmap) containing all
samples will be plotted. Needs to contain “bin” bed files
-l comma-seperated group ids (one for each group, default: group1,
group2)
- -bedtools path/filename of bedtools. Required if bedtools is not in PATH. For
installation, manual or problems please view the bedtools website.
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-R path/filename of R. Required if R is not in PATH. For installation, manual
or problems please view the R website.
BAT_DMRs
Basic usage
$ perl BAT_DMRs -q <string>
Parameter
parameter description
-q path/filename of metilene input file, if mode 1 (default, option -F 1),
DMR file, if mode 2 (option -F 2)
- -o path/prefix of output files (default: input_path/metilene)
-F mode: (1) call DMRs using metilene with default setting and group
names group1 and group2, followed by filtering of the called DMRs us-
ing cutoffs below (-o, -p, -c, -d, -l) (default), (2) filter already called DMR
file using cutoffs below (-o, -p, -c, -d, -l)
-p maximum (<) adj. p-value (q-value) for output of significant DMRs (de-
fault: 0.05)
-c minimum (�) cpgs (default: 10)
-d minimummean methylation difference (�) (default: 0.1)
-l minimum length of DMR [nt] (�) (post-processing, default: 0)
-a name of group A (default: “g1”)
-b name of group B (default: “g2”)
-z non-default parameter for callingmetilene in quotes (e. g., threads and
CpG distance: “-t <number> -M <number>”)
- -metilene path/filename of metilene. Required if metilene is not in PATH. For
installation, manual or problems please view the metilene website
-R path/filename of R. Required if R is not in PATH. For installation,manual
or problems please view the R website.
BAT_correlating
Basic usage
$ perl BAT_correlating -b <string> -e <string> -m <string> -i
<string> -g <string>
Parameter
parameter description
-b bedfile containing coordinates of region for methyla-
tion rate and name of associated gene identifier (format:
chr<tab>start<tab>end<tab>identifier), identifier need to match gene
identifier
-e file containing list of expression files (format: identi-
fier<tab>count<tab>expression_value)
-m file containing list of methylation bigwig files
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-g file containing list of group membership and identifier (order w/r/t to
order in expression and methylation files) (format: sample_label group)
-i comma-seperated list defining the two main groups and an additional
third group for plotting. Groups need to match groups in -g file.
- -o output directory (default: current directory)
- -min minimum number of bases covered by bigwig file in gene region to cal-
culate correlation (default: 5)
- -prov flag, if -e and -m already contain methylation (format: sam-
ple.id<tab>region<tab>gene.identifer<tab>methylation.rate)
and expression values (format: sam-
ple.id<tab>gene.identifer<tab>expression.value). Only -e, -m and
-d are required.
- -bw path/filename of UCSCtools bigWigAverageOverBed. Required if
UCSCtools bigWigAverageOverBed is not in PATH. For installation,
manual or problems please view the UCSC website
-R path/filename of R. Required if R is not in PATH. For installation, manual
or problems please view the R website.
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A.2 Detection of differential DNA methylation
A.2.1 Algorithm pseudocode
A.2.2 Usage
metilene is available from http://http://www.bioinf.uni-leipzig.
de/Software/metilene/ as pre-compiled versions for 32/64-bit linux, or as
source code to be built from source. It was mainly implemented by F. Jühling and
S. Hoffmann.
A.2.2.1 DMR annotation modes
DMR de-novo annotation. The default mode of metilene annotates DMRs de-
novo without using any prior information on genomic features, e. g., promoter
regions. Here a the fast circular binary segmentation approach described above
on the mean difference signal of both groups is used.
DMR annotation in known features. Instead of annotating de-novo DMRs,
metilene can be used to find significant DMRs within a given group of genomic
features. Here, the first step calling the circular binary segmentation algorithm
is skipped. Instead, statistical tests are performed for each feature, and corre-
sponding p-values are reported in the output. The -B <BED> option is used to
define windows through a BED file sorted equally to the methylation data input
file.
DMC annotation. metilene offers the possibility to test each CpG for differ-
ential methylation. Statistical tests (KS-test and Mann-Whitney-U test) are cal-
culated for each CpG site, and corresponding p-values are reported in the output.
A.2.2.2 Input
The input consists of a single sorted by genomic position and tab-separated file.
It must contain a header line of the format:
chr <tab> pos <tab> g1_xxx <tab> g1_xxx <tab> [...] <tab>
g2_xxx <tab> g2_xxx <tab> [...]
or
chr <tab> pos <tab> g2_xxx <tab> g3_xxx <tab> [...] <tab>
g1_xxx <tab> g2_xxx <tab> [...]
or any other unsorted order of the columns. The first column refers to the
chromosome, the second column to the genomic position of the CpG and all
following columns to the absolute methylation rate for each cytosine or CpG site,
depending on the users choice. The affiliations of samples is assigned through
a unique prefix, e. g., “g1”, “g2”, which are passed as arguments when calling
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Algorithm 1 The algorithm implemented in metilene for de-novo DMR predic-
tion as pseudocode.
1: diff=mean(group1)-mean(group2)
2: procedure S��-�������(distCpGs)
3: for all CpGs x,y do
4: if dist(x,y) > tdist then
5: subregion1 = [.,x]
6: subregion2 = [y,.]
7: end if
8: end for
9: end procedure
Phase 1 - Segment each sub-region [s,t]
10: for all s � a < b � t do
11: Calculate Zs,t(a,b)
12: end for
13: Zmax(a,b) = maxs�a<b�t|Zs,t(a,b)|
14: Define pre-segments as [s,a), [a,b], (b,t]
Phase 2 - Filter pre-segments
15: for all pre-segments do
16: if #CpGs�minCpGs then
17: Do 2D KS-test and calculate pnew
18: Label as potential DMR
19: else if low variation filter passed then
20: if majority filter passed then
21: Do 2D KS-test and calculate pnew
22: if exists(p[s,t]) AND pnew > p[s,t] then
23: Label as potential DMR
24: else
25: Goto Phase 1
26: end if
27: else
28: Goto Phase 1
29: end if
30: else
31: Goto Phase 1
32: end if
33: end for
Phase 3 - Call DMRs
34: DMR = argminpotentialDMRs(p_value)
35: Goto Phase 1 for [s,startDMR), (endDMR,t]
Phase 4 - Output DMRs
36: Merge all regions without p-value
37: for all regions labeled as potential DMR do
38: if diff� diffmin then
39: Do Mann-Whitney U test
40: end if
41: end for
42: Output all segments
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metilene. No underscore is required, and names can be labeled completely
freely. Options -a and -b indicate the groups that are considered. The methy-
lation rate columns order can be mixed, and other groups, e. g., g3_xxx, can be
present and will be omitted for a run calling -a g1 and -b g2.
Generate an input file from multiple BED files. To generate an appropriate
inputfile containing allmethylation rates, wewrote a scriptgenerateInput.pl
generating a sorted tab-separated input file from multiple BED-files. A basic
metilene call for the specific input file is printed to the command line.
generateInput.pl takes two comma-separated lists of sorted BED files and
creates a metilene input matrix out of it. The group affiliation can further be
specified- one for each group, that will show up in the header of the metilene
input file.
A metilene input file is created by generateInput.pl, by calling:
$ perl generateInput.pl --in1 <string> --in2 <string> [--out
<string>] [--h1 <string>] [--h2 <string>] [-b <string>]
parameter description
–in1 comma-seperated list of sorted BED/BedGraph input files of group 1
–in2 comma-seperated list of sorted BED/BedGraph input files of group 2
–out path/file of out file (metilene input) (default: metilene_g1_g2.input,
g1 set by –h1 option, g2 set by –h2 option)
–h1 identifier of group 1 (default: g1)
–h2 identifier of group 2 (default: g2)
-b path/executable of bedtools executable (default: in PATH)
A.2.2.3 Parameter
The entire call of metilene using all parameter is:
$ metilene [-M <n>] [-m <n>] [-d <n>] [-t <n>] [-f <n>] [-a
<string>] [-b <string>] [-B <string>] [-X <n>] [-Y <n>]
[-v <n>] methylation-file
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parameter unit default description
methylation-file sorted file containing the input data
-M, - -maxdist Integer 300 allowed nt distance between two CpGs
within a DMR
-m, - -mincpgs Integer 10 minimum # of CpGs in a DMR
-d, - -minMethDiff double 0.1 minimummean methylation difference
for calling DMRs
-t, - -threads Integer 1 number of threads
-f, - -mode Integer 1 method selection: 1: de-novo,
2: pre-defined regions, 3: DMCs
-a, - -groupA String g1 prefix of replicates in the 1st group
-b, - -groupB String g2 prefix of replicates in the 2nd group
-B, - -bed String sorted (equally to the input data) BED
file containing regions for mode 2
-X, - -minNoA Integer 80% minimal # of non-missing values for
estimating missing values in g1*
-Y, - -minNoB Integer 80% minimal # of non-missing values for
estimating missing values in g2*
-v, - -valley Double 0.7 stringency of the valley filter
(0.0 - 1.0)
*If not enough entries are available, the corresponding line is skipped due to too
many missing values.
Parameter -M. metilene works in two steps, first it pre-segments the whole
data into windows so that no large gaps without data are possible. The -M pa-
rameter sets this length in nucleotides. The default value of 300 means, that the
whole genome is cut whenever a stretch of 300 nucleotides or more without data
(CpGs) is found. E. g., if you the user does not want to find DMRs with stretches
without CpGs longer than 200 nucleotides, the option -M 200 should be used.
Parameter -m. The length parameter -m sets the minimum value of CpGs or
data points a DMRneed to contain to be reported. Asweuse a top-downapproach,
starting with long windows and segmenting them to short significant DMRs, this
is also a stop-criteria. Windows that contain a smaller number of CpGs are not
considered and skipped.
Parameter -d. The option -d sets the minimum mean methylation difference
between both groups for a window to be reported as a DMR. This prevents to call
regions with very small but significant significant methylation differences. We
think thatmost users do not want to call smallermean differences than 0.1, as the
difference would be too small to term those regions as differentially methylated.
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Parameter -t. metilene is completely multi-threaded implemented, the -t
parameter sets the number of possible threads. metilene uses multiple threads
to search for DMRswithin pre-segmentedwindows (see the -M parameter) in par-
allel. For time reasons, as many cores as possible should be used. However, read-
ing the input file could be another bottleneck in your environment.
Parameter -f. This parameter can be used to apply other search methods to
the data. If metilene is called using -f 2 it checks pre-defined regions given
in a bed file (see parameter -B) for differential methylation. Single differentially
methylated CpGs are searched using -f 3.
Parameters -a and -b. Both parameters specify the prefixes for columnnames
of both groups, described at the input section above.
Parameter -B. This parameter specifies a sorted (equally to the input data)BED
file containing regions of interest that should be checked for differential methy-
lation, see -f parameter. Only the first three columns of the BED file are used
(chr <tab> start <tab> stop)
Parameters -X and -Y. metilene can estimate missing from available data
of other replicates. Both parameters specify how many replicates must contain
data for a certain CpG position in group 1 (-X) or group 2 (-Y) to estimatemissing
ones. The default value is set to 80% of the number of replicates of each group.
However, when changing this by using these parameters, they are set to absolute
numbers of replicates, not to percentages.
Parameter -v. metilene’s valleyfilter prevents to call large regions as a single
DMR where a valley in the mean difference signal is inside. The -v parameter
sets a cutoff factor for the methylation difference when comparing global and
regional methylation differences. Thus forces to segment further until no more
valleys are found. Its influence can be reduced by decreasing this factor, or it can
be turned off by using -v 0. The effect of parameter settings on resulting DMR
calls at different valley length and depths within the mean methylation signal is
illustrated in Fig. 4.3.
A.2.2.4 Output
The output for the de-novo DMR annotation mode consists of a BED-like format:
chr <tab> start <tab> stop <tab> q-value <tab> mean
methylation difference <tab> #CpGs <tab> p-value (MWU) <tab>
p-value (2D KS) <tab> mean g1 <tab> mean g2
While “mean g1” and “mean g2” refer to the absolute mean methylation level
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for the corresponding segment in both groups, the difference is given in the 5th
column. Single CpGs are not tested using the 2D KS-test. Here, q-values are based
on MWU-test p-values. All outputs are unsorted when using multiple threads.
Filter output file and plot basic DMR statistics. An easy way to filter the al-
ready called DMRs is offered by filterOutput.pl. Furthermore, it will create
some basic statistic plots characterizing the DMRs, i. e., distribution of DMR dif-
ferences, DMR length in nucleotides and #CpGs, DMR differences vs. q-values,
mean methylation group 1 vs. mean methylation group 2 and DMR length in nu-
cleotides vs. length in CpGs (Fig. A.1). DMRs can by filtered by q-value, # CpGs,
length in nucleotides and mean methylation difference. 3 files are produced:
(i) BedGraph file containing the methylation difference for each DMR, (ii) ba-
sic statistic pdf and (iii) filtered BedGraph-like file, containing all information
already in the metilene output. The following call will filter the metilene out-
put file and plot the basic statistic plots (Fig. A.1):
$ perl filterOutput.pl -q <string>[-o <string>] [-p <n>] [-c
<n>] [-d <n>] [-l <n>] [-a <string>] [-b <string>]
parameter description
-q path/filename of metilene output
-o path/prefix of filtered output files,
i. e., BedGraph file, filtered output file and pdf
(default: metilene_qval_0.05.bed, metilene_qval_0.05.pdf)
-p maximum adj. p-value (q-value) for output of
significant DMRs (default: <0.05)
-c minimum #CpGs (default: �10)
-d minimummean methylation difference (default: �0.1)
-l minimum length of DMR [nt]
(post-processing, default: �0)
-a name of group A (default: “g1”)
-b name of group B (default: “g2”)
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Figure A.1: Statistic plots. Basic statistic plots produced with filterOutput.pl. top, left to
right: Distribution of the DMR differences, length distribution in nucleotides of the DMRs, length
distribution in cytosines of the DMRs. bottom, left to right: Scatter plot of DMR methylation dif-
ference versus DMR q-value, scatter plot of the average methylation rate of the two groups, scatter
plot of DMR length in cytosines versus nucleotides.
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Figure A.2: Boundary detection analyses. Boundary detection analyses for background 1+2 and
DMRs of class 1-4. MOABS did not predict any class 4 DMR and is therefore missing in the corre-
sponding figures. The fraction of predicted DMR boundaries of metilene, MOABS, and BSmooth
within different maximum absolute distances, ranging from 0 (no difference between simulated
and predicted boundary) to 20 CpGs. B) The fraction of distances (in CpGs) between predicted and
simulated boundaries for the three tools. Negative distances indicate that the predictions were too
short compared to the simulated ones while positive values indicate predictions extending beyond
the simulated DMRs.
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Figure A.3: Noisy data. Simulations with different percentages of noise introduced into DMR re-
gions. TPRs and PPVs on the CpG level (top) and the DMR level (bottom)weremeasured. metilene
and MOABS showed a very stable detection of DMRs also with high levels of noise. For DMRs with
almost 2
3
noise and only 1
3
signal both tools miss DMRs. BSmooth reports less than 1
3
DMRs in
general.
Figure A.4: TPR, PPV on simulated RRBS data. The performance of metilene, MOABS, BSmooth,
and BiSeq in terms of true positive rates (TPR) and positive predictive values (PPVs) for different
classes of DMRs and backgrounds on the RRBS simulations.
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Figure A.5: Boundary detection analyses on simulated RRBS data. Boundary detection analyses
for background 1+2 and DMRs of class 1-4. MOABS did not predict any class 4 DMR and is therefore
missing in the corresponding figures. The fraction of predicted DMR boundaries of metilene,
MOABS, BSmooth, and BiSeq within different maximum absolute distances, ranging from 0 (no
difference between simulated and predicted boundary) to 20 CpGs. B) The fraction of distances (in
CpGs) between predicted and simulated boundaries for the four tools. Negative distances indicate
that the predictions were too short compared to the simulated ones while positive values indicate
predictions extending beyond the simulated DMRs.
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Figure A.6: Low number of samples. Simulations with low number of samples. TPRs and PPVs on
the CpG level (top) and the DMR level (bottom) were measured while comparing groups consisting
of only 1, 3, 5 or 7 samples. Only metilene is able to compare 1 vs. 1 sample while both other tools
need at least 2 samples within each group.
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Figure A.7: Missing data. Simulations with different levels of missing data as well as different
amounts of estimated samples. The data set consisted of 10 vs. 10 samples while a certain amount
of values was removed from the data, and different numbers of samples (7, 5, 3, and 1) per CpG
position were allowed to be estimated by metilene using a beta distribution estimated from the
existingmethylation rates. TPRs and PPVsweremeasured on the CpG level (top) and the DMR level
(bottom).
A.2.4 Tables
WGBS RRBS
tmin real time memory real time memory
3 6m28s 0.74 GB 6s 0.08 GB
5 4m11s 0.73 GB 5s 0.08 GB
7 3m49s 0.73 GB 4s 0.08 GB
10 3m55s 0.73 GB 4s 0.08 GB
15 6m21s 0.73 GB 3s 0.08 GB
25 14m41s 0.73 GB 3s 0.08 GB
50 13m39s 0.73 GB 3s 0.08 GB
100 28m14s 0.73 GB 2s 0.08 GB
150 24m13s 0.73 GB 2s∗ 0.08 GB∗
200 21m41s 0.73 GB 2s∗ 0.08 GB∗
Table A.12: tmin evaluation. Running time andmemory requirements for metilenewith differ-
ent tmin settings. No DMRs were found anymore for settings flagged with ∗.
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cores metilene MOABS BSmooth BiSeq speedup
real 1 4s SF∗ 2m20s 8h21m35s 35x–7.524x
time 10 2s 20m27s 0m52s 8h19m18s 26x–14.979x
RAM 1 0.08 GB SF∗ 1.12 GB 1.42 GB
10 0.75 GB 7.54 GB 7.31 GB 1.42 GB
Table A.17: Running time and memory for simulated RRBS data. Running time and memory
requirements for metilene, MOABS, BiSeq and BSmooth for calling DMRs on the human chromo-
some 10 (hg19) with 10 vs. 10 simulated samples. In the simulations a total of 57,8 k CpG positions
was evaluated. SF∗: MOABS did not finish any of several test runs (segmentation faults) on one core
while we observed no problems for the same input data when running onmore than one core. E. g.,
the running time of MOABS on two cores was 73m35s with 7.03 GB RAM.
metilene MOABS BSmooth speedup
chromosome 10:
real time 0h0m52s 5h29m35s 0h17m25s 20x–380x
RAM 0.02 GB 6.8 GB 73.3 GB
whole genome:
real time 0h9m55s NA NA
RAM 0.09 GB NA NA
Table A.18: Running time and memory on real data. Running time and memory requirements
for metilene, MOABS, and BSmooth, each running on 10 cores, for calling DMRs on the human
chromosome 10, the human chromosome 1, and the whole human genome (hg19) with 8 vs. 12
real samples. Due to missing values this data set is not directly comparable to the simulations. For
chromosome 10 a total of 1.1M CpG positions was evaluated for all samples, while chromosome 1
comprised 1.9M valid CpG positions.
cores metilene MOABS BSmooth speedup
real time:
1 0h4m7s 65h35m11s 2h20m3s 34x–956x
10 0h1m14s 9h11m51s 0h23m19s 19x–447x
RAM:
1 0.7 GB 5.4 GB 10.7 GB
10 1.2 GB 6.8 GB 90.2 GB
Table A.19: Running time and memory for simulated WGBS data. Running time and memory
requirements for metilene, MOABS, and BSmooth for calling DMRs on the human chromosome 10
(hg19) with 10 vs. 10 simulated samples. In the simulations a total of 2.7M CpG positions was eval-
uated.
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samples metilene MOABS BSmooth speedup
real time:
2 vs. 2 04m21s 1d01h54m32s 2h01m26s 28x–357x
4 vs. 4 05m18s 3d04h30m28s 2h24m10s 27x–866x
8 vs. 8 08m21s 4d10h47m05s NA >1724x
16 vs. 16 14m12s NA NA NA
50 vs. 50 50m15s NA NA NA
RAM:
2 vs. 2 0.12 GB 17.85 GB 67.99 GB
4 vs. 4 0.09 GB 17.85 GB 176.34 GB
8 vs. 8 0.08 GB 17.85 GB NA
16 vs. 16 0.12 GB NA NA
50 vs. 50 0.08 GB NA NA
Table A.20: Running time and memory for different sample sizes. Running time and memory
requirements for metilene, MOABS, and BSmooth, each running on 10 cores, for calling DMRs on
the human genome (hg19) with different sample sizes, i. e.,, 2 vs. 2, 4 vs. 4, and 8 vs. 8 samples. All
“NA” entries were not evaluated due to run time/memory issues. Test input data sets with more
than 8 vs. 8 samples contained duplicates.
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A.3 Germinal-center B-cell lymphoma
A.3.1 Figures
Figure A.8: Control of confounding factors. A) DNA methylation of 37 BL as determined by 450k
BeadChip analysis. Only loci located in (left) DMR or (right) cDMR are included. Green boxes on
top of the heatmap: juvenile donors (<18 years), black boxes on top of the heatmap: adult donors
(>17 years), heatmap: blue: low methylation; yellow: high DNA methylation. B) Analysis of tu-
mor content and its effects on average per-sample methylation and transcription. No apparent
relationship between the average genome wide methylation rate and tumor content (left) nor the
differential expression between tumor and healthy control (right) is observed. C) Correlation of the
TF expression with the proliferation status measured by Ki-67 staining. All available probesets for
the TF genes were pooled and correlated with the proliferation marker (grey line). Apparently, no
relevant correlation between TF expression and proliferation was observed (Spearman cor.=0.02).
Ki-67 values were jittered to avoid overlaps as Ki-67 was measured in 5% steps. D) Correlation of
TF target gene expression with proliferation status. All available probesets for these target genes
were pooled and correlated with the proliferation marker (grey line). No apparent correlation was
detected (Spearman cor=-0.043). Ki-67 values were jittered. E) Analysis of the correlation of prolif-
eration rate and average methylation rate. No significant p-values were observed using spearman
correlation (BL p-val = 0.33, FL p-val = 0.77, both p-val = 0.11). F) Unsupervised hierarchical cluster
analysis of 450k BeadChip data obtained from 37 BL and 52 FL samples of CpG loci located in (left)
DMRs and (right) cDMR. Blue boxes on top of the heatmap indicate BL samples, gray boxes FL; blue:
low, yellow: high DNA methylation.
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Figure A.9: Gene expression heatmap of a subset genes enriched in IPA pathways. A) Genes
specifically downregulated in FL are enriched in GO Terms related to cell cycle and DNA repair.
Most frequent genes in GO Terms are displayed. B) Genes specifically downregulated in BL are
enriched in GO Terms related to the immune system and inflammatory and wounding response.
Most frequent genes in GO Terms are displayed.
Figure A.10: Integrative genome browser view of the IGF2BP1 locus. (Top) chromatin segmen-
tations of GM12878, BL2, DG-75 and KARPAS-422 cell lines; middle: Average CpGmethylation of BL,
FL and GC-B-cell samples; (bottom) Average RNA expression of BL, FL and GC-B-cell samples.
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Figure A.11: NFκB signaling pathway (Ingenuity Pathway Analysis Canonical Pathway). Shad-
ings signify significantly different RNA expression in pBL vs. pFL (red: pBL>pFL; green: pBL<pFL).
Blue edges mark cDMR-associated genes pairs that show significantly negative correlation.
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Figure A.12: Cyclins and Cell Cycle Regulation (Ingenuity Pathway Analysis Canonical Path-
way). Shadings signify significantly different RNA expression in pBL vs. pFL (red: pBL>pFL; green:
pBL<pFL). Blue edges mark cDMR-associated genes pairs that show significantly negative correla-
tion.
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Figure A.13: TCF3 binding site in TCF3 intron. TCF3 ChIP-Seq experiments [Schmitz 2012] for the
BL cell lines BL-41 A) and NAMALWA B). As compared to three control conditions (anti-Flag, anti-
TCF3 and Biotag Control) coverage profiles peak inside cDMR (white background) for wild type
TCF3 as well as TCF3 mutants (D561E, N551K, V557E) in BL-41 (A). In NAMALWA, only a weak TCF3
signal can be observed. C) TCF3/E2A binding motif annotated by Motifmap (motifmap.ics.uci.edu)
using a 46way-Multiz alignment. D) TCF3 TFBS motif overlaps with ChIP-Seq peak in BL-41. The
region is annotated as active promoter in BL (DG-75, BL2), DLBCL (KARPAS-422) and lymphoblastoid
(GM12878) cell lines. E) Expression array experiments confirm a higher expression of TCF3 in BL
cell lines (BL-41, DG-75, NAMALWA) as compared to non-BL cell lines KARPAS-422 and KARPAS-106
(MMML cohort). F) The scatterplot confirms the negative relation between the expression of TCF3
(measured with RNASeq in RPM) and the cDMR methylation (measured with 450k BeadChip) from
samples of the ICGC-MMML-Seq cohort. Note that the 450k BeadChip covers the cDMR with 2 CpG
(chr19:1648682,chr19:1649123).
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Figure A.14: Suppression of inhibitory G-protein-alpha-i signaling and activation of protein
kinase A (PKA) signaling in BL.A) Correlation ofmethylation and expression for PRKAR2B. B) RNA
expression of PRKAR2B in BL, FL and GC-B-cell determined by microarray analysis in an extended
lymphoma cohort. C) Treatment of the Burkitt lymphoma cell line Ca46 with the protein kinase A
inhibitor PKI-6-22 (IC50=2nM 52) did not affect cell viability. Burkitt lymphoma cell lines BL-2 and
BL-41 were not affected, either (data not shown).
Figure A.15: DNA methylation profiles at TFBS. Examples of methylation profiles at enriched
TFBS in cDMRs. The regions 5k up- and downstream of the annotated TFBS were used to analyze
the methylation profile. We found the lowest methylation rates located precisely in the middle of
the TFBS. Up- and downstream of the TFBS the methylation rates increase steeply and return to
background levels.
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Figure A.16: Integrative model of TCF3 and SMARCA4. A) In normal GC-B-cell TCF3 induces
its own inhibitor ID3, creating an autoregulatory loop that results in modulate expression of target
genes, e.g. SMARCA4. SMARCA4 is a component of the SWI/SNF complex, regulating the expression
of target genes by its helicase function. B) In Burkitt lymphoma mutations (red bolt) affecting ID3,
negative regulator of TCF3, foster TCF3 dependent gene expression. The same effect might also be
caused by mutations of TCF3 (not recurrently mutated in this data set, grey bolt). Furthermore,
the TCF3 gene harbours a hypomethylated cDMR for amplifying TCF3 transcription. High TCF3
expression results in higher expression of target genes. High SMARC4 expression and mutations
in SMARCA4 ablate helicase function directly, through interference with ATP-binding or indirectly
by obstructing the interaction of the helicase domains resulting in low expression of target genes.
Red and black arrows in different size indicating the protein level of expression, white lollipops in
headlong direction indicating an unmethylated status.
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PID
type
totalreadcount
%
mapped
%
uniquelymapped
R
2arraycorrelation
4118819
GC-B-cell
991,190,927
96.48
90.99
0.861
4122131
GC-B-cell
1,099,283,967
96.0
89.23
0.887
4160735
GC-B-cell
831,812,581
85.09
79.78
0.91
4174884
GC-B-cell
806,131,461
83.98
78.41
0.921
4112512
BL
745,957,354
89.41
78.68
0.929
4119027
BL
865,369,134
94.41
87.95
0.939
4125240
BL
728,907,037
90.39
83.13
0.922
4133511
BL
1,092,415,562
94.60
88.55
0.931
4142267
BL
1,027,372,107
96.99
91.09
0.907
4177434
BL
1,051,677,637
89.95
82.92
0.943
4177856
BL
1,088,090,219
95.58
88.88
0.942
4182393
BL
822,877,534
94.01
87.72
0.932
4189998
BL
1,103,050,124
96.04
89.56
0.935
4190495
BL
922,078,617
85.41
77.85
0.915
4193278
BL
910,056,125
95.48
88.75
0.930
4194218
BL
979,263,566
96.25
89.70
0.934
4194891
BL
765,168,759
86.49
78.99
0.935
4105105
FL
1,049,794,226
94.46
86.67
0.932
4121361
FL
975,443,989
96.21
89.79
0.915
4134005
FL
1,064,047,805
93.16
85.43
0.920
4158726
FL
1,050,825,693
95.46
88.97
0.919
4159170
FL
1,140,282,923
96.33
89.56
0.934
4175837
FL
1,004,341,522
96.19
90.56
0.908
4177376
FL
872,114,064
84.59
76.92
0.913
4188900
FL
861,302,178
85.52
77.13
0.910
4189200
FL
1,048,046,414
94.18
88.07
0.931
TableA.21:Statisticsofwhole-genomebisulfitesequencing.totalreadcount:numberofreadsobtainedfrom
sequencer;%
mapped:percentageofreadswhichcouldbe
mappedtoreferencegenome;%
uniquelymapped:percentageofreadswhichcouldbemappeduniquelytoreferencegenome;%
arraycorrelation:R
2oflinearmodelof
whole-genomebisulfitesequencingmethylationratesand450kBeadChipbetarates.
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TF ρ p-value
STAT5A 0.876923077 2.24*10−06
TCF3 0.818461538 2.30*10−06
MEF2 0.796153846 4.03*10−06
BCL3 0.793846154 4.38*10−06
PML 0.783076923 6.69*10−06
BATF 0.776923077 8.64*10−06
FOXM1 -0.766153846 1.35*10−05
RXRA 0.700769231 1.44*10−04
SMARCA4 -0.688461538 2.08*10−04
YY1 -0.683076923 2.43*10−04
RAD21 -0.646153846 6.48*10−04
ZEB1 -0.610769231 1.48*10−03
ETS1 0.553076923 4.74*10−03
NFIC 0.543076923 5.69*10−03
EBF1 0.52 8.51*10−03
RUNX3 0.519230769 8.62*10−03
PAX5 -0.48 1.62*10−02
ZBTB33 0.464615385 2.03*10−02
TAF1 0.457692308 2.25*10−02
POLE4 -0.449230769 2.54*10−02
SIX5 0.425384615 3.51*10−02
NFATC1 -0.390769231 5.44*10−02
ATF2 0.388461538 5.59*10−02
MTA3 -0.385384615 5.80*10−02
PU1 -0.303846154 1.40*10−01
SRF 0.290769231 1.58*10−01
ELF1 -0.276923077 1.80*10−01
BCLAF1 -0.231538462 2.64*10−01
CREB1 0.223076923 2.82*10−01
IRF4 0.221538462 2.86*10−01
PBX3 0.203076923 3.29*10−01
CEBPB 0.201538462 3.32*10−01
POU2 -0.183846154 3.77*10−01
POL2 0.106923077 6.10*10−01
SP1 0.099230769 6.36*10−01
GABPA -0.097692308 6.41*10−01
EGR1 0.073076923 7.28*10−01
TCF12 0.04 8.50*10−01
ATF3 0.031538462 8.82*10−01
BCL11 -0.007692308 9.72*10−01
Table A.23: Ranking of transcription factors by correlation coefficient (ρ) of cDMR-gene expression
and TF expression.
150 A
PID
type
totalreadcount
%
mapped
%
properlymapped
%
uniquelymapped
%
singletons
4118819
GC-B-cell
152,163,762
95.39
88.72
88.74
1.19
4122131
GC-B-cell
143,139,572
94.07
88.60
88.32
1.84
4174884
GC-B-cell
143,681,684
95.05
88.49
88.72
1.38
4112512
BL
100,040,596
95.92
91.96
88.75
1.21
4119027
BL
122,070,424
96.30
92.56
89.78
1.10
4125240
BL
118,552,896
92.88
89.35
85.79
2.92
4133511
BL
180,464,110
94.97
90.26
88.96
1.66
4142267
BL
147,502,168
93.93
88.95
84.78
2.10
4177434
BL
130,335,292
95.84
91.55
89.49
1.31
4177856
BL
147,673,376
94.95
90.33
88.18
1.67
4182393
BL
134,646,148
96.62
92.83
90.18
0.99
4189998
BL
168,560,268
94.81
90.26
87.22
1.78
4190495
BL
126,625,502
96.93
92.29
91.17
0.80
4193278
BL
173,013,412
93.42
88.47
85.58
2.38
4194218
BL
148,876,052
93.68
88.93
85.11
2.18
4194891
BL
170,697,768
93.82
88.77
86.79
2.19
4105105
FL
173,994,462
96.56
92.52
90.45
1.04
4121361
FL
140,160,636
96.74
92.68
89.10
0.92
4134005
FL
105,581,544
94.63
90.23
88.84
1.78
4158726
FL
190,901,256
94.14
89.07
88.85
1.96
4159170
FL
149,299,090
94.60
89.63
88.90
1.75
4175837
FL
183,318,574
93.42
87.86
87.49
2.24
4177376
FL
160,775,046
92.45
86.47
85.43
2.66
4188900
FL
168,897,502
93.23
87.70
87.61
2.31
4189200
FL
171,840,556
94.44
89.49
87.38
1.92
TableA.22:Statisticsofwhole-transcriptomesequencing.totalreadcount:numberofreadsobtainedfrom
sequencer;%
mapped:percentageofreadswhichcouldbe
mappedtoreferencegenome;%
properlypaired:percentageofreadswhichform
aproperpaironreferencegenome;%
uniquelymapped:percentageofreadswhichcould
bemappeduniquelytoreferencegenome;%
singletons:percentageofreadsforwhichnomatewasalignedbythemapper.
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A.4 Disturbance of poised chromatin in cancer
A.4.1 Tables
abbreviation full name
BL Burkitt Lymphoma
BLCA Bladder Urothelial Cancer
BRCA Breast Cancer
CESC Cervical Squamous Cell Carcinoma
COAD Colon Adenocarcinoma
ESCA Esophagus Cancer
FL Follicular Lymphoma
HNSC Head and Neck Squamous Cell Carcinoma
KIRC Kidney Renal Clear Cell Carcinoma
KIRP Kidney Renal Papillary Cell Carcinoma
LIHC Liver Hepatocellular Carcinoma
LUAD Lung Adenocarcinoma
LUSC Lung Squamous Cell Carcinoma
PAAD Pancreas Adenocarcinoma
PRAD Prostate Adenocarcinoma
READ Rectum Adenocarcinoma
SKCM Skin Cutaneous melanoma
THCA Head and Neck Thyroid Carcinoma
UCEC Uterine Corpus Endometrial Carcinoma
Table A.24: Abbreviations of cancer names.
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Project AUC poised promoter AUC poised enhancer AUC FPS
BL 0.928 0.883 0.9
BLCA-US 0.948 0.967 0.97
BRCA-US 0.925 0.958 0.963
CESC-US 1 1 1
COAD-US 0.982 0.984 0.979
ESCA 0.994 0.983 0.994
FL 0.945 0.923 0.921
HNSC-US 0.985 0.991 0.991
KIRC-US 0.987 0.847 0.944
KIRP-US 0.728 0.83 0.828
LIHC-US 0.92 0.904 0.92
LUAD-US 0.994 0.998 0.999
LUSC-US 0.995 0.995 0.998
PAAD-US 0.971 0.956 0.964
PRAD-US 0.893 0.911 0.909
READ-US 0.998 0.995 0.987
SKCM-US 0.965 0.968 0.978
STAD-US 0.824 0.73 0.794
THCA-US 0.875 0.867 0.885
UCEC-US 0.972 0.981 0.976
median 0.968 0.9625 0.967
Table A.25: AUC of classifiers for the different ICGC and TCGA data sets.
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